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Summary
Background The Millennium Declaration in 2000 brought special global attention to HIV, tuberculosis, and malaria 
through the formulation of Millennium Development Goal (MDG) 6. The Global Burden of Disease 2013 study 
provides a consistent and comprehensive approach to disease estimation for between 1990 and 2013, and an 
opportunity to assess whether accelerated progress has occured since the Millennium Declaration.
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Introduction
The Millennium Declaration in 2000 brought special 
global attention to HIV, tuberculosis, and malaria through 
the formulation of Millennium Development Goal 6 
(MDG 6). The high priority status of these three diseases 
in the development community was conﬁ rmed through 
the creation of the Global Fund to Fight AIDS, Tuberculosis 
and Malaria in 2002. Bilateral initiatives such as the 
President’s Emergency Plan for AIDS Relief and the 
President’s Malaria Initiative also added substantial new 
resources. From 2000 to 2011, multilaterals, bilaterals, 
foundations, and non-governmental organisations have 
invested US$51·6 billion for HIV, $11·3 billion for 
malaria, and $8·3 billion for tuberculosis (price in 2011 
US dollars) in development assistance for health (DAH).1 
Substantial beneﬁ ts of these investments have been 
documented in several studies.2–9 In the lead up to the 
MDG deadline of 2015 and amid the global debate on 
development goals post-2015, important questions have 
been raised about the advantages and disadvantages of 
maintaining focus on these three diseases.5,10–18 The rise of 
the importance of non-communicable diseases in some 
regions of the developing world19–26 have led to calls for 
goals that cover a broader range of diseases.10,15,17,19,20,24,25,27,28 
At the same time, ambitious goals of zero tuberculosis 
incidence and deaths and zero HIV incidence and deaths 
have been formulated by some groups;29–34 the Secretary-
General of the UN had already established a goal of zero 
malaria deaths by 2015.35 Understanding the distribution 
and trends of these three diseases and how they have been 
aﬀ ected by the MDG era is an important input to this 
wider debate.12,36
Because of their prominence, there are major UN eﬀ orts 
on an annual basis to track the epidemiology of these three 
Methods To estimate incidence and mortality for HIV, we used the UNAIDS Spectrum model appropriately modiﬁ ed 
based on a systematic review of available studies of mortality with and without antiretroviral therapy (ART). For 
concentrated epidemics, we calibrated Spectrum models to ﬁ t vital registration data corrected for misclassiﬁ cation of HIV 
deaths. In generalised epidemics, we minimised a loss function to select epidemic curves most consistent with prevalence 
data and demographic data for all-cause mortality. We analysed counterfactual scenarios for HIV to assess years of life 
saved through prevention of mother-to-child transmission (PMTCT) and ART. For tuberculosis, we analysed vital 
registration and verbal autopsy data to estimate mortality using cause of death ensemble modelling. We analysed data for 
corrected case-notiﬁ cations, expert opinions on the case-detection rate, prevalence surveys, and estimated cause-speciﬁ c 
mortality using Bayesian meta-regression to generate consistent trends in all parameters. We analysed malaria mortality 
and incidence using an updated cause of death database, a systematic analysis of verbal autopsy validation studies for 
malaria, and recent studies (2010–13) of incidence, drug resistance, and coverage of insecticide-treated bednets.
Findings Globally in 2013, there were 1·8 million new HIV infections (95% uncertainty interval 1·7 million to 
2·1 million), 29·2 million prevalent HIV cases (28·1 to 31·7), and 1·3 million HIV deaths (1·3 to 1·5). At the peak 
of the epidemic in 2005, HIV caused 1·7 million deaths (1·6 million to 1·9 million). Concentrated epidemics in 
Latin America and eastern Europe are substantially smaller than previously estimated. Through interventions 
including PMTCT and ART, 19·1 million life-years (16·6 million to 21·5 million) have been saved, 70·3% (65·4 to 
76·1) in developing countries. From 2000 to 2011, the ratio of development assistance for health for HIV to years 
of life saved through intervention was US$4498 in developing countries. Including in HIV-positive individuals, 
all-form tuberculosis incidence was 7·5 million (7·4 million to 7·7 million), prevalence was 11·9 million 
(11·6 million to 12·2 million), and number of deaths was 1·4 million (1·3 million to 1·5 million) in 2013. In the 
same year and in only individuals who were HIV-negative, all-form tuberculosis incidence was 7·1 million 
(6·9 million to 7·3 million), prevalence was 11·2 million (10·8 million to 11·6 million), and number of deaths was 
1·3 million (1·2 million to 1·4 million). Annualised rates of change (ARC) for incidence, prevalence, and death 
became negative after 2000. Tuberculosis in HIV-negative individuals disproportionately occurs in men and boys 
(versus women and girls); 64·0% of cases (63·6 to 64·3) and 64·7% of deaths (60·8 to 70·3). Globally, malaria 
cases and deaths grew rapidly from 1990 reaching a peak of 232 million cases (143 million to 387 million) in 2003 
and 1·2 million deaths (1·1 million to 1·4 million) in 2004. Since 2004, child deaths from malaria in sub-Saharan 
Africa have decreased by 31·5% (15·7 to 44·1). Outside of Africa, malaria mortality has been steadily decreasing 
since 1990.
Interpretation Our estimates of the number of people living with HIV are 18·7% smaller than UNAIDS’s estimates 
in 2012. The number of people living with malaria is larger than estimated by WHO. Incidence rates for HIV, 
tuberculosis, and malaria have all decreased since 2000. At the global level, upward trends for malaria and HIV deaths 
have been reversed and declines in tuberculosis deaths have accelerated. 101 countries (74 of which are developing) 
still have increasing HIV incidence. Substantial progress since the Millennium Declaration is an encouraging sign of 
the eﬀ ect of global action.
Funding Bill & Melinda Gates Foundation.
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diseases. UNAIDS now produces country estimates of HIV 
incidence, prevalence, and death every year.37 Over many 
years, they have developed a sophisticated modelling 
approach to track the epidemic—their primary input in 
generalised epidemics is annual antenatal clinic sero-
surveillance data and periodic household surveys that 
include blood testing.38,39 The annual Global Tuberculosis 
Report from the World Health Organization (WHO) 
provides estimates of incidence and deaths from 
tuberculosis by country. Crucial inputs to the assessment of 
incidence are case notiﬁ cations and national expert opinion 
on the case-detection rate, and separate modelling of cause 
of death data from vital registration systems and verbal 
autopsy studies. For the World Malaria Report, WHO uses 
a complicated strategy to estimate incidence and mortality 
that varies by region and age group. For child malaria 
deaths in sub-Saharan Africa, the main inputs are verbal 
autopsy studies and estimated malaria risk. Estimates are 
adjusted post-hoc for coverage of insecticide-treated 
bednets (ITNs). Outside of sub-Saharan Africa and for low-
transmission countries in Africa reported case numbers 
are combined with an assumed case-fatality rate. These 
three eﬀ orts have provided important insights into the 
geographical distribution and likely trends in the diseases.
Despite these eﬀ orts, extraordinary uncertainty exists at 
the country-level in the burden of all three. The burdens of 
HIV and malaria are concentrated in sub-Saharan Africa; 
countries that, other than South Africa, have very poor 
vital registration and incomplete notiﬁ cation systems. 
Tuberculosis is concentrated in Asia and southern Africa 
where a few more countries have better data systems but 
there are still huge gaps in information. Modelling 
strategies for tracking the diseases have evolved to be 
necessarily complex in view of the incomplete and often 
conﬂ icting nature of the data. For HIV and malaria, UN 
modelling eﬀ orts explicitly use information about 
intervention delivery and assumed beneﬁ ts of intervention. 
The distinction between data for disease outcomes and 
data for intervention coverage driving the results of these 
eﬀ orts is blurred. In the more complex modelling 
strategies, the compounded eﬀ ect of uncertainty about 
diﬀ erent parameters can be hard to characterise. Eﬀ orts to 
model the three diseases are largely independent of each 
other—the exception is recent coordinated eﬀ orts to 
understand the intersection of tuberculosis and HIV.40
The Global Burden of Disease 2010 Study provided a 
comprehensive update on levels and trends of a large 
number of diseases, injuries, and risk factors for 
187 countries from 1990 to 2010.41–48 The Global Burden of 
Disease collaboration is now generating annual updates, 
the ﬁ rst of which is the Global Burden of Disease, 
Injuries, and Risk Factors Study 2013 (GBD 2013). The 
GBD 2013 provides an opportunity to examine the 
evidence on the levels and trends in the three MDG 6 
diseases within the comprehensive and coherent 
framework of the GBD. Compared with GBD 2010, we 
have given special emphasis in the GBD 2013 to 
incorporate new data, to more rigorously identify and 
incorporate further key sources of uncertainty, and to 
incorporate adjustments for the biases that are present in 
diﬀ erent data sources. A crucial aspect of the GBD eﬀ ort 
is to quantify time trends; comparing trends from 1990 to 
2000 and from 2000 to 2013 provides an opportunity to 
see if there has been accelerated progress since the 
Millennium Declaration. The GBD 2013 supersedes all 
previously published GBD results.
Methods
Overview
The overall conceptual and analytical framework for the 
GBD is described elsewhere.41–48 Major reﬁ nements of the 
analytical approach for diﬀ erent diseases and risk factors 
are explored in other papers.49–51 We summarise here the 
methods used for the analysis of the three diseases, 
emphasising reﬁ nements since the GBD 2010. All 
reﬁ nements in methods have been applied to the full 
1990–2013 time series to ensure comparability of results. 
Metadata for input sources used in the GBD 2013 will be 
available in the Global Health Data Exchange on publication 
of the full GBD 2013 results.
Figure 1: UNAIDS compartmental model for estimating mortality in HIV-positive individuals in the absence of ART
ART=antiretroviral therapy.
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HIV
For the GBD 2010, we primarily used estimates of 
prevalence and mortality developed by UNAIDS. The 
main modiﬁ cation was the requirement that the sum 
of cause-speciﬁ c mortality from each cause in a 
country, age, sex, and year group equalled the estimate 
of all-cause mortality for that country, age, and sex 
group generated through the analysis of demographic 
sources.43 Modiﬁ cations of HIV deaths through this 
internal consistency process did not lead to revisions of 
incidence or prevalence for HIV in a particular age-sex-
country-year. For the GBD 2013, we have sought to 
develop a set of estimates of incidence, prevalence, and 
mortality from HIV that are internally consistent with 
each other and also meet the GBD requirement that 
the sum of each cause of death equals all-cause 
mortality. Internally consistent means the incidence, 
prevalence, and death ﬁ gures are mathematically 
possible given that prevalence is a function of past 
incidence, remission, and death rates for any age 
cohort.
Modiﬁ ed Spectrum Model
UNAIDS uses two key analytical components in their 
epidemiological estimation. The Estimation and 
Projections Package (EPP) is used to estimate incidence 
trajectories that are consistent with prevalence surveys 
and other prevalence measurements such as antenatal 
clinic serosurveillance.52 Spectrum is a compartmental 
HIV progression model used to generate age-speciﬁ c 
incidence, prevalence, and death rates from the EPP 
incidence curves and assumptions about intervention 
scale-up and local variation in epidemiology.53 We have 
recoded Spectrum in Python, an open source higher 
level language that can easily be run on a parallelised 
computational cluster, following the exact structure of 
Spectrum to facilitate faster computation required for 
the uncertainty analysis and consistency analysis with 
all-cause mortality. We have also made four important 
modiﬁ cations to the assumptions.
First, we have altered the Spectrum assumptions 
about mortality without antiretroviral therapy (ART). 
Following UNAIDS assumptions, mortality is modelled 
as shown in ﬁ gure 1. The death and progression rates 
between CD4 categories vary by age according to four 
age-groups, 15–24 years, 25–34 years, 35–44 years, and 
45 years or older. UNAIDS estimates a single set of 
progression and death rates by ﬁ rst ﬁ tting a Weibull 
distribution to data from three east African seroconverter 
cohorts from the ALPHA network and one miners 
cohort from South Africa,54 and then selecting a set of 
progression and death rates in Excel Solver that 
minimises the sum of the squared diﬀ erences between 
the predicted and Weibull survival probabilities.55,56 
Uncertainty in their estimates for this component was 
approximated by assuming a coeﬃ  cient of variation of 
0·05 for each mortality rate. To better characterise 
uncertainty in the progression and death rates, we 
systematically reviewed the literature on mortality 
without ART. We searched terms related to pre-ART or 
ART-naive survival since seroconversion—exact search 
terms are in the appendix (p 132). After screening, we 
identiﬁ ed 13 cohort studies that included the cohorts 
used by UNAIDS from which we extracted survival at 
Women (time since initiation) Men (time since initiation)
0–6 months 7–12 months 13–24 months 0–6 months 7–12 months 13–24 months
<50 CD4 cells per μL 40·6 (20·4–71·5) 8·9 (6·0–13·4) 4·0 (2·7–5·7) 53·1 (26·5–93·5) 11·6 (7·9–17·5) 5·2 (3·6–7·5)
50–99 CD4 cells per μL 17·4 (12·2–25·0) 6·5 (5·0–8·4) 3·0 (2·3–3·9) 22·8 (16·2–32·4) 8·6 (6·5–11·2) 3·9 (3·0–5·1)
100–199 CD4 cells per μL 14·1 (10·4–18·4) 5·7 (4·4–7·2) 2·6 (2·0–3·3) 18·4 (13·6–24·2) 7·4 (5·8–9·5) 3·4 (2·6–4·3)
200–249 CD4 cells per μL 12·5 (8·9–16·6) 5·1 (3·8–6·5) 2·4 (1·8–3·1) 16·3 (11·6–21·7) 6·6 (4·9–8·6) 3·1 (2·3–4·0)
250–349 CD4 cells per μL 10·7 (7·0–14·8) 4·4 (3·0–6·0) 2·0 (1·4–2·7) 14·0 (9·3–19·4) 5·7 (3·9–7·8) 2·6 (1·8–3·6)
350–499 CD4 cells per μL 8·1 (4·7–12·0) 3·1 (1·8–4·8) 1·4 (0·7–2·2) 10·5 (6·0–15·8) 4·1 (2·4–6·2) 1·8 (1·0–2·8)
≥500 CD4 cells per μL 6·3 (0·9–11·0) 2·3 (0·1–4·4) 0·9 (0·0–2·0) 8·2 (1·2–14·7) 3·0 (0·1–5·7) 1·2 (0·0–2·6)
Data in parentheses are 95% uncertainty intervals.
Table 1: HIV-speciﬁ c mortality rates for adults aged 25–34 years on antiretroviral therapy in sub-Saharan Africa, by time since initiation, sex, and initial 
CD4 count (per 100 person-years)
Figure 2: HIV relative survival after seroconversion for male and female individuals aged 25–34 years based 
on the analysis of 13 ART-naive cohort studies
Solid lines show means; shaded area shows 95% uncertainty intervals (uncertainty intervals not available for 
UNAIDS data). ART=antiretroviral therapy.
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each 1-year point after infection. We modelled the logit 
of the conditional probability of death between years in 
these studies using the following formula:
logit (mijk) =   0 + ∑ + ∑ + uk +1iβ β β εi 2jtj ijk
4
i=1
12
a
j=1
In the formula, m is conditional probability of death from 
year t j to tj+1, ai is an indicator variable for age group at 
seroconversion (15–24 years, 25–34 years, 35–44 years, and 
45 years or older), tj is an indicator variable of year since 
seroconversion, and uκ is a study-level random eﬀ ect. By 
sampling the variance-covariance matrix of the regression 
coeﬃ  cients and the study level random eﬀ ect, we generated 
1000 survival curves for each age group that capture the 
systematic variation in survival across the available studies 
(ﬁ gure 2, appendix p 18). Across all age groups, median 
survival ranges from 3·6 years to 29·5 years. For each of 
the 1000 survival curves, we use the UNAIDS optimisation 
framework to ﬁ nd a set of progression and death rates that 
minimises the sum of the squared errors for the ﬁ t to the 
survival curve. For the death rates generated from the 
optimisation, the coeﬃ  cient of variation across the set of 
1000 is 0·44–1·00 depending on the age-group, which is 
substantially higher than the UNAIDS assumption of 0·05.
Second, for mortality on ART, UNAIDS used data from 
ﬁ ve regional cohorts from the IeDEA network to directly 
estimate death rates by age, sex, and CD4 count, which 
have been used as the default for all countries in a region.57,58 
Through their country consultation process some of these 
defaults have been modiﬁ ed. For example, Myanmar 
assumes a constant mortality rate by initial CD4 group, 
without any variation by age, sex, or time on treatment. To 
better characterise real variation in the death rates on ART 
across programmes, we searched the published literature. 
Using the terms “HIV”, “mortality”, and “antiretroviral 
therapy” we identiﬁ ed 4996 titles. Screening the abstracts 
and papers yielded 102 total papers for extraction (appendix 
p 133). These included mortality and loss to follow-up data 
for 80 cohorts, age hazard ratios for 40 cohorts, and sex 
hazard ratios for 86 cohorts. We corrected reported 
probabilities of death for loss to follow-up using an update 
of the approach developed by Verguet and colleagues.59 
Verguet and colleagues used tracing and follow-up studies 
to empirically estimate the relation between death in loss to 
follow-up and the rate of loss to follow-up. We used 
DisMod-MR 2.0 to do a meta-regression of the data for on-
ART mortality by initial CD4 count separately for high-
income countries, GBD developing countries outside of 
sub-Saharan Africa, and sub-Saharan Africa (appendix p 7). 
We meta-analysed region-speciﬁ c age hazard ratios using 
DisMod-MR 2.0, and region-speciﬁ c sex hazard ratios 
using the Stata command metan. The age and sex hazard 
ratios were applied to the CD4-speciﬁ c mortality rates, 
accounting for the distribution of ages and sexes in the 
mortality data. We used 1000 draws from the posterior 
distribution for each age, sex, and CD4 category for 
conditional probabilities of death for 0–6 months, 
7–12 months, and 13–24 months after initiation of ART as 
inputs to Spectrum. Table 1 shows HIV-speciﬁ c mortality 
rates for people aged 25–34 years on ART in sub-Saharan 
Africa (see appendix pp 136–38 for HIV-speciﬁ c mortality 
for other age groups and regions).
Third, to better capture variation in the age-pattern of 
incidence, we used the UNAIDS distributions of the 
relative incidence by age prepared for UNAIDS based on 
selected cohort studies. To capture the possibility that 
there is greater variation across countries in the age 
incidence pattern than in these studies, we increased the 
uncertainty ranges by an arbitrary 50%.
Fourth, for all other input parameters including the 
number of individuals receiving ART, prevention of 
Figure 3: HIV deaths in Thailand (A) and Russia (B) by age in 2005 for both sexes combined
Data are for vital registration deaths assigned to HIV (red), deaths coded to garbage codes redistributed to HIV (blue), 
and misclassiﬁ ed deaths reassigned to HIV (green). The height of the bar is the ﬁ nal number of deaths in each age group.
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mother-to-child transmission (PMTCT), or co-trimoxazole 
prophylaxis, we randomly sampled a uniform distribution 
from 0·9 to 1·1 and used the draw to adjust each 
parameter. For the sex ratio of incidence, we sampled a 
wider but arbitrary range from 0·8 to 1·2, because the 
demographic data in many generalised epidemics 
indicate that there is less of a diﬀ erence between the 
sexes than seen in the population prevalence surveys.
Generalised epidemics
UNAIDS identiﬁ ed 41 countries as generalised 
epidemics; this distinction is important because for these 
epidemics the primary sources of information about 
prevalence come from antenatal clinic serosurveillance 
and household surveys. In addition to these 41 countries, 
we have included in this category Senegal, Niger, and 
India because of the availability of population-based 
surveys. Prevalence data from countries with generalised 
epidemics has been analysed by UNAIDS using EPP to 
generate 1000 samples of incidence curves for people 
aged 15–49 years consistent with the prevalence data. For 
each of these 1000 incidence curves, we randomly 
sampled the parameter distributions for all input 
parameters ten times to generate 10 000 epidemic curves 
of incidence, prevalence, and death by age and sex. The 
selection of 10 000 iterations was based on testing that it 
would ensure stable uncertainty intervals. Some of these 
10 000 death curves exceed in one or more age-sex-year 
groups the estimate of all-cause mortality based on 
demographic sources. Because the demographic 
estimates of all-cause mortality are based on substantial 
empirical data, these HIV epidemic curves are unlikely 
Figure 5: Bayesian meta-regression estimates for tuberculosis prevalence (A), incidence (B), remission (C), excess mortality (D), and cause-speciﬁ c mortality 
(E) for male individuals in Kenya, 2013
For each observation in black, the length of the horizontal bar refers to the age interval of the observation and the length of the verticle bar refers to the uncertainty 
interval. To stabilise estimates, all data from 2008 to 2013 are included.
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to represent reality. These mismatches occur more often 
in southern Africa. We identiﬁ ed the 250 modiﬁ ed 
Spectrum curves and all-cause mortality curves that are 
most consistent with each other. We deﬁ ne a loss 
function using the following formula:
er = ∑∑∑ max(0,mHIV —0·8*mr,t,a,sr,t,a,s
t a s
all–cause)
For run r of a given country, excess mortality, e, is equal 
to the sum of all non-zero diﬀ erences between HIV 
mortality, mHIV, and 0·8 times a randomly selected all-
cause mortality draw, mall-cause , across all year-age-sex 
combinations (t, a, and s, respectively). We compared the 
Spectrum estimates to 0·8 times the all-cause estimates 
because this is the highest recorded fraction of deaths in 
any age-group in any country’s cause of death data due to 
HIV. We randomly paired each of the 10 000 modiﬁ ed 
spectrum outputs with one of the 1000 all-cause mortality 
curves generated from the demographic analysis. The 
250 pairs that minimised the loss function were selected. 
When more than 250 have a loss function equal to zero, 
we randomly chose among this set. We resampled the 
250 draws to 1000; 250 are used with resampling for 
computational convenience. The appendix (pp 18–20) 
shows mortality at ages 15–59 years from the full set of 
10 000 modiﬁ ed spectrum models and the subset that is 
selected through the matching process for Uganda, 
South Africa, and Ghana. Demographic data matching 
selects in South Africa epidemic curves that are at the 
low end of the distribution with longer median survival; 
in Uganda this eﬀ ect is slightly less pronounced and in 
Ghana pre-matching and post-matching were identical.
Concentrated epidemics with vital registration data
UNAIDS estimates for concentrated epidemics depend 
critically on two inputs: ﬁ rst, the assessment of prevalence 
of HIV in high-risk groups (people who inject drugs, men 
who have sex with men, and female sex workers) for 
which there is much information in many countries;60–72 
and second, assumptions on the percentage of the 
population in high-risk groups. Although there is 
guidance on measurement,73 real data in most countries 
are limited. In many countries, UNAIDS estimates are 
based on local opinion. Resulting assumptions have been 
highly variable across countries. For example, Uruguay 
deﬁ nes 4·5% of its population as men who have sex with 
men while neighbouring Argentina deﬁ nes only 1% of its 
population as men who have sex with men. An alternative 
source in many countries is cause of death data from 
national vital registration systems. To track the epidemic 
using cause of death data can require up to three important 
adjustments. First, in some middle-income countries, 
vital registration is incomplete. Wang and colleagues have 
used death distribution methods43 to assess completeness 
in all countries with vital registration; we have used this 
information to correct upwards incomplete registration. 
Second, a key aspect of the GBD is to redistribute deaths 
that are assigned to immediate or intermediate causes of 
death rather than underlying causes of death (garbage 
codes).74 In addition to garbage codes, because HIV was 
not included in the International Classiﬁ cation of Diseases 
(ICD)-9 until 1986 and not implemented in many 
countries until later, deaths were often assigned to other 
codes such as graft versus host disease or Kaposi’s 
sarcoma. Third, in some places, because of stigma or 
misdiagnosis, HIV deaths can be assigned to other 
underlying causes of death such as tuberculosis, endocrine 
disorders, meningitis, or encephalitis. Birnbaum and 
colleagues developed a method to identify these 
misclassiﬁ ed deaths.75 We applied this method to all 
countries. Misclassiﬁ cation of HIV deaths in Birnbaum 
and colleagues’ method is based on fulﬁ lling three criteria. 
First, the temporal trend for a cause should coincide with 
the HIV epidemic. Second, the pattern of the relative 
death rate by age should shift towards the ages of 
15–49 years during the epidemic years. Third, the temporal 
and age-pattern shifts cannot be explained by other known 
epidemiological trends. Applying these methods, we 
Figure 6: Meta-analysis of published validation studies of verbal autopsy for 
malaria in adults (A) and children (B), both sexes combined
The solid lines show 95% uncertainty intervals (ui); the dotted lines show the 
point estimate of the pooled estimate (the diamond). The age cutoﬀ  for children 
is <15 years.
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transfer deaths from 47 causes in 52 countries. Figure 3 
shows the number of HIV deaths directly coded to HIV, 
the number of deaths re-assigned to HIV from garbage 
code redistribution, and the number of deaths from the 
application of the HIV misclassiﬁ cation method for 
Thailand and Russia. The height of the bar is the ﬁ nal 
number of deaths in each age group.
For countries with corrected vital registration, we 
imputed missing years of data to generate a complete 
time series for HIV from the estimated start year of the 
epidemic using spatial-temporal Gaussian Process 
Regression (ST-GPR).43,76,77 ST-GPR using a linear mean 
function and a Matern covariance has been widely used 
for time-series estimation in global health descriptive 
studies such as for tobacco prevalence, obesity prevalence, 
or child and adult mortality. To generate an internally 
consistent set of incidence, prevalence, and death curves 
with uncertainty, we used the observed HIV death 
numbers to calibrate the modiﬁ ed Spectrum models. 
First, we started with a modiﬁ ed Spectrum model 
constructed based on the analysis of high-risk groups—
where no high-risk group analysis was available we used 
a regional default model. Second, for each of the 
1000 draws from this model, we modiﬁ ed the incidence 
at time t by the ratio of observed deaths to modiﬁ ed 
spectrum deaths at time t+λ, where λ is the lag between 
incidence and death. We drew from a distribution of lags 
of 10–15 years to generate 6000 diﬀ erent adjusted 
incidence curves. For incidence for the last λ time 
periods, we drew a random weight between 0 and 1 from 
a uniform distribution and used it to calculate a weighted 
average of adjusted incidence in year t + λ and unadjusted 
incidence multiplied by the deaths ratio in year t + λ. 
Using these modiﬁ ed incidence curves, we reran the 
modiﬁ ed Spectrum generating 6000 possible epidemic 
curves. As a ﬁ nal step, for each of these 6000 we 
computed the mean squared error of predicted deaths 
compared with observed deaths. The 1000 curves with 
the lowest mean squared error were selected as the ﬁ nal 
set for analysis. Figure 4 shows the results of this process 
for Panama and the comparison with the UNAIDS high-
risk group analysis; the corrected vital registration data 
suggest a much smaller epidemic with diﬀ erent timing.
Concentrated epidemics with high-risk group analysis and 
insuﬃ  cient or no cause of death data
There were 17 countries with concentrated epidemics 
where we had no or insuﬃ  cient vital registration or verbal 
autopsy data to inform our cause of death analysis. For 
these countries we ran modiﬁ ed Spectrum to output 1000 
draws of incidence, randomly selecting 1000 time series 
of the death ratios generated in the process described 
above, and multiplying each draw of incidence by the 
selected set of ratios. We selected incidence adjustments 
only for countries with a cumulative number of HIV 
deaths greater than 5000 to avoid exaggerated stochastic 
variation in the ratios. We then derived estimates of 
mortality by running the adjusted incidence curves back 
through Spectrum. By using random draws across these 
countries, the average correction and uncertainty in this 
correction is propagated into the corrections for these 
countries with little or no data.
Concentrated epidemics with no high-risk group analysis and 
no cause of death data 
For 13 countries (Andorra, United Arab Emirates, Iraq, 
Federated States of Micronesia, Libya, Marshall Islands, 
Figure 7: Global HIV incidence (A), prevalence (B), and mortality (C), 1990–2013, for all ages and both 
sexes combined
Shaded areas are 95% uncertainty intervals.
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State of Palestine, Solomon Islands, Timor-Leste, 
Vanuatu, Samoa, Tonga, and North Korea) no analysis of 
high-risk groups has been undertaken and no cause of 
death data are available. For these countries, we picked 
regional or neighbouring countries to approximate the 
death rate. We used these approximate death rates to ﬁ t a 
Spectrum model. In all these cases, the number of 
estimated deaths was less than 250 per year.
Comparisons to prevalence survey data
As a form of empirical validation, we compared our ﬁ nal 
estimated prevalence with national population-based 
surveys collected through the Demographic and Health 
Surveys, AIDS Indicator Surveys, the 2005–2006 Indian 
National Family Health Survey, and the 2012 South African 
National HIV Prevalence, Incidence, and Behaviour 
Survey.78–80 In total, we extracted data from 46 surveys in 
35 countries between 2001 and 2012. These surveys had 
response rates for HIV testing ranging from 63% in male 
respondendts in Malawi in 2004 to 98% for both sexes in 
Rwanda in 2011; median response rate was 85%. These 
comparisons are made for adults aged 15–49 by sex and 
5-year age groups. We tested for signiﬁ cant diﬀ erences in 
means (p<0·05) for each estimate and compared the 
distribution of survey estimates to GBD and UNAIDS via 
ordinary least squares (OLS) regression with robust 
standard errors to account for heteroscedasticity.
HIV intervention counterfactual scenario
Spectrum uses as inputs the numbers reported by 
governments of individuals receiving PMTCT, co-
trimoxazole, and child and adult ART. To help understand 
the role of interventions including ART, PMTCT, and co-
trimoxazole prophylaxis, we have rerun the ﬁ nal 1000 
modiﬁ ed Spectrum models for each country using a no 
intervention counterfactual scenario. We turn all HIV-
related interventions to zero including ART, PMTCT, and 
co-trimoxazole prophylaxis for all years. We compared the 
number of deaths and person-years lived each year from 
the base case to this counterfactual to assess the changes 
due to intervention. Using published results on DAH for 
HIV, we computed the ratio of DAH to years of life saved.
Tuberculosis
For the GBD 2010, we estimated tuberculosis mortality 
and then estimated population incidence through mixed 
eﬀ ects regression as a function of tuberculosis mortality, 
case-notiﬁ cations, and an indicator variable for health 
system access used as a proxy for completeness of 
registration. For GBD 2013, we have shifted to using all 
available data for diﬀ erent outcomes and simultaneously 
estimating incidence, remission, excess mortality, 
prevalence, and cause-speciﬁ c mortality using the GBD 
Bayesian meta-regression environment, DisMod-MR 2.0 
(appendix p 11). There are four potential sources of 
information to estimate national levels and trends for 
tuberculosis in a country: annual case notiﬁ cations, expert 
judgment on the case-detection rate, prevalence surveys, 
and cause of death data. Additionally, to facilitate 
convergence of the meta-regression, estimated excess 
mortality and remission rates have been used. The 
approach is predicated on the principle that incidence, 
prevalence, and mortality might be measured imperfectly 
and that a statistical triangulation of all the sources for a 
country will provide a more robust assessment. Our meta-
regression analysis was done for all forms of tuberculosis. 
As a ﬁ nal step we estimated incidence, prevalence, and 
death in individuals who are HIV-positive and those who 
are HIV-negative. We explain in more detail the preparation 
of each of these sources.
Adjusted case notiﬁ cations and incidence
Case deﬁ nitions for tuberculosis since 1995 have been 
standardised by WHO and widely applied. Countries have 
Figure 8: Global age-sex distribution of new HIV infections (A) and deaths (B) in 2013
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varied however in the completeness of reporting for 
younger age-groups and some countries have reported only 
pulmonary smear-positive cases for selected years. We use 
the age and sex-speciﬁ c notiﬁ cations in our analysis and 
impute the missing age-groups for three forms of 
tuberculosis notiﬁ cations (pulmonary smear-positive, 
pulmonary smear-negative, or extra-pulmonary) in two 
steps. First, for each country-sex category with missing age-
groups in some years, we imputed the missing values by 
regressing the log of the case notiﬁ cation rate on dummy 
variables for 5-year age-groups and random eﬀ ects on year 
using all the data for a country over the interval 1990–2013.
Second, we estimated the relation between all forms of 
tuberculosis and smear-positive tuberculosis and the 
relation between all forms and bacteriologically positive 
tuberculosis. Using country-years with complete 
Age–standardised rates in 2013
(per 100 000 population)
Annualised rate of change (%)
1990–2000 2000–2013
Incidence Prevalence Mortality Incidence Prevalence Mortality Incidence Prevalence Mortality
Worldwide 24·84
(23·10 to 28·26)
400·98
(385·51 to 435·10)
18·51
(17·38 to 20·46)
1·27
(0·24 to 2·16)
8·87
(8·36 to 9·52)
13·62
(11·93 to 15·38)
–3·92
(–4·50 to –3·15)
–0·20
(–0·42 to 0·05)
–1·54
(–2·36 to –0·59)
High-income 
Asia Paciﬁ c
0·49
(0·28 to 0·70)
7·22
(4·81 to 9·97)
0·10
(0·08 to 0·13)
7·74
(3·65 to 13·26)
6·94
(5·12 to 9·46)
0·77
(–1·11 to 2·92)
–1·55
(–5·91 to 1·57)
6·29
(4·49 to 8·22)
1·13
(–0·55 to 3·20)
Central Asia 7·02
(3·62 to 15·56)
61·98
(38·09 to 105·12)
2·67
(1·52 to 4·08)
8·17
(–3·90 to 19·78)
13·11
(1·09 to 24·09)
21·91
(9·43 to 33·39)
4·18
(–2·22 to 12·58)
5·46
(1·76 to 9·62)
2·65
(–2·01 to 5·83)
East Asia 2·28
(1·31 to 4·09)
26·37
(14·36 to 41·32)
0·77
(0·60 to 1·05)
38·86
(27·75 to 62·64)
41·29
(30·82 to 62·45)
45·26
(29·11 to 70·18)
1·41
(–3·60 to 6·83)
8·07
(4·79 to 11·46)
6·09
(2·91 to 10·38)
South Asia 2·69
(0·85 to 5·51)
93·97
(84·36 to 112·06)
5·42
(4·43 to 7·18)
–9·72
(–15·85 to –5·81)
3·91
(1·89 to 5·98)
13·67
(7·68 to 23·47)
–13·93
(–19·71 to –8·09)
–7·85
(–8·67 to –6·64)
–11·58
(–14·45 to –7·11)
Southeast Asia 13·88
(6·66 to 41·04)
176·39
(113·22 to 421·49)
7·54
(3·90 to 23·55)
–10·46
(–15·54 to –4·52)
8·07
(5·78 to 12·44)
29·51
(25·47 to 33·97)
1·29
(–2·74 to 7·36)
0·97
(–0·78 to 3·51)
–3·87
(–6·62 to 1·36)
Australasia 1·50
(0·81 to 2·32)
35·09
(22·80 to 50·24)
0·37
(0·26 to 0·53)
–7·07
(–11·53 to –3·51)
–1·86
(–3·67 to –0·18)
–11·88
(–14·40 to –9·10)
0·41
(–1·27 to 2·85)
1·07
(–0·53 to 2·49)
–4·51
(–6·49 to –2·60)
Caribbean 32·24
(25·95 to 39·68)
497·47
(450·24 to 551·29)
23·30
(19·26 to 29·15)
–6·32
(–8·01 to –4·81)
1·07
(–0·46 to 3·04)
9·02
(4·68 to 12·88)
–2·93
(–4·21 to –1·46)
–0·83
(–1·46 to –0·25)
–6·04
(–6·91 to –5·03)
Central Europe 0·95
(0·71 to 1·23)
16·62
(13·41 to 20·11)
0·44
(0·37 to 0·51)
1·29
(–1·78 to 4·40)
8·90
(6·61 to 11·36)
8·06
(6·44 to 10·09)
–0·55
(–3·44 to 2·08)
2·37
(1·20 to 3·44)
0·19
(–1·28 to 1·41)
Eastern Europe 22·58
(16·56 to 31·65)
263·86
(209·53 to 347·22)
11·14
(8·75 to 14·14)
25·17
(18·06 to 34·84)
18·47
(14·57 to 24·08)
13·07
(9·88 to 16·41)
–1·53
(–3·75 to 0·86)
4·75
(3·18 to 6·14)
8·51
(6·41 to 10·74)
Western Europe 3·26
(2·56 to 4·22)
80·97
(66·16 to 99·08)
1·06
(0·90 to 1·24)
–9·15
(–14·34 to –5·01)
0·92
(–0·14 to 2·04)
–6·75
(–8·06 to –5·34)
0·05
(–1·77 to 2·05)
0·60
(–0·21 to 1·62)
–3·59
(–4·72 to –2·25)
Andean Latin 
America
7·96
(4·64 to 16·84)
106·52
(76·06 to 171·80)
3·92
(2·40 to 9·39)
1·91
(–16·44 to 14·95)
11·70
(2·21 to 21·36)
19·73
(11·89 to 28·79)
–1·09
(–6·07 to 4·63)
1·15
(–1·96 to 4·60)
–3·52
(–6·58 to 0·62)
Central 
Latin America
9·43
(7·48 to 11·55)
139·92
(118·12 to 167·80)
4·08
(3·13 to 6·16)
–2·00
(–8·23 to 1·40)
7·04
(3·66 to 9·32)
13·13
(10·27 to 16·05)
–0·64
(–1·81 to 0·37)
0·99
(–1·33 to 2·31)
–5·46
(–7·10 to –3·86)
Southern 
Latin America
10·11
(7·11 to 14·94)
173·57
(144·31 to 210·86)
3·12
(2·23 to 4·10)
–0·75
(–4·84 to 3·85)
8·44
(5·39 to 12·40)
10·00
(6·17 to 13·76)
–0·24
(–3·40 to 3·08)
2·60
(1·08 to 3·97)
–2·76
(–5·37 to –0·65)
Tropical 
Latin America
11·64
(8·93 to 15·83)
188·35
(125·90 to 244·16)
4·83
(3·83 to 6·09)
–7·15
(–10·27 to –3·64)
2·20
(0·13 to 4·56)
1·09
(–2·41 to 6·19)
0·37
(–1·16 to 2·50)
1·10
(–0·25 to 2·23)
–2·20
(–4·57 to 0·01)
North Africa and 
Middle East
2·84
(1·93 to 4·93)
26·45
(21·31 to 39·26)
1·66
(1·26 to 2·39)
11·52
(0·35 to 25·42)
16·98
(7·18 to 30·42)
20·66
(9·81 to 35·43)
–0·35
(–4·01 to 5·02)
1·94
(–0·71 to 5·64)
3·05
(–0·99 to 7·85)
High–income 
North America
7·43
(3·46 to 17·16)
135·49
(78·21 to 220·57)
2·65
(1·68 to 3·69)
–8·87
(–13·56 to –3·10)
–3·31
(–6·16 to –1·52)
–10·20
(–13·49 to –7·99)
2·01
(–3·23 to 9·49)
1·24
(–1·09 to 4·97)
–2·89
(–5·95 to –0·10)
Oceania 16·09
(11·07 to 22·43)
341·52
(287·06 to 403·52)
18·80
(13·86 to 25·16)
15·64
(5·25 to 27·08)
23·43
(17·21 to 30·47)
31·68
(27·45 to 36·49)
–9·47
(–11·74 to –7·34)
0·30
(–2·04 to 3·13)
1·21
(–3·80 to 6·92)
Central sub-
Saharan Africa
94·53
(78·72 to 113·99)
1328·37
(1222·40 to 1439·78)
94·45
(81·17 to 111·04)
–0·25
(–1·66 to 0·93)
2·92
(1·96 to 3·97)
5·71
(3·57 to 8·17)
–3·89
(–5·15 to –2·60)
–1·43
(–2·09 to –0·78)
–2·42
(–3·47 to –1·14)
Eastern sub-
Saharan Africa
177·08
(163·51 to 191·29)
3416·89
(3249·05 to 3609·25)
164·58
(154·75 to 175·06)
–3·87
(–4·99 to –2·81)
5·92
(5·27 to 6·51)
14·50
(12·89 to 16·00)
–4·40
(–5·14 to –3·65)
–1·74
(–1·98 to –1·51)
–3·78
(–4·82 to –2·65)
Southern sub-
Saharan Africa
647·13
(606·40 to 693·70)
11 850·47
(11 368·38 to 12 327·29)
511·41
(467·65 to 556·63)
10·60
(9·80 to 11·47)
21·69
(21·08 to 22·58)
31·17
(28·62 to 33·63)
–4·58
(–5·16 to –4·00)
1·13
(0·90 to 1·35)
3·41
(1·54 to 4·88)
Western sub-
Saharan Africa
90·89
(77·20 to 107·09)
1833·57
(1692·97 to 1999·25)
114·36
(103·20 to 127·44)
5·79
(3·88 to 8·08)
13·12
(11·69 to 14·69)
18·75
(16·65 to 21·01)
–7·26
(–8·40 to –6·19)
–0·84
(–1·56 to –0·20)
0·82
(–0·38 to 2·01)
Data in parentheses are 95% uncertainty intervals.
Table 2: Age-standardised HIV/AIDS incidence, prevalence, and mortality rates, and annualised rates of change for both sexes for 21 Global Burden of Disease regions
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Persian Gulf
<0·7
0·7 to <1·8
1·8 to <4·7
4·7 to <8·9
8·9 to <15
15 to <36
36 to <120
120 to <348
348 to <572
≥572
Incidence per 100 000 population
<9·2
9·2 to <25
25 to <57
57 to <129
129 to <221
221 to <722
722 to <2292
2292 to <7734
7734 to <12 133
≥12 133
Prevalence per 100 000 population
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Figure 9: Age-standardised HIV incidence (A) and prevalence (B) in 2013, both sexes
ATG=Antigua and Barbuda. VCT=Saint Vincent and the Grenadines. Isl=Islands. FSM=Federated States of Micronesia. LCA=Saint Lucia. TTO=Trinidad and Tobago. TLS=Timor-Leste.
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notiﬁ cations (all three forms), we used a compositional 
analysis model to simultaneously estimate the fraction of 
cases due to all three forms as a function of dummy 
variables for 5-year age-groups and sex and the smear-
positive tuberculosis rate. This regression was used to 
impute missing values for pulmonary smear-negative 
and extra-pulmonary cases. Because of substantial 
variation in the diagnostic rates for extrapulmonary 
tuberculosis and the potential for misclassiﬁ cation, we 
used the predicted values for extrapulmonary cases for all 
countries from the regression.
At the country-level several smear-unknown and relapsed 
cases are recorded that are not captured in the age-speciﬁ c 
and sex-speciﬁ c notiﬁ cations. We used the relation 
between these forms and pulmonary smear-positive cases 
in the country-level data to inﬂ ate the adjusted age-speciﬁ c 
and sex-speciﬁ c pulmonary smear-positive notiﬁ cations 
used in our analysis. Case notiﬁ cations, however, do not 
capture all true incidence cases in the population. Case 
notiﬁ cations can be incomplete because some cases are 
not diagnosed and some diagnosed cases are not reported 
to the national tuberculosis programme. Population-based 
incidence studies for tuberculosis based on active 
surveillance are rare and have not been done at the national 
level.81 In the absence of direct measurement of true 
incidence, the case detection rate must be approximated. 
Since 2008, WHO has been consulting with national 
tuberculosis programme managers in 96 countries to 
collect expert opinion on the case detection rate including 
some notion of subjective uncertainty.82 For the remaining 
countries, case-detection estimates are based on the 
judgment of WHO staﬀ . We divided adjusted case 
notiﬁ cations by the estimated case detection rate to 
generate the incidence inputs used for DisMod-MR 2.0. 
We expanded the subjective uncertainty intervals reported 
so they are at a minimum plus or minus 20% from the 
estimated values or for values less than 20% we assume 
the standard error is half the midpoint estimate.
Tuberculosis prevalence surveys
Prevalence surveys have been periodically undertaken in a 
few countries such as South Korea and China. WHO 
standardised the protocol and the Global Fund to Fight 
AIDS, Tuberculosis and Malaria has helped fund 24 
surveys in 21 countries between 2002 and 2013 with 12 
additional surveys in eight new countries planned.82–84 
Because the prevalence rates for tuberculosis are often 
comparatively low (eg, 200 per 100 000 population), 
prevalence surveys need to be large to provide breakdowns 
by age and sex. On the basis of the literature and country 
reports, we have identiﬁ ed 27 national and 24 subnational 
prevalence surveys in 24 countries spanning the time 
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Figure 10: Age-standardised HIV mortality in 2013, both sexes
ATG=Antigua and Barbuda. VCT=Saint Vincent and the Grenadines. Isl=Islands. FSM=Federated States of Micronesia. LCA=Saint Lucia. TTO=Trinidad and Tobago. TLS=Timor-Leste.
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All ages incidence and deaths (2013) Annualised rate of change (%)
Male population Female population Total 1990–2000 2000–13
Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths
Worldwide 924 776
(845 603 to 
1 104 526)
723 124
(670 708 to 
831 754)
922 869
(863 238 to 
1 007 549)
617 850
(570 414 to 
677 695)
1 847 645
(1 719 830 to 
2 101 652)
1 340 974
(1 257 838 to 
1 482 611)
1·27
(0·24 to 
2·16)
13·62
(11·93 to 
15·38)
–3·92
(–4·50 to 
–3·15)
–1·54
(–2·36 to 
–0·59)
Developed countries 74 405
(57 060 to 
104 422)
35 884
(29 743 to 
43 334)
20 947
(15 405 to 
29 844)
8746
(6465 to 
11 375)
95 352
(72 788 to 
132 862)
44 630
(36 750 to 
53 676)
1·53
(–1·30 to 
4·82)
–5·46
(–7·13 to 
–4·17)
–0·35
(–2·27 to 
2·45)
2·18
(0·76 to 
3·83)
Developing countries 850 371
(777 712 to 
1 030 189)
687 240
(636 836 to 
792 586)
901 923
(842 259 to 
987 825)
609 104
(562 000 to 
668 733)
1 752 294
(1 631 535 to 
2 014 476)
1 296 344
(1 214 834 to 
1 435 882)
0·74
(–0·35 to 
1·70)
15·07
(12·86 to 
17·34)
–4·32
(–4·92 to 
–3·48)
–2·01
(–2·87 to 
–1·00)
High-income 
Asia Paciﬁ c
590
(352 to 847)
149
(120 to 185)
268
(144 to 407)
58
(41 to 104)
857
(493 to 1228)
207
(164 to 270)
7·74
(3·65 to 
13·26)
0·77
(–1·11 to 
2·92)
–1·55
(–5·91 to 
1·57)
1·13
(–0·55 to 
3·20)
Brunei 43
(32 to 57)
32
(27 to 40)
7
(5 to 11)
2
(1 to 4)
50
(37 to 68)
35
(29 to 44)
3·21
(–10·55 to 
12·48)
21·17
(14·06 to 
29·36)
0·02
(–2·14 to 
2·46)
–0·61
(–2·49 to 
1·95)
Japan 153
(86 to 230)
45
(30 to 67)
55
(31 to 82)
17
(11 to 24)
208
(120 to 308)
61
(43 to 90)
3·28
(–0·33 to 
7·00)
–2·54
(–4·84 to 
–0·11)
–0·54
(–4·55 to 
1·91)
–2·26
(–4·86 to 
–0·13)
Singapore 52
(23 to 110)
16
(9 to 30)
26
(11 to 56)
7
(4 to 12)
78
(35 to 164)
23
(14 to 42)
–13·07
(–20·83 to 
–1·69)
12·38
(5·24 to 
20·14)
3·37
(–4·69 to 
11·26)
–4·29
(–8·00 to 
–0·43)
South Korea 342
(118 to 591)
56
(37 to 82)
179
(62 to 308)
32
(19 to 77)
522
(184 to 874)
88
(57 to 148)
15·87
(9·91 to 
26·23)
–3·51
(–8·50 to 
2·60)
–3·46
(–10·76 to 
0·83)
6·76
(2·61 to 
11·41)
Central Asia 4490
(2252 to
10 200)
1711
(965 to
2561)
1784
(913 to
3521)
497
(265 to
801)
6274
(3253 to
13 832)
2207
(1270 to
3346)
8·17
(–3·90 to 
19·78)
21·91
(9·43 to 
33·39)
4·18
(–2·22 to 
12·58)
2·65
(–2·01 to 
5·83)
Armenia 20
(9 to 42)
6
(3 to 10)
5
(2 to 10)
1
(0 to 2)
25
(11 to 51)
7
(4 to 12)
87·64
(54·77 to 
144·28)
89·27
(52·19 to 
137·94)
–1·36
(–10·11 to 
4·10)
14·06
(7·12 to 
24·32)
Azerbaijan 315
(141 to 603)
161
(45 to 320)
83
(37 to 158)
32
(9 to 78)
398
(177 to 764)
193
(53 to 395)
16·42
(4·71 to 
36·74)
22·22
(7·00 to 
33·51)
3·19
(–3·81 to 
8·73)
8·45
(0·42 to 
15·03)
Georgia 45
(22 to 74)
8
(6 to 10)
23
(11 to 38)
3
(2 to 4)
68
(34 to 110)
11
(8 to 14)
34·85
(24·05 to 
45·34)
35·00
(21·69 to 
50·13)
8·01
(3·08 to 
13·16)
11·71
(8·46 to 
14·92)
Kazakhstan 2177
(510 to 7608)
899
(212 to 1708)
633
(141 to 2224)
173
(30 to 429)
2810
(647 to 9972)
1072
(240 to 2118)
10·31
(–26·44 to 
45·69)
28·30
(5·67 to 
85·36)
5·73
(–7·49 to 
27·27)
3·14
(–8·16 to 
8·76)
Kyrgyzstan 683
(115 to 1720)
214
(60 to 379)
195
(33 to 511)
43
(6 to 93)
878
(151 to 2218)
257
(68 to 469)
–2·16
(–16·93 to 
16·12)
25·71
(12·31 to 
38·25)
11·06
(0·14 to 
20·67)
3·14
(–6·69 to 
10·25)
Mongolia 4
(0 to 20)
1
(0 to 4)
2
(0 to 9)
0
(0 to 1)
6
(0 to 29)
1
(0 to 6)
–27·80
(–44·31 to 
–6·63)
0·06
(–13·83 to 
15·83)
30·42
(1·12 to 
52·69)
–7·87
(–22·36 to 
9·43)
Tajikistan 391
(72 to 989)
108
(18 to 247)
455
(81 to 1139)
145
(14 to 290)
846
(154 to 2119)
253
(33 to 537)
10·63
(–23·93 to 
51·46)
19·30
(–4·33 to 
63·17)
8·54
(–3·57 to 
23·08)
4·76
(–10·22 to 
17·68)
Turkmenistan 338
(76 to 1209)
114
(49 to 213)
128
(28 to 461)
34
(15 to 65)
466
(103 to 1667)
148
(65 to 272)
5·29
(–29·36 to 
34·92)
21·57
(–2·08 to 
68·63)
6·55
(–5·74 to 
27·61)
3·16
(–3·99 to 
7·62)
Uzbekistan 518
(297 to 789)
200
(115 to 348)
259
(152 to 403)
66
(36 to 130)
777
(458 to 1188)
266
(156 to 466)
11·31
(–0·46 to 
23·84)
31·77
(21·98 to 
41·37)
–3·01
(–7·00 to 
0·37)
–3·85
(–8·97 to 
0·63)
East Asia 25 342
(14 456 to 
45 002)
9317
(7316 to 
12 472)
10 968
(6165 to 
19 647)
3259
(2213 to
4653)
36 310
(20 768 to 
64 990)
12 575
(9827 to 
17 026)
38·86
(27·75 to 
62·64)
45·26
(29·11 to 
70·18)
1·41
(–3·60 to 
6·83)
6·09
(2·91 to 
10·38)
China 24 843
(13 863 to 
44 316)
8988
(7010 to
12 114)
10 822
(6058 to 
19 487)
3157
(2118 to
4554)
35 665
(20 128 to 
64 616)
12 145
(9418 to 
16 555)
38·58
(27·80 to 
49·41)
45·85
(28·95 to 
79·48)
1·47
(–3·62 to 
7·00)
5·99
(2·76 to 
10·39)
(Table 3 continues on next page)
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North Korea 189
(56 to 380)
152
(118 to 194)
91
(29 to 185)
75
(56 to 98)
280
(83 to 565)
227
(179 to 287)
21·59
(12·20 to 
37·57)
33·79
(21·86 to 
53·69)
–1·88
(–12·11 to 
4·93)
8·90
(6·28 to 
12·71)
Taiwan 
(Province of China)
309
(113 to 743)
176
(129 to 246)
55
(20 to 130)
26
(18 to 39)
365
(135 to 873)
203
(148 to 283)
28·85
(16·22 to 
48·47)
35·27
(20·08 to 
55·54)
–1·66
(–12·16 to 
13·51)
10·02
(6·43 to 
15·42)
South Asia 28 607
(9 436 to 
63 683)
52 794
(41 230 to 
70 403)
17 265
(5343 to 
30 460)
30 592
(20 739 to 
41 289)
45 872
(14 702 to 
93 994)
83 387
(68 991 to 
106 495)
–9·72
(–15·85 to 
–5·81)
13·67
(7·68 to 
23·47)
–13·93
(–19·71 to 
–8·09)
–11·58
(–14·45 to 
–7·11)
Afghanistan 325
(40 to 1346)
117
(11 to 597)
127
(15 to 541)
47
(4 to 215)
452
(55 to 1897)
163
(16 to 824)
2·20
(–19·25 to 
18·88)
8·71
(–3·05 to 
28·80)
5·71
(–2·95 to 
16·86)
2·16
(–5·67 to 
9·65)
Bangladesh 710
(459 to 1212)
390
(303 to 505)
431
(272 to 713)
181
(109 to 273)
1141
(754 to 1885)
571
(441 to 753)
12·62
(–20·78 to 
41·01)
59·57
(36·71 to 
81·23)
1·68
(–2·46 to 
6·44)
1·87
(–1·75 to 
6·80)
Bhutan 36
(5 to 168)
20
(3 to 94)
43
(6 to 197)
20
(2 to 101)
79
(11 to 368)
40
(5 to 199)
8·81
(–8·17 to 
21·25)
18·88
(6·58 to 
30·69)
2·90
(–3·96 to 
13·81)
5·11
(–1·62 to 
11·75)
India 18 408
(2247 to 
23 936)
49 345
(38 882 to 
63 680)
12 649
(1845 to 
16 944)
29 318
(20 048 to 
38 653)
31 057
(4091 to 
39 459)
78 662
(66 197 to 
96 173)
–9·78
(–15·95 to 
–5·85)
13·72
(7·78 to 
23·46)
–16·29
(–27·75 to 
–11·94)
–11·84
(–14·55 to 
–7·73)
Nepal 710
(96 to 2864)
1202
(103 to 6065)
372
(51 to 1512)
326
(23 to 2170)
1082
(151 to 4424)
1527
(130 to 8087)
36·93
(13·55 to 
63·73)
30·17
(14·86 to 
46·41)
–12·91
(–20·16 to 
–1·74)
2·47
(–4·47 to 
8·63)
Pakistan 8418
(1124 to 
39 250)
1721
(140 to
7984)
3643
(497 to
15 460)
701
(49 to
3405)
12 061
(1617 to
54 744)
2422
(191 to
11 133)
11·79
(–6·98 to 
25·04)
14·11
(4·32 to 
25·39)
15·09
(6·58 to 
26·35)
11·47
(3·15 to 
19·37)
Southeast Asia 65 708
(32 957 to 
184 964)
38 199
(20 695 to 
113 552)
26 753
(10 929 to 
87 732)
10 141
(4248 to 
36 852)
92 460
(44 216 to 
273 917)
48 340
(24 900 to 
150 426)
–10·46
(–15·54 to 
–4·52)
29·51
(25·47 to 
33·97)
1·29
(–2·74 to 
7·36)
–3·87
(–6·62 to 
1·36)
Cambodia 904
(137 to
4475)
1073
(125 to
6154)
490
(71 to
2349)
330
(40 to
1330)
1394
(208 to
6873)
1403
(168 to
7430)
–7·21
(–25·86 to 
7·49)
34·36
(19·14 to 
48·40)
–7·75
(–15·10 to 
3·78)
–11·46
(–15·95 to 
–5·90)
Indonesia 29 204
(3669 to 
127 307)
9846
(666 to
48 942)
15 954
(2027 to
70 429)
4601
(227 to 
24 839)
45 159
(5646 to 
194 375)
14 446
(912 to
72 555)
0·00
(0·00 to 
0·00)
0·00
(0·00 to 
0·00)
28·07
(13·66 to 
46·43)
87·51
(52·11 to 
113·93)
Laos 576
(83 to 2427)
239
(25 to 1388)
242
(34 to 1061)
80
(7 to 501)
818
(120 to 3481)
320
(32 to 1862)
13·35
(–5·81 to 
27·67)
19·67
(7·19 to 
35·71)
–0·18
(–7·62 to 
10·96)
1·11
(–5·62 to 
8·15)
Malaysia 3070
(2313 to
4137)
1994
(1680 to
2469)
469
(325 to
674)
131
(74 to
226)
3539
(2655 to
4799)
2125
(1774 to
2652)
3·67
(–10·07 to 
12·94)
21·63
(14·52 to 
29·80)
–0·25
(–2·43 to 
2·20)
–0·65
(–2·52 to 
1·91)
Maldives 0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
–9·47
(–14·88 to 
–4·94)
14·92
(10·85 to 
17·60)
–8·71
(–17·42 to 
–1·64)
–6·22
(–11·69 to 
–2·61)
Myanmar 3215
(422 to
18 254)
5831
(635 to
31 666)
924
(119 to
5048)
920
(103 to
5732)
4139
(557 to
23 177)
6751
(743 to 
38 390)
9·78
(–8·01 to 
23·04)
45·14
(31·23 to 
54·70)
–15·43
(–24·74 to 
–3·19)
–6·13
(–11·88 to 
1·03)
Philippines 6590
(3411 to 
11 564)
3607
(2424 to
4613)
2670
(1362 to
4666)
1466
(967 to
1924)
9260
(4907 to
16 077)
5073
(3423 to
6397)
2·00
(–15·41 to 
13·40)
23·37
(11·46 to 
36·25)
2·32
(–2·51 to 
8·42)
1·04
(–2·36 to 
2·86)
Sri Lanka 84
(52 to 135)
43
(32 to 57)
49
(31 to 79)
20
(12 to 29)
133
(82 to 211)
63
(46 to 83)
11·34
(4·50 to 
16·40)
29·55
(26·10 to 
32·38)
–0·15
(–3·60 to 
3·65)
1·04
(–2·02 to 
3·54)
Thailand 8657
(4349 to 
13 097)
9421
(5777 to
15 345)
3879
(1907 to
5996)
2173
(1354 to
3324)
12 536
(6320 to 
18 644)
11 595
(7310 to 
18 164)
–27·50
(–43·89 to 
–17·76)
29·04
(24·91 to 
32·94)
3·21
(–7·02 to 
15·57)
–9·64
(–13·16 to 
–5·95)
(Table 3 continues on next page)
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Timor-Leste 9
(4 to 35)
3
(2 to 6)
5
(2 to 19)
2
(1 to 3)
13
(7 to 54)
5
(4 to 9)
30·46
(16·69 to 
49·60)
39·58
(17·00 to 
61·09)
–1·90
(–7·73 to 
11·22)
10·23
(4·43 to 
50·18)
Vietnam 13 311
(6001 to 
22 013)
6087
(4485 to
8580)
2035
(914 to
3405)
404
(271 to
603)
15 346
(7019 to
25 391)
6492
(4817 to
9107)
26·87
(15·01 to 
36·30)
34·21
(25·75 to 
44·35)
–2·57
(–9·79 to 
2·24)
6·69
(3·36 to 
11·31)
Australasia 392
(211 to 608)
105
(70 to 157)
51
(27 to 79)
15
(10 to 23)
444
(240 to 689)
120
(82 to 174)
–7·07
(–11·53 to 
–3·51)
–11·88
(–14·40 to 
–9·10)
0·41
(–1·27 to 
2·85)
–4·51
(–6·49 to 
–2·60)
Australia 358
(181 to 576)
94
(60 to 146)
45
(22 to 72)
13
(7 to 20)
403
(203 to 645)
107
(70 to 160)
–7·60
(–12·57 to 
–3·82)
–11·94
(–14·74 to 
–8·91)
0·29
(–1·59 to 
2·88)
–4·61
(–6·80 to 
–2·48)
New Zealand 34
(19 to 61)
10
(7 to 15)
7
(3 to 12)
2
(1 to 4)
41
(22 to 73)
13
(8 to 18)
–0·07
(–4·38 to 
5·45)
–11·22
(–13·58 to 
–9·33)
0·95
(–3·48 to 
7·30)
–3·80
(–6·68 to 
–1·05)
Caribbean 7561
(6045 to
9227)
5654
(4692 to
7082)
6961
(5436 to
8854)
4805
(3661 to
6350)
14 521
(11 695 to 
17 898)
10 459
(8670 to 
13 050)
–6·32
(–8·01 to 
–4·81)
9·02
(4·68 to 
12·88)
–2·93
(–4·21 to 
–1·46)
–6·04
(–6·91 to 
–5·03)
Antigua and 
Barbuda
9
(4 to 21)
7
(5 to 9)
4
(2 to 9)
3
(2 to 4)
13
(6 to 29)
10
(8 to 12)
–5·71
(–13·65 to 
4·72)
15·77
(9·28 to 
27·19)
–2·30
(–8·08 to 
6·04)
–4·62
(–7·05 to 
–2·67)
Barbados 49
(33 to 76)
21
(14 to 33)
21
(14 to 33)
6
(4 to 9)
69
(48 to 108)
27
(19 to 40)
–2·18
(–6·56 to 
1·26)
13·21
(11·66 to 
14·86)
–0·14
(–2·54 to 
3·38)
–7·07
(–9·61 to 
–4·41)
Belize 73
(38 to 115)
37
(24 to 50)
45
(23 to 72)
12
(7 to 17)
118
(63 to 188)
49
(32 to 65)
15·27
(5·16 to 
27·29)
35·46
(29·57 to 
42·53)
–5·02
(–10·63 to 
–0·61)
–2·45
(–6·17 to 
0·55)
Cuba 698
(446 to 1003)
186
(146 to 239)
217
(136 to 321)
35
(25 to 50)
916
(585 to 1309)
221
(175 to 284)
8·96
(3·54 to 
12·14)
10·21
(7·74 to 
12·60)
3·26
(0·73 to 
6·30)
–1·61
(–3·64 to 
1·33)
Dominica 5
(2 to 15)
4
(2 to 6)
3
(1 to 8)
2
(1 to 3)
7
(2 to 23)
5
(4 to 9)
–8·82
(–28·52 to 
0·28)
10·81
(3·49 to 
21·57)
–1·49
(–9·18 to 
13·52)
–5·87
(–9·11 to 
–1·67)
Dominican Republic 1089
(417 to 1746)
445
(306 to 621)
693
(264 to 1139)
206
(139 to 292)
1783
(699 to 2830)
650
(459 to 893)
0·57
(–8·57 to 
4·79)
19·83
(16·78 to 
23·02)
–3·22
(–9·66 to 
–0·13)
–7·69
(–10·58 to 
–5·15)
Grenada 18
(8 to 55)
11
(9 to 13)
10
(4 to 31)
5
(4 to 6)
28
(13 to 87)
16
(13 to 19)
–2·69
(–12·50 to 
30·67)
15·29
(9·87 to 
25·13)
–3·02
(–8·75 to 
7·03)
–4·70
(–6·66 to 
–3·09)
Guyana 421
(318 to 536)
253
(171 to 326)
290
(215 to 377)
92
(48 to 145)
710
(549 to 887)
345
(230 to 443)
4·20
(–7·06 to 
14·46)
25·23
(17·37 to 
34·21)
0·09
(–1·40 to 
2·16)
–2·18
(–5·58 to 
0·21)
Haiti 3339
(2437 to
4692)
3458
(2648 to
4714)
4299
(3138 to
5784)
3655
(2678 to
5042)
7638
(5740 to
10 244)
7113
(5556 to
9397)
–8·98
(–11·68 to 
–6·91)
7·96
(3·38 to 
12·22)
–5·08
(–6·73 to 
–2·93)
–6·95
(–8·04 to 
–5·47)
Jamaica 366
(269 to 534)
171
(133 to 226)
192
(139 to 287)
57
(41 to 79)
557
(418 to 809)
229
(179 to 296)
–10·26
(–19·24 to 
–0·14)
19·83
(13·08 to 
25·24)
–0·76
(–3·64 to 
1·53)
–8·96
(–11·10 to 
–6·63)
Saint Lucia 21
(9 to 48)
15
(12 to 18)
12
(5 to 27)
7
(5 to 8)
32
(14 to 76)
21
(18 to 25)
–1·48
(–14·23 to 
34·47)
15·22
(9·92 to 
24·76)
–2·63
(–8·23 to 
5·86)
–4·62
(–6·44 to 
–3·15)
Saint Vincent and 
the Grenadines
19
(9 to 56)
13
(10 to 17)
10
(5 to 29)
5
(4 to 7)
28
(14 to 86)
19
(15 to 23)
–5·21
(–16·74 to 
16·48)
19·54
(13·36 to 
35·02)
–2·00
(–7·38 to 
9·74)
–4·69
(–6·83 to 
–2·79)
Suriname 146
(100 to 204)
77
(52 to 114)
88
(59 to 125)
28
(19 to 42)
234
(161 to 328)
105
(75 to 149)
2·59
(–7·99 to 
13·67)
24·68
(15·58 to 
35·47)
–0·68
(–3·39 to 
2·37)
–3·81
(–6·79 to 
–0·44)
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The Bahamas 104
(79 to 146)
70
(50 to 92)
59
(44 to 86)
21
(14 to 30)
163
(127 to 229)
90
(66 to 118)
–9·21
(–12·37 to 
–6·27)
10·55
(8·71 to 
12·38)
0·14
(–2·17 to 
3·37)
–6·98
(–9·45 to 
–4·59)
Trinidad and 
Tobago
317
(201 to 489)
188
(87 to 319)
181
(109 to 282)
49
(27 to 92)
498
(317 to 758)
237
(119 to 397)
–3·82
(–6·88 to 
–1·48)
12·26
(8·66 to 
19·34)
1·31
(–1·96 to 
4·59)
–3·91
(–8·63 to 
0·08)
Central Europe 901
(665 to 1166)
497
(419 to 574)
332
(248 to 426)
123
(99 to 150)
1232
(923 to 1593)
620
(524 to 719)
1·29
(–1·78 to 
4·40)
8·06
(6·44 to 
10·09)
–0·55
(–3·44 to 
2·08)
0·19
(–1·28 to 
1·41)
Albania 2
(0 to 4)
1
(1 to 2)
1
(0 to 2)
0
(0 to 1)
3
(0 to 6)
2
(1 to 2)
–0·43
(–21·75 to 
16·57)
16·85
(5·51 to 
30·86)
1·19
(–11·91 to 
15·03)
0·29
(–5·18 to 
3·74)
Bosnia and 
Herzegovina
1
(0 to 3)
0
(0 to 1)
1
(0 to 3)
0
(0 to 0)
2
(1 to 6)
1
(1 to 1)
23·41
(–8·35 to 
41·70)
27·08
(13·51 to 
48·89)
2·76
(–7·44 to 
28·85)
13·71
(9·82 to 
18·06)
Bulgaria 179
(99 to 330)
105
(61 to 157)
41
(22 to 77)
19
(7 to 34)
221
(122 to 400)
124
(71 to 188)
7·77
(3·42 to 
14·35)
9·07
(4·50 to 
16·42)
3·82
(0·03 to 
8·92)
5·22
(1·32 to 
8·36)
Croatia 21
(12 to 35)
9
(6 to 13)
10
(5 to 17)
3
(2 to 5)
31
(18 to 53)
12
(8 to 17)
2·54
(–2·09 to 
6·66)
7·78
(4·26 to 
11·34)
0·91
(–3·20 to 
5·10)
1·47
(–1·15 to 
3·93)
Czech Republic 25
(9 to 43)
12
(9 to 16)
10
(4 to 19)
3
(2 to 5)
35
(13 to 62)
16
(12 to 20)
17·51
(12·02 to 
21·32)
12·23
(7·65 to 
16·94)
–5·74
(–13·40 to 
–1·53)
3·86
(1·07 to 
6·74)
Hungary 35
(1 to 73)
43
(33 to 56)
8
(0 to 18)
8
(5 to 11)
43
(2 to 90)
51
(39 to 66)
1·04
(–1·27 to 
4·30)
–3·52
(–5·69 to 
–0·65)
–7·63
(–29·64 to 
0·40)
–5·44
(–7·02 to 
–3·66)
Macedonia 2
(0 to 3)
1
(1 to 2)
1
(0 to 2)
1
(0 to 1)
3
(1 to 6)
2
(1 to 3)
8·80
(–6·31 to 
18·34)
14·07
(3·70 to 
25·04)
–1·38
(–10·27 to 
6·27)
2·47
(–1·54 to 
6·00)
Montenegro 1
(0 to 2)
1
(0 to 1)
1
(0 to 1)
0
(0 to 1)
1
(0 to 4)
1
(1 to 2)
–7·56
(–30·37 to 
5·80)
13·19
(3·02 to 
22·95)
1·33
(–14·79 to 
19·86)
–1·24
(–7·99 to 
3·21)
Poland 359
(166 to 555)
189
(147 to 236)
110
(49 to 178)
37
(26 to 52)
469
(217 to 728)
226
(177 to 281)
–1·31
(–7·24 to 
3·30)
20·93
(15·87 to 
27·41)
–1·80
(–8·76 to 
2·35)
1·00
(–1·25 to 
3·10)
Romania 180
(97 to 277)
101
(69 to 139)
117
(63 to 185)
42
(29 to 62)
298
(162 to 453)
143
(99 to 194)
4·19
(–3·96 to 
13·76)
21·05
(15·17 to 
35·98)
–1·83
(–7·61 to 
3·00)
–0·70
(–4·26 to 
2·20)
Serbia 73
(31 to 132)
28
(14 to 52)
24
(10 to 45)
7
(3 to 17)
97
(41 to 177)
35
(17 to 67)
–11·33
(–20·97 to 
–0·67)
4·62
(1·63 to 
7·84)
10·23
(2·52 to 
19·43)
–3·11
(–8·73 to 
2·27)
Slovakia 12
(6 to 24)
4
(2 to 5)
5
(2 to 9)
1
(1 to 1)
17
(8 to 33)
5
(3 to 6)
6·92
(1·24 to 
12·86)
17·06
(12·39 to 
24·48)
3·51
(–1·36 to 
8·87)
3·04
(–0·55 to 
5·98)
Slovenia 12
(2 to 30)
3
(1 to 6)
2
(0 to 5)
0
(0 to 1)
14
(2 to 35)
3
(1 to 6)
–6·64
(–13·05 to 
10·19)
–1·26
(–7·91 to 
8·38)
11·29
(–0·09 to 
20·62)
1·76
(–4·88 to 
6·93)
Eastern Europe 41 070
(30 301 to 
58 405)
22 838
(18 002 to 
28 949)
11 207
(7772 to
15 653)
4823
(3063 to
7241)
52 277
(38 281 to 
73 913)
27 662
(21 651 to 
35 479)
25·17
(18·06 to 
34·84)
13·07
(9·88 to 
16·41)
–1·53
(–3·75 to 
0·86)
8·51
(6·41 to 
10·74)
Belarus 573
(362 to 820)
379
(244 to 531)
127
(77 to 190)
35
(23 to 50)
699
(439 to 1013)
413
(277 to 571)
29·51
(16·04 to 
51·15)
42·29
(28·40 to 
98·54)
0·09
(–3·53 to 
3·25)
9·91
(5·90 to 
12·80)
Estonia 77
(44 to 111)
26
(21 to 36)
20
(12 to 29)
5
(3 to 7)
97
(55 to 139)
31
(24 to 42)
50·08
(34·32 to 
73·58)
57·11
(44·12 to 
89·50)
–2·04
(–7·16 to 
0·54)
11·41
(7·09 to 
16·50)
(Table 3 continues on next page)
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Latvia 134
(75 to 226)
69
(47 to 98)
115
(69 to 189)
73
(53 to 100)
249
(148 to 408)
142
(108 to 189)
 16·45
(10·92 to 
22·03)
 13·96
(8·23 to 
19·03)
 1·42
(–3·52 to 
6·38)
 9·21
(6·44 to 
11·94)
Lithuania 48
(26 to 88)
38
(24 to 55)
85
(46 to 160)
77
(52 to 108)
133
(74 to 243)
116
(77 to 157)
3·04
(–0·95 to 
7·72)
9·24
(6·12 to 
13·00)
0·92
(–3·70 to 
6·42)
2·14
(–0·56 to 
4·26)
Moldova 444
(270 to 674)
233
(139 to 321)
104
(62 to 161)
31
(20 to 46)
548
(336 to 827)
264
(162 to 359)
13·94
(6·78 to 
24·00)
12·03
(7·78 to 
19·63)
4·17
(–0·57 to 
8·83)
4·08
(0·20 to 
7·96)
Russia 30 851
(22 352 to 
46 994)
14 423
(10 797 to 
19 740)
6672
(4431 to
10 667)
1715
(903 to
3196)
37 523
(27 617 to 
57 331)
16 138
(11 963 to 
22 526)
25·22
(15·86 to 
50·69)
9·60
(6·86 to 
13·39)
0·70
(–1·22 to 
3·57)
8·66
(5·96 to 
11·53)
Ukraine 8943
(4013 to 
14 168)
7670
(5455 to 
10 529)
4084
(1803 to
6534)
2889
(1515 to
4597)
13 027
(5869 to
20 307)
10 558
(7415 to 
14 758)
30·36
(16·36 to 
72·39)
32·65
(11·72 to 
119·99)
–6·10
(–12·25 to 
–2·28)
8·50
(5·63 to 
11·93)
Western Europe 11 225
(8795 to 
14 694)
4336
(3542 to
5326)
2896
(2225 to
3750)
1168
(948 to
1457)
14 122
(11 057 to 
18 340)
5504
(4591 to 
6583)
–9·15
(–14·34 to 
–5·01)
–6·75
(–8·06 to 
–5·34)
0·05
(–1·77 to 
2·05)
–3·59
(–4·72 to 
–2·25)
Andorra 18
(4 to 40)
5
(2 to 7)
4
(1 to 9)
1
(0 to 2)
22
(5 to 48)
6
(3 to 8)
3·38
(–24·91 to 
15·91)
2·70
(–5·28 to 
20·32)
0·56
(–7·50 to 
13·32)
–1·09
(–6·77 to 
4·30)
Austria 439
(111 to 1114)
58
(25 to 105)
108
(28 to 281)
15
(7 to 29)
547
(142 to 1378)
73
(32 to 129)
2·62
(–1·67 to 
10·93)
–4·20
(–8·86 to 
1·90)
7·82
(0·38 to 
15·57)
5·51
(0·00 to 
10·23)
Belgium 155
(66 to 283)
41
(25 to 66)
64
(28 to 116)
18
(11 to 32)
219
(93 to 392)
59
(39 to 86)
–2·70
(–10·42 to 
3·11)
3·37
(0·16 to 
6·76)
–0·80
(–6·58 to 
4·69)
–1·48
(–4·16 to 
1·11)
Cyprus 3
(1 to 6)
1
(0 to 1)
2
(1 to 3)
0
(0 to 1)
4
(2 to 9)
1
(1 to 2)
19·87
(–13·23 to 
34·14)
26·48
(16·01 to 
41·70)
–1·36
(–11·44 to 
24·06)
3·17
(–0·67 to 
8·77)
Denmark 202
(87 to 433)
28
(15 to 44)
40
(17 to 87)
6
(3 to 9)
242
(105 to 518)
34
(19 to 52)
–5·46
(–10·62 to 
0·51)
–11·24
(–15·04 to 
–7·09)
4·04
(–1·37 to 
12·18)
–1·13
(–4·49 to 
3·19)
Finland 20
(10 to 37)
6
(4 to 8)
5
(2 to 10)
2
(1 to 2)
25
(12 to 46)
7
(5 to 10)
–0·56
(–5·45 to 
3·94)
0·82
(–1·64 to 
3·99)
0·46
(–4·77 to 
5·57)
–2·06
(–4·73 to 
–0·10)
France 1816
(840 to 3599)
839
(486 to 1335)
503
(223 to 999)
229
(139 to 366)
2319
(1076 to 4501)
1068
(658 to 1636)
–3·96
(–8·52 to 
6·36)
–12·37
(–15·59 to 
–8·23)
–0·43
(–4·61 to 
5·10)
–2·80
(–5·51 to 
0·66)
Germany 1401
(827 to 2299)
435
(285 to 623)
306
(172 to 523)
99
(62 to 150)
1707
(1023 to 2796)
535
(354 to 752)
–2·80
(–5·95 to 
2·02)
–10·02
(–12·93 to 
–6·57)
2·24
(0·02 to 
5·13)
–3·15
(–4·75 to 
–1·14)
Greece 39
(22 to 54)
10
(7 to 15)
13
(7 to 18)
3
(2 to 5)
51
(30 to 71)
14
(9 to 20)
3·56
(0·73 to 
9·42)
–11·52
(–15·44 to 
–6·10)
–1·99
(–6·00 to 
0·18)
–2·49
(–5·44 to 
0·06)
Iceland 1
(0 to 1)
0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
1
(0 to 2)
0
(0 to 0)
–0·85
(–6·56 to 
4·83)
–1·07
(–4·21 to 
2·38)
–0·31
(–6·77 to 
7·62)
–3·09
(–6·63 to 
0·48)
Ireland 40
(18 to 73)
12
(8 to 18)
18
(8 to 32)
6
(4 to 9)
57
(26 to 105)
17
(12 to 25)
0·83
(–7·24 to 
6·66)
4·51
(0·68 to 
9·85)
–2·78
(–9·97 to 
3·14)
–3·64
(–6·79 to 
–0·86)
Israel 52
(25 to 94)
13
(9 to 20)
58
(28 to 106)
14
(10 to 20)
110
(52 to 193)
27
(20 to 36)
–3·86
(–10·49 to 
2·30)
6·06
(3·40 to 
8·34)
–0·89
(–7·21 to 
3·44)
–2·94
(–5·17 to 
–0·78)
Italy 2328
(1269 to 3636)
775
(492 to 1290)
646
(346 to 1042)
242
(144 to 407)
2974
(1631 to 4601)
1017
(651 to 1549)
–16·06
(–27·75 to 
–4·02)
–8·82
(–12·23 to 
–5·51)
1·90
(–0·40 to 
6·14)
–3·07
(–5·22 to 
–0·46)
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Luxembourg 1
(1 to 2)
0
(0 to 1)
1
(1 to 2)
0
(0 to 1)
2
(1 to 4)
1
(1 to 1)
3·47
(–5·21 to 
13·05)
27·76
(19·37 to 
41·86)
–2·35
(–8·82 to 
2·40)
–2·39
(–6·22 to 
0·92)
Malta 1
(0 to 2)
0
(0 to 1)
0
(0 to 1)
0
(0 to 0)
1
(1 to 3)
0
(0 to 1)
–17·62
(–23·63 to 
–11·72)
0·34
(–3·00 to 
4·44)
4·19
(–2·47 to 
12·25)
–5·36
(–9·13 to 
–1·84)
Netherlands 236
(106 to 456)
73
(40 to 125)
51
(22 to 99)
17
(9 to 30)
287
(128 to 552)
91
(52 to 147)
–12·47
(–19·81 to 
–5·75)
–3·00
(–6·29 to 
–0·13)
0·76
(–5·61 to 
6·65)
–4·36
(–7·46 to 
–1·54)
Norway 26
(12 to 45)
8
(5 to 14)
23
(11 to 41)
7
(4 to 12)
49
(23 to 84)
15
(10 to 23)
–4·16
(–13·90 to 
1·95)
1·34
(–1·81 to 
6·43)
–1·95
(–8·14 to 
2·80)
–3·79
(–7·12 to 
–1·07)
Portugal 1978
(906 to 3669)
679
(436 to 944)
394
(184 to 752)
146
(85 to 234)
2371
(1102 to 4392)
825
(574 to 1109)
–0·31
(–7·39 to 
5·92)
12·07
(6·83 to 
18·41)
–1·18
(–7·84 to 
4·58)
–3·32
(–5·86 to 
–0·67)
Spain 1811
(1180 to 2780)
1075
(627 to 1618)
408
(254 to 639)
252
(140 to 416)
2219
(1454 to 3387)
1327
(792 to 1976)
–15·24
(–19·37 to 
–10·81)
–5·11
(–7·45 to 
–2·22)
–1·34
(–4·32 to 
0·83)
–6·66
(–9·66 to 
–4·50)
Sweden 46
(20 to 82)
15
(9 to 24)
15
(6 to 26)
5
(3 to 9)
61
(26 to 108)
20
(13 to 30)
–9·91
(–18·59 to 
–2·93)
–1·05
(–3·98 to 
1·43)
–2·54
(–8·88 to 
1·44)
–5·28
(–8·03 to 
–2·79)
Switzerland 251
(85 to 539)
79
(43 to 131)
111
(39 to 241)
36
(20 to 59)
362
(124 to 782)
115
(69 to 175)
–19·00
(–24·99 to 
–8·36)
–6·25
(–9·63 to 
–2·61)
6·82
(0·92 to 
12·82)
–3·43
(–6·63 to 
–0·05)
UK 349
(24 to 964)
178
(119 to 255)
125
(9 to 342)
68
(43 to 104)
474
(33 to 1316)
246
(168 to 333)
0·83
(–5·08 to 
7·15)
–4·45
(–7·40 to 
–1·00)
–8·49
(–27·01 to 
–0·11)
–1·57
(–4·46 to 
0·53)
Andean Latin America 3316
(1938 to 7058)
1588
(987 to 3617)
1225
(683 to 2571)
465
(240 to 1304)
4541
(2649 to 9597)
2053
(1258 to 4917)
1·91
(–16·44 to 
14·95)
19·73
(11·89 to 
28·79)
–1·09
(–6·07 to 
4·63)
–3·52
(–6·58 to 
0·62)
Bolivia 396
(13 to 1969)
446
(46 to 2345)
181
(5 to 845)
171
(12 to 1043)
577
(18 to 2770)
617
(59 to 3398)
21·87
(–12·59 to 
47·06)
46·78
(11·24 to 
77·78)
–11·15
(–29·50 to 
2·73)
–1·91
(–11·59 to 
8·44)
Ecuador 1711
(997 to 3749)
687
(495 to 1081)
607
(350 to 1341)
193
(114 to 330)
2318
(1378 to 5097)
880
(645 to 1409)
8·55
(–4·91 to 
19·31)
18·12
(11·55 to 
27·83)
0·17
(–3·88 to 
7·10)
1·89
(–1·82 to 
8·67)
Peru 1209
(503 to 3735)
455
(287 to 790)
437
(182 to 1330)
101
(64 to 178)
1646
(695 to 5100)
556
(357 to 960)
–4·68
(–29·03 to 
15·07)
18·81
(9·18 to 
30·45)
0·23
(–4·84 to 
10·22)
–8·83
(–12·74 to 
–3·34)
Central Latin America 17 775
(14 156 to 
21 628)
7555
(6042 to
9924)
5706
(4418 to
7440)
1965
(1207 to
4529)
23 480
(18 630 to 
28 703)
9521
(7325 to 
14 456)
–2·00
(–8·23 to 
1·40)
13·13
(10·27 to 
16·05)
–0·64
(–1·81 to 
0·37)
–5·46
(–7·10 to 
–3·86)
Colombia 4464
(2799 to 6030)
1712
(1294 to 2358)
1188
(754 to 1645)
321
(219 to 482)
5651
(3627 to 7520)
2033
(1553 to 2791)
7·92
(–4·88 to 
15·09)
29·60
(23·63 to 
34·51)
–0·44
(–2·72 to 
2·70)
–2·88
(–5·92 to 
0·76)
Costa Rica 291
(206 to 395)
110
(81 to 143)
74
(51 to 103)
20
(14 to 27)
366
(261 to 497)
130
(95 to 167)
0·21
(–4·92 to 
4·30)
7·98
(5·90 to 
10·21)
0·59
(–2·11 to 
3·52)
–4·58
(–7·00 to 
–2·56)
El Salvador 536
(258 to 852)
184
(124 to 275)
249
(117 to 418)
59
(39 to 87)
785
(382 to 1262)
243
(166 to 358)
1·30
(–5·70 to 
8·69)
17·00
(10·64 to 
22·67)
–2·27
(–7·03 to 
0·09)
–6·24
(–9·58 to 
–2·90)
Guatemala 1163
(545 to 1944)
465
(271 to 733)
679
(308 to 1139)
185
(108 to 308)
1841
(858 to 3044)
650
(384 to 1011)
19·84
(10·31 to 
32·38)
32·69
(26·07 to 
41·94)
–4·85
(–13·12 to 
–0·29)
–0·24
(–5·99 to 
5·65)
Honduras 381
(54 to 1630)
537
(49 to 2613)
508
(75 to 2243)
586
(38 to 3056)
889
(131 to 3925)
1123
(91 to 5692)
–11·00
(–26·53 to 
0·94)
14·55
(4·46 to 
23·16)
–6·65
(–14·25 to 
3·99)
–11·51
(–16·65 to 
–5·96)
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Mexico 7066
(4827 to 9603)
3076
(2343 to 4368)
1797
(1214 to 2539)
514
(339 to 800)
8863
(6156 to 12 054)
3590
(2763 to 5024)
–6·14
(–11·86 to 
–2·01)
9·58
(6·71 to 
12·81)
–0·20
(–1·20 to 
0·41)
–6·62
(–8·53 to 
–4·22)
Nicaragua 978
(522 to 1739)
199
(130 to 284)
407
(215 to 741)
53
(29 to 94)
1386
(736 to 2471)
252
(165 to 364)
19·78
(6·54 to 
35·63)
14·90
(3·90 to 
38·22)
10·61
(2·14 to 
17·90)
11·62
(6·35 to 
16·80)
Panama 500
(295 to 763)
282
(193 to 410)
167
(95 to 263)
58
(35 to 107)
666
(392 to 1011)
340
(233 to 505)
–8·12
(–15·64 to 
–2·07)
12·99
(9·44 to 
16·66)
–0·88
(–4·14 to 
0·97)
–6·63
(–10·00 to 
–2·21)
Venezuela 2396
(1506 to 3591)
992
(770 to 1470)
637
(386 to 968)
168
(111 to 248)
3033
(1912 to 4504)
1160
(900 to 1687)
1·77
(–9·28 to 
12·66)
17·73
(9·64 to 
32·27)
–0·32
(–3·01 to 
3·08)
–5·43
(–8·14 to 
–1·48)
Southern 
Latin America
4938
(3436 to 7580)
1722
(1230 to 2253)
1593
(1084 to 2210)
291
(171 to 490)
6531
(4590 to 9658)
2013
(1437 to 2650)
–0·75
(–4·84 to 
3·85)
10·00
(6·17 to 
13·76)
–0·24
(–3·40 to 
3·08)
–2·76
(–5·37 to 
–0·65)
Argentina 3459
(2343 to 4525)
1396
(937 to 1932)
1310
(859 to 1785)
231
(113 to 420)
4769
(3211 to 6214)
1627
(1082 to 2247)
–0·87
(–4·70 to 
3·65)
9·37
(5·29 to 
13·37)
–0·99
(–4·42 to 
1·51)
–2·74
(–5·78 to 
–0·30)
Chile 1162
(399 to 3636)
219
(132 to 386)
184
(60 to 558)
34
(20 to 57)
1346
(461 to 4214)
253
(154 to 441)
–0·85
(–13·55 to 
11·49)
16·21
(5·51 to 
26·62)
2·44
(–5·07 to 
14·88)
–5·29
(–9·44 to 
–0·24)
Uruguay 317
(197 to 457)
107
(58 to 227)
98
(60 to 149)
26
(16 to 48)
415
(257 to 600)
133
(77 to 275)
6·73
(–12·63 to 
23·80)
14·36
(–0·41 to 
26·97)
0·36
(–4·96 to 
5·94)
4·14
(0·28 to 
9·24)
Tropical Latin America 17 874
(13 687 to 
24 490)
8091
(6273 to 
10 287)
7958
(5860 to
11 125)
2353
(1676 to
3175)
25 832
(19 842 to 
35 094)
10 444
(8400 to 
13 074)
–7·15
(–10·27 to 
–3·64)
1·09
(–2·41 to 
6·19)
0·37
(–1·16 to 
2·50)
–2·20
(–4·57 to 
0·01)
Brazil 17 156
(13 016 to 
23 725)
7912
(6086 to 
10 130)
7661
(5536 to 
10 846)
2305
(1628 to
3122)
24 817
(18 802 to 
34 189)
10 217
(8168 to 
12 829)
–7·34
(–10·43 to 
–3·78)
0·99
(–2·54 to 
6·14)
0·28
(–1·27 to 
2·43)
–2·26
(–4·65 to 
0·02)
Paraguay 718
(376 to 1377)
179
(132 to 254)
297
(148 to 573)
47
(30 to 78)
1015
(533 to 1909)
227
(169 to 326)
9·89
(–2·03 to 
20·95)
16·01
(10·41 to 
26·36)
2·29
(–3·20 to 
8·98)
0·94
(–2·22 to 
4·82)
North Africa and 
Middle East
11 022
(7339 to
19 715)
5905
(4360 to
8749)
4482
(3048 to
7671)
2181
(1582 to
3191)
15 503
(10 523 to 
27 132)
8087
(6008 to 
11 698)
11·52
(0·35 to 
25·42)
20·66
(9·81 to 
35·43)
–0·35
(–4·01 to 
5·02)
3·05
(–0·99 to 
7·85)
Algeria 370
(144 to 953)
68
(45 to 110)
334
(126 to 815)
50
(29 to 95)
704
(278 to 1737)
118
(78 to 197)
22·04
(1·42 to 
55·08)
31·05
(19·30 to 
58·72)
3·63
(–4·30 to 
14·24)
2·06
(–4·20 to 
10·92)
Bahrain 25
(15 to 47)
11
(8 to 15)
10
(5 to 19)
4
(3 to 5)
35
(20 to 66)
15
(11 to 19)
4·50
(–10·68 to 
20·37)
19·32
(9·48 to 
41·05)
2·66
(–1·34 to 
7·95)
1·52
(–1·64 to 
8·28)
Egypt 208
(121 to 315)
54
(36 to 76)
175
(100 to 264)
55
(40 to 72)
383
(224 to 568)
109
(81 to 143)
8·02
(3·18 to 
13·53)
20·36
(16·78 to 
24·35)
5·61
(0·35 to 
10·52)
4·30
(1·75 to 
6·54)
Iran 1246
(572 to 2287)
308
(191 to 441)
152
(66 to 282)
17
(9 to 28)
1398
(641 to 2550)
325
(201 to 464)
32·59
(7·25 to 
56·24)
42·61
(11·52 to 
101·76)
5·64
(–0·97 to 
13·56)
12·98
(5·92 to 
19·99)
Iraq 318
(143 to 685)
139
(101 to 181)
185
(83 to 417)
72
(52 to 98)
503
(227 to 1092)
211
(159 to 273)
5·61
(–7·68 to 
23·46)
21·16
(12·84 to 
44·26)
2·85
(–2·60 to 
9·54)
2·38
(–1·00 to 
5·44)
Jordan 8
(4 to 17)
5
(3 to 6)
10
(5 to 21)
5
(4 to 6)
19
(10 to 37)
9
(7 to 11)
10·32
(–4·09 to 
38·26)
27·10
(18·13 to 
53·81)
1·09
(–3·61 to 
7·21)
1·60
(–1·86 to 
5·63)
Kuwait 55
(32 to 101)
24
(18 to 35)
25
(13 to 48)
9
(7 to 13)
80
(45 to 149)
33
(25 to 46)
4·81
(–10·41 to 
20·69)
19·61
(9·84 to 
41·52)
2·49
(–1·51 to 
7·82)
1·53
(–1·69 to 
10·13)
(Table 3 continues on next page)
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Lebanon 241
(7 to 1200)
89
(8 to 471)
93
(3 to 435)
26
(2 to 173)
334
(10 to 1662)
116
(10 to 645)
20·24
(–5·86 to 
65·16)
4·87
(–5·96 to 
19·21)
5·79
(–14·18 to 
19·40)
6·76
(–4·92 to 
17·15)
Libya 15
(7 to 32)
7
(5 to 8)
12
(6 to 24)
5
(4 to 6)
27
(13 to 55)
11
(9 to 14)
10·67
(–2·77 to 
39·02)
23·15
(14·81 to 
48·67)
3·01
(–1·88 to 
8·66)
4·20
(1·56 to 
7·24)
Morocco 343
(213 to 548)
108
(72 to 161)
294
(187 to 452)
61
(42 to 96)
637
(403 to 980)
169
(117 to 255)
21·12
(11·44 to 
27·17)
29·89
(26·98 to 
33·37)
0·53
(–2·02 to 
4·36)
4·19
(0·82 to 
8·25)
Oman 180
(92 to 388)
31
(23 to 43)
43
(21 to 91)
7
(4 to 12)
223
(114 to 480)
38
(28 to 53)
28·03
(9·34 to 
65·46)
34·56
(22·53 to 
65·06)
1·78
(–4·83 to 
11·39)
4·86
(0·85 to 
13·07)
Palestine 20
(10 to 42)
6
(5 to 7)
11
(5 to 22)
3
(2 to 4)
31
(15 to 64)
9
(8 to 11)
17·60
(3·68 to 
45·75)
22·60
(11·17 to 
47·43)
5·85
(0·32 to 
12·81)
10·89
(8·35 to 
13·98)
Qatar 8
(3 to 20)
4
(2 to 5)
1
(0 to 3)
0
(0 to 1)
10
(3 to 23)
4
(2 to 6)
–2·05
(–14·81 to 
18·73)
10·34
(–0·04 to 
37·07)
3·15
(–2·65 to 
11·69)
–1·70
(–5·16 to 
2·00)
Saudi Arabia 354
(168 to 771)
197
(140 to 318)
206
(100 to 436)
87
(62 to 118)
559
(272 to 1200)
283
(206 to 415)
2·20
(–14·17 to 
18·84)
19·30
(8·77 to 
44·67)
2·77
(–1·56 to 
9·53)
1·49
(–2·03 to 
7·73)
Sudan 4999
(2880 to 9359)
4154
(2976 to 5843)
1934
(1141 to 3575)
1533
(1040 to 2244)
6933
(4020 to 12 757)
5687
(4109 to 8024)
11·50
(–2·67 to 
34·18)
22·51
(8·28 to 
53·14)
–4·10
(–9·07 to 
2·83)
2·62
(–2·11 to 
9·16)
Syria 0
(0 to 1)
0
(0 to 0)
1
(0 to 1)
0
(0 to 0)
1
(0 to 3)
0
(0 to 1)
25·96
(9·85 to 
59·84)
34·00
(20·32 to 
67·81)
1·74
(–4·46 to 
8·97)
7·05
(2·48 to 
13·48)
Tunisia 227
(31 to 1041)
53
(4 to 284)
94
(13 to 435)
19
(1 to 110)
322
(44 to 1443)
72
(6 to 388)
12·85
(–14·69 to 
44·00)
22·94
(–2·16 to 
61·79)
11·96
(0·97 to 
22·98)
2·76
(–6·40 to 
12·29)
Turkey 408
(233 to 698)
107
(85 to 142)
195
(110 to 331)
42
(31 to 59)
602
(351 to 1029)
149
(120 to 198)
25·03
(20·34 to 
29·29)
28·45
(22·14 to 
48·56)
1·99
(–1·56 to 
7·16)
9·82
(6·51 to 
15·83)
United Arab 
Emirates
304
(175 to 560)
101
(76 to 128)
77
(42 to 150)
27
(19 to 36)
382
(217 to 704)
128
(97 to 161)
4·68
(–10·37 to 
20·37)
19·26
(9·51 to 
40·77)
2·45
(–1·53 to 
7·73)
1·37
(–1·78 to 
8·62)
Yemen 1677
(215 to 7497)
433
(45 to 2027)
625
(77 to 2998)
156
(10 to 807)
2302
(289 to 10 511)
589
(56 to 2857)
8·17
(–12·05 to 
27·46)
17·84
(–1·57 to 
44·45)
10·06
(1·53 to 
21·58)
7·14
(–1·35 to 
16·57)
High–income 
North America
20 227
(9394 to 
47 347)
7959
(4591 to 
11 627)
6193
(2730 to
14 401)
2560
(1398 to 
4064)
26 420
(12 244 to 
61 760)
10 518
(6635 to 
14 804)
–8·87
(–13·56 to 
–3·10)
–10·20
(–13·49 to 
–7·99)
2·01
(–3·23 to 
9·49)
–2·89
(–5·95 to 
–0·10)
Canada 720
(253 to 1205)
263
(173 to 392)
134
(47 to 242)
57
(33 to 95)
854
(297 to 1445)
319
(215 to 458)
–9·30
(–17·42 to 
–3·34)
–10·55
(–12·93 to 
–8·22)
–0·75
(–9·26 to 
3·88)
–4·81
(–8·13 to 
–1·82)
USA 19 503
(8675 to 
46 702)
7694
(4306 to 
11 351)
6058
(2608 to 
14 298)
2503
(1333 to
4016)
25 561
(11 370 to 
60 381)
10 197
(6265 to 
14 519)
–8·86
(–13·93 to 
–2·53)
–10·19
(–13·64 to 
–7·88)
2·13
(–3·39 to 
9·82)
–2·80
(–5·96 to 
0·06)
Oceania 1137
(774 to 1591)
1461
(1043 to 2000)
515
(359 to 721)
255
(160 to 372)
1652
(1148 to 2288)
1716
(1249 to 2335)
15·64
(5·25 to 
27·08)
31·68
(27·45 to 
36·49)
–9·47
(–11·74 to 
–7·34)
1·21
(–3·80 to 
6·92)
Federated States 
of Micronesia
2
(1 to 4)
1
(0 to 1)
3
(1 to 5)
1
(0 to 1)
5
(2 to 9)
1
(1 to 2)
1·63
(–6·48 to 
6·93)
17·73
(13·87 to 
23·24)
5·41
(–2·00 to 
11·14)
–2·70
(–7·89 to 
1·15)
Fiji 19
(7 to 34)
7
(4 to 11)
26
(10 to 46)
7
(3 to 12)
45
(17 to 78)
14
(7 to 22)
1·63
(–6·46 to 
6·94)
17·76
(13·92 to 
23·26)
5·45
(–1·98 to 
11·19)
–2·68
(–7·88 to 
1·17)
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Kiribati 1
(0 to 2)
0
(0 to 0)
0
(0 to 1)
0
(0 to 0)
1
(0 to 2)
0
(0 to 0)
–7·11
(–14·42 to 
6·66)
–4·00
(–7·74 to 
1·02)
10·13
(–0·37 to 
19·60)
–1·82
(–6·60 to 
4·26)
Marshall Islands 1
(0 to 2)
1
(0 to 1)
1
(0 to 2)
1
(0 to 1)
1
(0 to 4)
1
(1 to 1)
5·87
(–6·26 to 
14·52)
25·45
(13·97 to 
32·22)
–5·17
(–17·67 to 
5·47)
0·67
(–2·56 to 
2·76)
Papua New Guinea 992
(671 to 1404)
1279
(907 to 1761)
419
(280 to 596)
213
(127 to 316)
1411
(973 to 1972)
1493
(1071 to 2046)
15·78
(5·11 to 
27·92)
32·78
(27·56 to 
38·72)
–10·09
(–12·45 to 
–7·90)
1·09
(–4·12 to 
7·19)
Samoa 2
(0 to 6)
1
(1 to 2)
2
(0 to 8)
1
(1 to 2)
4
(1 to 14)
2
(2 to 3)
2·62
(–17·47 to 
13·91)
24·01
(14·89 to 
32·03)
–2·37
(–17·51 to 
10·40)
–0·76
(–4·60 to 
2·35)
Solomon Islands 5
(1 to 15)
4
(3 to 5)
7
(1 to 22)
5
(3 to 6)
13
(2 to 37)
8
(6 to 11)
6·58
(–4·75 to 
15·92)
27·79
(17·67 to 
35·23)
–4·58
(–17·19 to 
7·03)
–1·12
(–4·26 to 
1·73)
Tonga 1
(0 to 2)
1
(1 to 1)
1
(0 to 3)
1
(1 to 1)
2
(0 to 5)
2
(1 to 2)
6·23
(–2·77 to 
14·77)
26·75
(15·90 to 
33·45)
–5·28
(–17·56 to 
5·29)
0·09
(–2·85 to 
2·26)
Vanuatu 5
(2 to 10)
2
(1 to 3)
7
(3 to 13)
2
(1 to 3)
13
(5 to 22)
4
(2 to 6)
1·60
(–6·49 to 
6·93)
17·68
(13·81 to 
23·22)
5·45
(–1·97 to 
11·18)
–2·68
(–7·86 to 
1·16)
Central sub-Saharan 
Africa
40 520
(33 684 to 
48 736)
34 484
(29 112 to 
40 928)
46 721
(38 841 to 
56 310)
33 317
(26 990 to 
41 399)
87 241
(73 529 to 
104 384)
67 801
(57 201 to 
81 462)
–0·25
(–1·66 to 
0·93)
5·71
(3·57 to 
8·17)
–3·89
(–5·15 to 
–2·60)
–2·42
(–3·47 to 
–1·14)
Angola 15 931
(11 412 to 
21 253)
7668
(5298 to 
10 586)
18 844
(14 120 to 
24 425)
8531
(6012 to 
11 969)
34 775
(25 849 to 
45 207)
16 199
(11 785 to 
22 209)
4·19
(0·33 to 
7·97)
17·14
(13·88 to 
21·02)
1·01
(–2·19 to 
4·30)
2·30
(–0·13 to 
4·95)
Central African 
Republic
3030
(2107 to
4276)
3822
(3112 to
4827)
3830
(2639 to
5249)
4199
(3022 to
5765)
6860
(4771 to
9421)
8021
(6348 to 
10 313)
–5·56
(–8·92 to 
–2·29)
5·10
(0·91 to 
9·99)
–5·85
(–7·56 to 
–4·06)
–5·43
(–7·70 to 
–2·89)
Congo 2115
(1607 to
2798)
2814
(2208 to
3561)
2450
(1858 to
3280)
2314
(1656 to
3222)
4565
(3534 to
5925)
5127
(4074 to 
6664)
–5·70
(–8·48 to 
–3·46)
8·21
(5·13 to 
11·42)
–7·19
(–9·26 to 
–4·54)
–6·18
(–7·41 to 
–4·45)
DR Congo 17 438
(13 583 to 
22 693)
17 392
(13 740 to 
22 269)
20 175
(15 383 to 
26 302)
17 223
(13 018 to 
23 364)
37 613
(29 660 to 
47 421)
34 615
(27 369 to 
44 771)
0·02
(–2·40 to 
1·29)
3·93
(2·46 to 
6·28)
–5·37
(–6·62 to 
–4·03)
–2·55
(–3·58 to 
–1·22)
Equatorial Guinea 838
(453 to 1332)
555
(246 to 945)
905
(499 to 1414)
490
(209 to 744)
1743
(977 to 2789)
1046
(457 to 1689)
11·45
(8·33 to 
14·54)
15·68
(10·22 to 
34·39)
–1·78
(–5·32 to 
2·40)
4·23
(0·35 to 
8·07)
Gabon 1169
(642 to 1872)
2233
(1778 to 2582)
517
(302 to 888)
560
(376 to 748)
1686
(986 to 2716)
2793
(2291 to 3203)
11·49
(8·03 to 
14·5)
23·03
(19·71 to 
26·02)
–12·91
(–17·46 to 
–7·35)
1·92
(–0·64 to 
4·99)
Eastern sub-Saharan 
Africa
259 900
(239 354 to 
285 112)
210 586
(198 215 to 
224 774)
322 401
(296 688 to 
349 447)
205 015
(189 971 to 
222 792)
582 301
(537 558 to 
630 227)
415 601
(393 233 to 
442 517)
–3·87
(–4·99 to 
–2·81)
14·50
(12·89 to 
16·00)
–4·40
(–5·14 to 
–3·65)
–3·78
(–4·82 to 
–2·65)
Burundi 2360
(1033 to 4252)
2997
(2222 to 4069)
3000
(1304 to 5465)
2515
(1648 to 3596)
5360
(2369 to 9678)
5513
(3966 to 7471)
–16·72
(–26·18 to 
–9·75)
20·87
(17·06 to 
24·49)
–2·27
(–9·44 to 
6·08)
–9·50
(–12·11 to 
–4·71)
Comoros 41
(5 to 183)
25
(4 to 117)
18
(2 to 88)
10
(1 to 48)
59
(8 to 276)
35
(4 to 168)
33·81
(12·67 to 
50·96)
42·10
(23·55 to 
57·50)
–1·72
(–12·18 to 
10·65)
11·67
(2·98 to 
20·10)
Djibouti 129
(52 to 261)
373
(259 to 492)
152
(60 to 330)
407
(273 to 584)
281
(111 to 571)
780
(516 to 1027)
22·37
(12·52 to 
28·20)
38·98
(33·20 to 
47·80)
–18·66
(–25·15 to 
–12·54)
3·07
(–2·38 to 
8·01)
Eritrea 578
(266 to 964)
1174
(837 to 1687)
676
(302 to 1064)
1200
(861 to 1695)
1254
(569 to 1996)
2374
(1703 to 3356)
–6·64
(–17·29 to 
9·76)
20·01
(13·04 to 
33·39)
–11·86
(–17·58 to 
–6·58)
–7·36
(–11·05 to 
–0·91)
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Ethiopia 15 851
(12 139 to 
20 542)
27 417
(22 586 to 
33 072)
19 151
(14 997 to 
24 731)
24 989
(18 874 to 
33 145)
35 002
(27 389 to 
44 699)
52 405
(43 394 to 
64 763)
–0·16
(–3·45 to 
2·72)
19·29
(14·50 to 
23·62)
–13·56
(–15·59 to 
–10·99)
–7·16
(–9·66 to 
–3·28)
Kenya 38 877
(33 698 to 
43 684)
30 059
(25 652 to 
34 355)
46 716
(41 140 to 
52 977)
26 704
(21 777 to 
31 960)
85 593
(78 186 to 
93 863)
56 763
(49 968 to 
63 388)
–6·21
(–8·43 to 
–3·27)
29·44
(26·50 to 
32·03)
–2·80
(–4·62 to 
–1·14)
–4·48
(–7·33 to 
–1·48)
Madagascar 1258
(169 to 5565)
1819
(313 to 8089)
1383
(187 to 5867)
1904
(335 to 8507)
2641
(356 to 11 358)
3722
(653 to 16 368)
–6·62
(–23·17 to 
5·79)
27·96
(14·15 to 
37·39)
–4·77
(–13·15 to 
6·25)
–0·41
(–4·72 to 
4·04)
Malawi 25 256
(21 686 to 
29 780)
21 829
(19 080 to 
24 746)
33 126
(28 119 to 
39 534)
20 006
(16 290 to 
24 470)
58 382
(51 810 to 
67 436)
41 835
(37 165 to 
46 538)
–4·27
(–5·74 to 
–3·02)
12·80
(10·23 to 
17·05)
–4·38
(–5·95 to 
–2·93)
–3·63
(–6·36 to 
–1·44)
Mauritius 75
(51 to 99)
28
(22 to 37)
19
(12 to 26)
5
(3 to 6)
94
(63 to 124)
32
(26 to 42)
25·10
(18·27 to 
31·79)
30·68
(20·31 to 
39·63)
–0·82
(–4·50 to 
0·37)
3·21
(0·35 to 
6·23)
Mozambique 64 009
(50 297 to 
78 047)
35 558
(30 206 to 
40 857)
73 592
(59 146 to 
89 609)
39 419
(34 459 to 
44 370)
137 600
(109 740 to 
165 615)
74 978
(66 037 to 
83 282)
18·97
(16·40 to 
21·12)
35·66
(33·58 to 
38·21)
–3·88
(–5·13 to 
–2·54)
8·71
(6·97 to 
10·42)
Rwanda 4307
(3471 to 5579)
4419
(3595 to 5205)
5902
(4708 to 7378)
3724
(2919 to 4754)
10 209
(8282 to 13 029)
8143
(6779 to 9513)
–10·69
(–15·45 to 
–7·39)
9·21
(5·96 to 
13·75)
–4·28
(–6·93 to 
–0·18)
–8·40
(–10·82 to 
–5·09)
Seychelles 3
(0 to 21)
2
(1 to 2)
2
(0 to 16)
1
(1 to 1)
5
(1 to 36)
3
(2 to 4)
–3·27
(–17·68 to 
26·72)
30·37
(22·07 to 
54·20)
–1·47
(–10·74 to 
21·52)
–3·28
(–5·45 to 
–0·70)
Somalia 1441
(784 to 2358)
1179
(782 to 1671)
1555
(823 to 2531)
1177
(688 to 1801)
2996
(1629 to 4855)
2356
(1492 to 3432)
9·81
(–8·51 to 
34·47)
27·10
(6·39 to 
56·79)
–3·01
(–8·99 to 
3·03)
2·36
(–3·15 to 
9·30)
South Sudan 6555
(2895 to
9574)
5755
(3527 to
7575)
6137
(2979 to
8666)
4848
(3142 to
6518)
12 692
(5963 to 
18 663)
10 603
(6648 to 
14 068)
18·26
(–11·84 to 
53·75)
38·10
(0·83 to 
84·78)
–3·84
(–11·36 to 
2·50)
6·90
(–0·73 to 
19·03)
Tanzania 30 308
(24 975 to 
37 174)
35 376
(30 606 to 
41 040)
39 352
(31 857 to 
48 818)
33 666
(26 958 to 
40 319)
69 660
(58 592 to 
85 895)
69 041
(61 368 to 
78 390)
–7·83
(–10·68 to 
–5·07)
15·73
(14·13 to 
18·32)
–4·64
(–6·22 to 
–2·58)
–3·00
(–5·29 to 
–0·87)
Uganda 48 542
(33 485 to 
60 232)
26 727
(22 583 to 
31 140)
62 057
(45 900 to 
75 069)
26 212
(21 621 to 
31 785)
110 599
(80 312 to 
133 132)
52 939
(45 914 to 
60 909)
–16·94
(–20·40 to 
–13·18)
12·54
(8·09 to 
16·61)
3·81
(1·52 to 
6·44)
–5·74
(–7·21 to 
–3·73)
Zambia 20 161
(16 536 to 
24 105)
15 695
(12 805 to 
19 018)
29 368
(24 555 to 
34 316)
18 086
(14 231 to 
21 569)
49 529
(42 630 to 
56 376)
33 781
(28 877 to 
38 397)
–2·38
(–4·09 to 
–0·56)
6·08
(3·98 to 
9·04)
–4·41
(–5·98 to 
–2·95)
–5·66
(–7·75 to 
–3·21)
Southern sub-Saharan 
Africa
222 423
(198 348 to 
248 797)
160 280
(142 399 to 
180 385)
280 376
(256 508 to 
309 801)
160 992
(133 568 to 
185 435)
502 799
(470 822 to 
537 266)
321 272
(296 529 to 
350 970)
10·60
(9·80 to 
11·47)
31·17
(28·62 to 
33·63)
–4·58
(–5·16 to 
–4·00)
3·41
(1·54 to 
4·88)
Botswana 4457
(3568 to
5441)
2858
(2225 to
3707)
5232
(4268 to
6316)
2730
(2035 to
3583)
9689
(7945 to
11 571)
5588
(4576 to 
6765)
3·95
(2·35 to 
5·40)
33·85
(31·41 to 
36·43)
–8·02
(–9·67 to 
–6·19)
–6·19
(–9·00 to 
–2·81)
Lesotho 7068
(5955 to
8215)
4479
(3813 to
5359)
8259
(6785 to
9749)
4694
(3910 to
5581)
15 328
(12 983 to 
17 837)
9173
(8060 to 
10 485)
17·08
(14·96 to 
18·84)
48·45
(45·79 to 
51·23)
–4·27
(–5·72 to 
–2·82)
4·03
(1·60 to 
5·76)
Namibia 3058
(2256 to
3881)
2393
(1709 to
3089)
3886
(2991 to
4776)
1744
(1354 to
2172)
6944
(5240 to
8424)
4137
(3356 to
5038)
15·63
(14·02 to 
17·22)
35·74
(32·74 to 
38·70)
–8·69
(–10·19 to 
–7·14)
–1·81
(–3·89 to 
1·56)
South Africa 175 519
(151 842 to 
200 204)
124 429
(107 696 to 
143 955)
221 112
(198 114 to 
249 156)
127 484
(101 377 to 
150 172)
396 631
(369 966 to 
432 109)
251 912
(229 223 to 
280 072)
27·56
(26·72 to 
28·72)
54·64
(51·50 to 
57·39)
–4·68
(–5·32 to 
–4·06)
7·12
(4·50 to 
9·04)
Swaziland 4882
(3845 to
5942)
2801
(2370 to
3265)
5671
(4582 to
6959)
2465
(2045 to
2957)
10 553
(8530 to
12 964)
5266
(4702 to
5938)
16·56
(14·67 to 
18·68)
54·18
(50·68 to 
58·14)
–3·55
(–5·40 to 
–1·84)
2·41
(–0·69 to 
4·81)
(Table 3 continues on next page)
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All ages incidence and deaths (2013) Annualised rate of change (%)
Male population Female population Total 1990–2000 2000–13
Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths
(Continued from previous page)
Zimbabwe 27 438
(23 254 to 
31 845)
23 321
(19 787 to 
27 956)
36 217
(30 580 to 
41 205)
21 874
(17 670 to 
25 549)
63 655
(55 522 to 
71 292)
45 195
(40 323 to 
51 392)
–10·26
(–12·34 to 
–8·24)
24·73
(22·23 to 
27·49)
–2·57
(–4·44 to 
–0·79)
–3·38
(–6·12 to 
–1·03)
Western sub-Saharan 
Africa
139 760
(119 664 to 
165 598)
147 892
(131 751 to 
171 029)
167 215
(140 949 to 
192 831)
152 976
(133 303 to 
173 924)
306 975
(263 141 to 
356 401)
300 868
(270 318 to 
337 006)
5·79
(3·88 to 
8·08)
18·75
(16·65 to 
21·01)
–7·26
(–8·40 to 
–6·19)
0·82
(–0·38 to 
2·01)
Benin 2367
(1718 to
3196)
2050
(1541 to
2757)
2590
(1846 to
3458)
1960
(1356 to
2827)
4957
(3622 to
6595)
4010
(3091 to
5459)
6·90
(2·75 to 
10·95)
26·96
(21·60 to 
31·83)
–7·64
(–9·56 to 
–5·86)
–3·12
(–5·91 to 
0·32)
Burkina Faso 2484
(1638 to
3488)
2444
(1808 to
3188)
3618
(2393 to
5149)
2683
(1828 to
3826)
6103
(4070 to
8571)
5127
(3737 to
6724)
–20·54
(–30·80 to 
–14·01)
9·51
(5·32 to 
13·94)
–2·41
(–7·84 to 
5·77)
–12·63
(–14·84 to 
–9·11)
Cameroon 18 364
(14 701 to 
22 135)
15 653
(12 216 to 
19 636)
22 103
(17 903 to 
27 084)
15 669
(12 898 to 
18 786)
40 467
(33 508 to 
48 609)
31 322
(26 088 to 
36 873)
11·89
(9·80 to 
14·27)
34·05
(31·97 to 
36·27)
–5·71
(–7·06 to 
–4·28)
2·42
(0·39 to 
5·05)
Cape Verde 17
(6 to 40)
21
(11 to 35)
9
(3 to 22)
5
(4 to 8)
26
(9 to 63)
26
(15 to 42)
–9·59
(–23·30 to 
1·20)
18·26
(11·73 to 
26·57)
–11·77
(–18·77 to 
–1·81)
–13·57
(–20·21 to 
–6·18)
Chad 4580
(3216 to
6211)
4715
(3913 to
5774)
4904
(3431 to
6421)
4241
(3314 to
5247)
9484
(6804 to
12 391)
8956
(7597 to 
10 794)
0·15
(–5·82 to 
6·92)
14·54
(11·35 to 
18·87)
–6·62
(–10·35 to 
–3·55)
–1·05
(–3·90 to 
1·46)
Côte d’Ivoire 11 756
(8303 to 
15 969)
14 804
(11 522 to 
18 328)
12 913
(9713 to
16 926)
11 511
(8942 to 
14 260)
24 670
(18 594 to 
32 159)
26 315
(21 554 to 
31 624)
1·29
(–3·49 to 
5·05)
17·76
(14·34 to 
21·24)
–7·91
(–10·88 to 
–4·88)
–3·15
(–5·63 to 
–0·34)
Ghana 4562
(2807 to
6873)
7302
(5449 to
9719)
6214
(3844 to
9119)
7413
(5136 to 
10 470)
10 775
(6634 to
15 847)
14 715
(11 072 to 
19 639)
2·08
(–2·57 to 
6·45)
19·90
(15·13 to 
25·45)
–10·73
(–14·08 to 
–7·89)
–4·28
(–6·87 to 
–0·80)
Guinea 5288
(3327 to 7872)
3190
(2051 to 4909)
6118
(3853 to 8838)
3236
(2104 to 4951)
11 406
(7224 to 16 543)
6425
(4343 to 9729)
15·40
(10·07 to 
19·71)
22·54
(18·87 to 
27·50)
–2·32
(–5·40 to 
0·42)
4·03
(1·06 to 
7·06)
Guinea–Bissau 1713
(1074 to 2533)
1200
(845 to 1597)
2052
(1253 to 3137)
1300
(914 to 1797)
3765
(2397 to 5676)
2500
(1713 to 3432)
21·73
(16·50 to 
25·97)
32·16
(29·45 to 
35·80)
–3·06
(–6·89 to 
–0·10)
8·85
(5·19 to 
12·38)
Liberia 315
(137 to 553)
1063
(842 to 1343)
366
(155 to 639)
1089
(843 to 1398)
681
(293 to 1186)
2152
(1746 to 2627)
10·04
(5·46 to 
14·39)
34·21
(24·64 to 
42·30)
–19·21
(–25·38 to 
–14·51)
–2·69
(–6·83 to 
1·78)
Mali 1976
(847 to 3299)
2616
(1762 to 3605)
2358
(963 to 4093)
2230
(1382 to 3417)
4334
(1866 to 7275)
4846
(3188 to 6966)
0·24
(–8·31 to 
8·15)
22·52
(17·20 to 
27·07)
–9·26
(–16·68 to 
–3·40)
–4·37
(–6·98 to 
–0·98)
Mauritania 123
(11 to 595)
204
(21 to 1193)
144
(12 to 716)
249
(19 to 1486)
267
(23 to 1293)
453
(40 to 2640)
13·71
(–4·12 to 
26·42)
22·05
(10·46 to 
32·73)
–14·15
(–24·77 to 
–2·41)
–1·00
(–8·02 to 
5·55)
Niger 739
(279 to 1477)
2131
(1530 to 2889)
600
(233 to 1234)
1246
(787 to 1776)
1340
(516 to 2678)
3377
(2382 to 4617)
11·14
(4·39 to 
16·80)
26·52
(19·89 to 
36·62)
–18·89
(–27·70 to 
–11·84)
–1·62
(–6·29 to 
3·50)
Nigeria 80 309
(61 339 to 
100 239)
83 530
(70 612 to 
104 376)
97 025
(73 874 to 
120 279)
92 271
(74 817 to 
111 822)
177 334
(140 750 to 
223 268)
175 801
(152 011 to 
208 115)
8·76
(5·07 to 
13·97)
20·63
(17·02 to 
26·66)
–7·03
(–9·22 to 
–5·28)
4·09
(1·71 to 
5·95)
São Tomé and 
PrÍncipe
33
(4 to 151)
42
(4 to 230)
19
(2 to 87)
18
(1 to 121)
52
(7 to 235)
59
(5 to 366)
34·76
(8·14 to 
55·50)
44·76
(16·38 to 
63·23)
–10·01
(–18·48 to 
1·68)
7·12
(–0·99 to 
15·06)
Senegal 668
(169 to 1392)
1447
(953 to 2073)
934
(226 to 1967)
2406
(1483 to 3468)
1602
(400 to 3361)
3852
(2494 to 5417)
10·98
(8·36 to 
13·64)
16·05
(12·65 to 
19·20)
–15·04
(–24·99 to 
–8·92)
3·50
(1·37 to 
5·39)
Sierra Leone 2058
(759 to 4122)
2050
(1217 to 3303)
2243
(838 to 4491)
2018
(1199 to 3301)
4301
(1616 to 8689)
4069
(2504 to 6569)
20·95
(13·19 to 
28·46)
24·42
(14·25 to 
32·72)
–5·30
(–11·74 to 
–0·08)
9·12
(5·02 to 
13·17)
(Table 3 continues on next page)
Articles
1028 www.thelancet.com   Vol 384   September 13, 2014
period 1985–2013. We have included in our analysis, 
surveys reporting on pulmonary smear-positive tuber-
culosis and bacteriologically positive tuberculosis. We 
included in the Bayesian meta-regression study level 
dummy variables for the diﬀ erent measured outcomes 
with the reference category being bacteriologically positive. 
We allowed for non-sampling variance for sub-national 
surveys to be larger which eﬀ ectively down-weighted their 
importance for the estimation in a given country. Because 
mortality and incidence data are for all forms of 
tuberculosis, we adjusted prevalence surveys to account for 
extra pulmonary cases using the same factors used in the 
adjustment of case notiﬁ cation data.
Mortality
We used 2731 country-years of nationally representative 
vital registration data and 166 site-years of verbal autopsy 
data to estimate tuberculosis mortality. Vital registration 
data were adjusted for garbage coding following GBD 
algorithms74,85 and misclassiﬁ ed HIV deaths described 
above. We modelled deaths by age and sex for tuberculosis 
using the Cause of Death Ensemble modelling (CODEm) 
approach.76 CODEm has been extensively used in global 
cause of death analyses.74 Using CODEm, we tested a wide 
range of potential models and used out-of-sample 
predictive validity to select the best individual models and 
the best ensemble of these models. The appendix 
(pp 152–186) shows details on the application of CODEm 
to tuberculosis. We ran CODEm separately for male and 
female individuals. The ﬁ nal ensemble models selected 
had a root-mean squared error of the log of the age-speciﬁ c 
death rate of 0·29 in-sample and 0·63 out-of-sample for 
males and 0·70 in-sample and 1·05 out-of-sample for 
females. In the out-of-sample predictive validity testing 
(cross-validation), the coverage of the 95% data prediction 
uncertainty interval was 93% and 91% for males and 
females, respectively.
CODEm results are largely informed by ICD-coded 
data, which by deﬁ nition exclude tuberculosis mortality 
in HIV-positive individuals. The overall Bayesian model, 
however, is for all forms of tuberculosis in HIV-negative 
and HIV-positive people because prevalence data rarely 
distinguish HIV status. We estimated the fraction of HIV 
deaths due to tuberculosis-HIV and added these to 
tuberculosis mortality in HIV-negative people. The model 
for the fraction of tuberculosis-HIV mortality was based 
on 1022 country-years of data when cause of death data 
for tuberculosis-HIV and HIV overall were available. We 
estimated the relation between the logit-transformed 
fraction of HIV deaths due to tuberculosis-HIV and the 
log-transformed tuberculosis death rate, a dummy 
variable for sex, year, and country random eﬀ ects. We 
used this regression to predict the fraction of HIV deaths 
due to tuberculosis-HIV in all countries.
Remission and excess mortality estimates
To help inform the model, we generated a Bayesian prior 
for remission by examining the ratio of incidence to 
prevalence in the country-years where prevalence surveys 
have been undertaken. We used a simple regression with 
random eﬀ ects to generate priors for countries with 
surveys and those without. Cause-speciﬁ c mortality 
estimates inform estimates of prevalence through excess 
mortality in DisMod-MR 2.0. To provide the model with 
the range of age-speciﬁ c and sex-speciﬁ c excess mortality 
hazards associated with tuberculosis we analysed historical 
data where we had both tuberculosis mortality data and 
incidence data that were believed to be nearly complete. 
For this analysis, we used the WHO case notiﬁ cations 
from 1980 onwards with the supplement of age-sex-speciﬁ c 
case notiﬁ cations back to the 1950s for Australia, Canada, 
the UK, USA, Japan, and Germany. Case notiﬁ cation data 
were combined with tuberculosis deaths recorded in the 
vital registration systems to generate 743 country-year 
observations from 70 countries that could be used to 
inform our analysis. We estimated the relation between 
incidence and mortality for each sex, by regressing the 
logit-transformed ratio of incidence to mortality against 
age, lag-distributed income per head, and country random 
eﬀ ects. The addition of HIV prevalence oﬀ -ART to the 
regression gave inconsistent coeﬃ  cients between females 
and males and was not included in the ﬁ nal model. We 
estimated the relation between incidence and prevalence 
as a function of lag-distributed income per head with 
All ages incidence and deaths (2013) Annualised rate of change (%)
Male population Female population Total 1990–2000 2000–13
Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths
(Continued from previous page)
The Gambia 306
(170 to 458)
296
(196 to 411)
392
(223 to 590)
234
(144 to 350)
698
(399 to 1035)
529
(355 to 739)
21·09
(18·06 to 
24·27)
21·36
(15·98 to 
29·34)
–8·00
(–12·18 to 
–4·68)
3·62
(0·46 to 
7·61)
Togo 2100
(1380 to 2771)
3133
(2563 to 3808)
2611
(1766 to 3610)
3196
(2524 to 3915)
4710
(3259 to 6327)
6329
(5267 to 7440)
8·40
(6·28 to 
10·25)
24·73
(19·89 to 
31·75)
–11·53
(–14·44 to 
–9·09)
0·60
(–2·10 to 
3·14)
Data in parentheses are 95% uncertainty intervals.
 Table 3: HIV/AIDS incidence and deaths for all ages by sex and annualised rates of change for 21 Global Burden of Disease regions and 188 countries
Australia (Prof G J Hankey MD); 
Parc Sanitari Sant Joan de Déu, 
CIBERSAM, University of 
Barcelona, Sant Boi de 
Llobregat, Barcelona, Spain 
(Prof J M Haro MD); Mazandaran 
University of Medical Sciences, 
Sari, Mazandaran, Iran 
(Prof M T Hedayati PhD); 
National Institute of Public 
Health of Mexico, Cuernavaca, 
Morelos, Mexico 
(I B Heredia Pi PhD, 
F Mejia-Rodriguez MD, 
A D Quezada MSc, 
Prof E E Servan-Mori MSc); 
Parnassia Psychiatric Institute, 
The Hague, Netherlands 
(Prof H W Hoek MD); Cedar 
Associates, Menlo Park, CA, 
USA (Prof J C Hornberger MD); 
Albert Einstein College of 
Medicine, Bronx, NY, USA 
(Prof H D Hosgood PhD); Baylor 
College of Medicine, Houston, 
TX, USA (Prof P J Hotez PhD); 
Aarhus University, Aarhus, 
Denmark (K M Iburg PhD); 
National Institute for Health 
Development, Tallinn, Estonia 
(K Innos PhD, M Leinsalu PhD); 
George Mason University, 
Fairfax, VA, USA 
(K H Jacobsen PhD); Centre for 
Chronic Disease Control, New 
Delhi, India (P Jeemon PhD); 
Tianjin Centers for Diseases 
Control and Prevention, 
Tianjin, China (Prof G Jiang MD); 
Department of 
Ophthalmology, Medical 
Faculty Mannheim of the 
University of Heidelberg, 
Mannheim, Germany 
(Prof J B Jonas MD); The 
National Institute of Public 
Health, Copenhagen, Denmark 
(Prof K Juel PhD); Fudan 
University, Shanghai, China 
(Prof H Kan MD); University of 
Balamand, Beirut, Lebanon 
(Prof N E Karam MD); Helmholtz
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country random eﬀ ects. We transformed predicted death 
to incidence ratios and incidence to prevalence ratios into 
estimates of excess mortality and remission using the 
mathematical relations between them (appendix p 7).
DisMod-MR 2.0
For each country we included in the DisMod-MR 2.0 
estimation the adjusted case notiﬁ cations, prevalence 
survey data if available, estimated excess mortality hazard 
by age and sex, estimated remission, and the tuberculosis-
HIV adjusted cause-speciﬁ c mortality estimates from 
our CODEm model. DisMod-MR 2.0 provides internally 
consistent estimates for 1990, 1995, 2000, 2005, 2010, and 
2013 for 188 countries of incidence, remission, excess 
mortality, prevalence, and cause-speciﬁ c mortality using 
all forms of data or priors in the estimation. Figure 5 
shows the internally consistent ﬁ t for Kenya in 2013. For 
intervening years, we interpolated rates.
Estimating tuberculosis incidence, prevalence, and death in 
individuals who are HIV-positive
We used tuberculosis all-forms estimates from 
DisMod-MR 2.0 to estimate incidence and prevalence in 
HIV-positive people using a relative risk approach. We 
reviewed the literature using the search terms 
“incidence”, “risk ratio”, “HIV”, ”tuberculosis”, and 
“antiretroviral therapy” and used meta-regression to 
estimate a relative risk of tuberculosis incidence in HIV-
positive individuals in the absence of ARTs based on 
seven studies86–92 of 8·7 (95% CI 5·9–11·7). Findings 
from previous studies show that the relative risk of 
tuberculosis incidence is a function of CD4 count and 
ART; to parse out the increasing risk ratios of tuberculosis 
by decreasing CD4 count and the decreasing risk ratio on 
ART we used data from the Badri and colleagues’ study.93 
The relative risks we calculated from this analysis were 
15·7 (10·6–21·1) for a CD4 cell count less than 200, 
10·8 (7·3–14·5) for a cell count of 200–350, 3·2 (2·2–4·3) 
for a count greater than 350, and 1·7 (1·2–2·3) for the on-
ART category. We computed population-attributable 
fractions for each category using the outputs of Spectrum 
above. For prevalence, we assumed that each category of 
incident tuberculosis cases in HIV-positive individuals 
has the same duration. Tuberculosis-HIV mortality was 
estimated as described above.
Malaria
Murray and colleagues developed estimates of mortality 
and incidence for malaria for the GBD 2010.74,94 They 
estimated malaria mortality using vital registration and 
verbal autopsy data analysed using CODEm. Published 
community incidence studies were meta-analysed to 
generate a model of incidence as a function of mortality, 
age, sex and region. We have modiﬁ ed this method for 
the GBD 2013 update. Much debate emerged since the 
publication of that analysis on the validity of verbal 
autopsy for adult malaria deaths.95–100 For the GBD 2013, 
we undertook a systematic review of the literature on 
the validity of verbal autopsy for malaria. Our inclusion 
criteria were validation studies that used physician-
certiﬁ ed verbal autopsies, reported both sensitivity and 
speciﬁ city for malaria, and had hospital diagnosis as 
the gold standard. However, the quality of the gold 
standards used in these studies was variable, and in 
some of them malaria cases were not conﬁ rmed with a 
blood smear or did not use a case deﬁ nition with a 
threshold of parasitaemia. We identiﬁ ed seven 
studies.101–107 We ﬁ rst tested in a meta-regression if there 
was any statistically signiﬁ cant diﬀ erence between 
studies with and without parasitaemia conﬁ rmation 
Figure 11: Years of life saved (YLS) through prophylactic treatment by region in 1990–2003 (A), 2004–08 (B), and 2009–13 (C), both sexes
Treatment includes antiretroviral therapy, prevention of mother-to-child transmission, and co-trimoxazole prophylaxis.
A 1990–2003 (1·50 million YLS)
Region:
B 2004–08 (3·88 million YLS) C 2009–13 (13·67 million YLS)
Andean Latin America
Australasia
Caribbean
Central Asia
Central Europe
Central Latin America
Central sub-Saharan Africa
East Asia
Eastern Europe
Eastern sub-Saharan Africa
High-income Asia Paciﬁc
High-income North America
North Africa and Middle East
Oceania
South Asia
Southeast Asia
Southern Latin America
Southern sub-Saharan Africa
Tropical Latin America
Western Europe
Western sub-Saharan Africa
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(E A Khan MPH); Institute of 
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Australia (Y Kinfu PhD); 
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and Department of Health 
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Epidemiologic Informatics, 
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and identiﬁ ed none. We meta-analysed these studies to 
estimate sensitivity and speciﬁ city, separately for 
children and adults. Forest plots for adult and children 
are shown in ﬁ gure 6. As a sensitivity analysis, we used 
this correction but it leads to substantially larger 
numbers of estimated deaths in adults from malaria 
(appendix p 21). We have chosen not to correct the data 
for the main results of this paper because it would 
adjust deaths in adults upwards which is contrary to 
expert opinion in the literature.
In view of the fact that we have not applied the 
sensitivity and speciﬁ city corrections, we have instead 
modiﬁ ed the redistribution of garbage codes such as 
fever of unknown origin or ill-deﬁ ned deaths, so that we 
do not redistribute garbage codes to malaria in adults. 
We have also updated all the times-series covariates 
tested in the models: rainfall, health-system access, 
antimalarial drug resistance weighted by drug use, ITN 
coverage, indoor residual spraying coverage, income per 
head, and educational attainment. We have also included 
in the model the 2010 P falciparum parasite rate (PfPR) 
map from the Malaria Atlas Project.108 A coherent analysis 
of PfPR overtime is underway but was not available for 
this analysis (see the appendix pp 223–40 for details on 
the CODEm model analysis). As in the Murray and 
colleagues study, we developed separate models for sub-
Saharan Africa and outside of Africa (with the exception 
of South Africa, which was modelled with countries 
outside of Africa, given the low malaria endemicity), age 
under 5 years and 5 years or higher, and males and 
females.
For countries that have only or mainly Plasmodium 
vivax transmission we used the number of deaths by year 
and age from vital registration data as a simple predictor 
of malaria mortality using a negative binomial regression 
model.
We estimated malaria cases separately for three sets of 
countries, which were divided on the basis of the 
availability and quality of malaria incidence data (see 
appendix pp 241–42 for the list of countries). The ﬁ rst 
group contained countries with unavailable or unreliable 
malaria case reporting systems. We estimated malaria 
incidence in these countries using a mortality-incidence 
model, in which we predicted malaria incidence by 
regressing the log-transformed study-level incidence on 
the log-transformed malaria mortality rate, age-group 
indicators, a sub-Saharan Africa indicator, an indicator 
distinguishing active versus passive case detection (set 
to active when generating predictions), and the ratio of 
the site-speciﬁ c PfPR to national PfPR (from MAP 2010; 
set to the value 1 when generating predictions so that the 
estimates are nationally representative). In this model, 
the incidence data came from available studies and the 
mortality data came from our CODEm analysis. The 
second group included countries for which there were 
incomplete administrative data, for which we predicted 
malaria incidence by regressing incidence data from the 
World Malaria Report 2013 on national-level PfPR. We 
corrected for underreporting using a composite indicator 
for health system access as a proxy. The third group 
contained countries with complete and reliable adminis-
trative case reports, for which we used reported numbers 
as published in the World Malaria Report.
CoDCorrect algorithm
As with all causes of death analysed for the GBD, we 
require that the sum of each individual cause of death for 
a country, age, sex, and year equals the estimate of all-
cause mortality. The CoDCorrect algorithm rescales the 
sum of causes at the individual draw level. The eﬀ ect of 
this simple algorithm is to change causes that have larger 
uncertainty intervals if there is a mismatch between the 
sum of cause-speciﬁ c mortality and all-cause mortality. 
To preserve the relations between incidence, prevalence, 
and death that come from the Spectrum analysis, the 
entire epidemic curve for HIV is scaled in CoDCorrect.
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The authors had access to the data 
in the study and the ﬁ nal responsibility to submit the 
paper for publication.
Results
Figure 7 shows the estimated trend in global numbers of 
incident cases, people living with HIV (prevalence), and 
deaths from HIV. Global HIV incidence peaked in 1997 
Figure 12: Comparison of 43 national HIV prevalence survey results for people aged 15–49 to prevalence 
estimates from the GBD 2013 and UNAIDS for the same year and age-group
Each point corresponds to an estimate for a particular country, survey year, sex, and 5-year age group. The solid 
line indicates the line of equivalence.
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with 2·8 million (95% uncertainty intervals 2·7 to 3·1) 
new infections and has since decreased at 2·7% 
(2·0 to 3·1) per year. From 1997 to 2005, incidence 
decreased at 3·8% (3·0 to 4·6) per year and from 2005 to 
2013 at 1·6% (0·6 to 2·4) per year. New infections in 
children decreased from 340 000 (323 000 to 363 000) in 
2000 to 134 000 (123 000 to 152 000) in 2013 at an 
annualised rate of change (ARC) of –7·2% (–7·8 to –6·4%), 
while new infections in adults decreased from 2·3 million 
(2·1 million to 2·4 million) to 1·7 million (1·6 million to 
2·0 million), falling at 2·4% (1·6 to 3·0) per year, on 
average, during this period. Annual incidence estimated 
by UNAIDS is uniformly higher in the years shown and 
shows a sharper rate of decrease. Prevalence of individuals 
infected with HIV has steadily risen to 29·2 million 
(28·1 million to 31·7 million) in 2013 rising more rapidly 
from 1990 until about 2000 at an annual rate of change of 
10·6% (10·1 to 11·3), and increasing at 1·2% (0·9 to 1·4) 
per year since (ﬁ gure 7). Compared with UNAIDS’s 
estimations, our estimation for 2012 suggest 6·6 million 
fewer individuals living with HIV. 32·0% of this 
diﬀ erence is in sub-Saharan Africa and 68·0% is 
elsewhere. Figure 7 shows trends for HIV deaths 
compared with UNAIDS estimations, with a peak 
mortality of 1·7 million (1·6 million to 1·9 million) in 
2005. Annual mortality has subsequently fallen to 
1·3 million (1·3 million to 1·5 million) in 2013, an ARC of 
–3·1% (–4·0 to 2·2). While the time trend of mortality 
estimated by UNAIDS is similar to ours, the estimated 
number of deaths is substantially greater. At the peak of 
the epidemic in 2005, our revised assessment of the HIV 
epidemic suggests 635 000 fewer deaths than UNAIDS’s 
estimates, although the diﬀ erence (240 000) narrows 
substantially by 2012, the last year available from 
UNAIDS. For the interval 2005–12, the UNAIDS ARC for 
death numbers was –5·0% (–5·6 to –4·5), reﬂ ecting the 
lower assumed death rates on ART in the UNAIDS 
version of Spectrum.
New HIV infections are concentrated in young adults 
and to a much lesser extent, in children under 5 years of 
age (ﬁ gure 8); 4·1% (3·8 to 4·5) of new infections occur 
in idividuals older than 60 years. New cases in 2013 
occurred equally in both sexes. However, there are more 
infections in women than men at ages 15–24 years. 
Incidence in children, and in older adults, is similar for 
both sexes. Showing a mean survival time of more than 
10 years in most countries and age-groups, the age 
pattern of deaths peaks in women at ages 35–39 years 
and in men at 40–44 years (ﬁ gure 8). More deaths are in 
male individuals (53·9% [51·9 to 56·1]) than in female 
individuals. The proportion of deaths that occur beyond 
age 60 years (6·8% [6·2 to 7·4]) is larger than the 
proportion of incident cases that occur beyond age 
60 years (4·1% [3·8 to 4·5]).
Table 2 shows the ARCs for 1990–2000 and 2000–13 for 
incidence, prevalence, and death for the 21 GBD regions 
and the world. ARCs between two ﬁ xed time periods 
need to be interpreted bearing in mind that measures of 
the HIV epidemic such as incidence and death will have 
peaked and decreased in particular countries at diﬀ erent 
times during the interval. Nevertheless, our ﬁ ndings 
show the accelerated progress in most of the world’s 
regions. The only regions with a reversal in the ARC 
such that incidence was decreasing but in the later period 
is increasing or stagnating are southeast Asia, high-
income North America, western Europe, Australasia, and 
Tropical Latin America. The reversal in southeast Asia 
Figure 13: Global tuberculosis incidence (A), prevalence (B), and deaths (C), 1990–2013, for all ages and both 
sexes combined
Shaded areas show 95% uncertainty intervals.
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can be explained by the large decrease in the 1990s 
achieved by a successful campaign to reduce infection 
through commercial sex encounters in Thailand, the 
country in the region with the largest epidemic. The 
reversal of incidence trends in North America might 
show a wearing oﬀ  of the eﬀ ect of public health measures 
to reduce the risk of transmission in men who have sex 
with men.
Age-standardised HIV incidence rates per 
100 000 population (ﬁ gure 9) in 2013 ranged from less than 
0·7 in a group of countries ringing the Eastern 
Mediterranean, parts of northern and central Europe, and 
Mongolia, to more than 570 in South Africa, Lesotho, and 
Swaziland. HIV infection follows distinct geographic 
patterns with continued high levels of infection throughout 
eastern and southern Africa, with some exceptions. 
Rwanda, Burundi, DR Congo, Congo, and Gabon all have 
incidence rates less than 120 per 100 000 population, lower 
than their neighbouring countries. Incidence rates vary 
widely in sub-Saharan Africa, but are more homogenous 
across countries in Asia as well as North and South 
America. Important exceptions to these patterns include 
incidence rates above 15 per 100 000 population in many 
Caribbean countries. Incidence rates are notably higher in 
Portugal and Ukraine, as well as Russia and some Central 
Asian republics. Figure 9 shows prevalence rates in 
countries in 2013. Geographical patterns are similar to 
incidence, although some diﬀ erences are noteworthy. 
Prevalence levels are highest in Botswana, Lesotho, and 
Swaziland (above 12 000 per 100 000 population). There is 
substantial variation within sub-Saharan Africa; prevalence 
rates in Botswana, for example, are 15 times higher than in 
the DR Congo and 40 times higher than in Niger. In 
southeast Asia, prevalence is substantially higher in 
Thailand and Papua New Guinea. Prevalence rates are 
comparatively high in parts of Europe and central Asia 
(Portugal, Spain, Ukraine, Russia, and Kazakhstan) and in 
Latin America and the Caribbean (Panama, Honduras, 
Belize, Guatemala, Guyana, Suriname, Haiti, Dominican 
Republic, Jamaica, and Bahamas) prevalence levels exceed 
220 per 100 000 population. Comparison of incidence and 
prevalence in ﬁ gure 9 draws attention to some diﬀ erences 
for countries in their comparative ranking, such as for 
Sweden and Australia. Cross-national variations in HIV 
mortality rates per 100 000 population, largely mirror the 
pattern reported for prevalence, varying from less than 
0·2 in northern and central Europe and the Eastern 
Mediterranean, to more than 520 in southern Africa, a 
roughly 2500-fold diﬀ erence (ﬁ gure 10). Table 3 shows 
more detail on the estimated number of new infections and 
deaths in 2013 for both sexes, individually and combined, 
for 188 countries, along with ARCs in age-standardised 
incidence and death rates for both sexes combined.
By comparing the estimated number of person-years lived 
in a no-intervention scenario with actual estimates, we can 
compute the years of life saved through ART, PMTCT, and 
co-trimoxazole prophylaxis. Figure 11 shows cumulative 
years of life saved by GBD region as a result of these 
interventions during three phases of scale-up. From 1990 to 
2003, 1·5 million years of life (1·2 million to 1·9 million) 
were saved, of which only 22·7% (14·2 to 32·1) were in 
populations living in developing countries, largely in Brazil. 
The number of years of life saved increased substantially in 
the period 2004 to 2008 to 3·9 million (3·2 million to 
4·7 million), and the share in populations in developing 
countries increased to 52·6% (44·1 to 62·2). Between 2009 
and 2013, the number of life-years saved was 13·7 million 
(11·8 million to 15·7 million). A much greater share 
(40·8% [33·8 to 47·6]) of these life-years saved were in 
eastern and southern sub-Saharan Africa, and a further 
12·1% (9·0 to 15·7) in western sub-Saharan Africa. Other 
regions to beneﬁ t substantially from HIV interventions 
include high-income North America, western Europe, and 
south Asia. The number of years of life saved continues to 
Figure 14: Global age-sex distribution of tuberculosis incidence (A) and deaths (B) in HIV-negative 
individuals in 2013
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grow rapidly due both to the continued expansion of ART 
and the cumulative eﬀ ect of infections prevented in 
children. By 2013, the global cumulative number of years of 
life saved was 19·1 million (16·6 million to 21·5 million); 
14·2% (12·4 to 16·2) at ages younger than 15 years, 
49·7% (45·8 to 53·4) at age 15–49 years, and 
36·1% (32·7 to 39·5) at 50 years of age or older.
Since 2000, cumulative DAH for HIV up through 2011 
totals $51·6 billion, of which $32·7 billion can be traced to 
speciﬁ c developing country programmes in 2011 US 
dollars.109 Comparison of the total amount invested in HIV 
prevention and treatment to the years of life saved during 
2000–11 yields in developing countries a ratio of $4498 per 
life-year saved. The ratio of DAH for HIV to years of life 
saved varies widely from $2·38 in Uruguay per life-year 
saved to $1·87 million in Mongolia per life-year saved.
The scale-up of ART has been variable across countries. 
Because of the temporal dynamics of the epidemic in 
Age–standardised rates in 2013 (per 100 000 population) Annualised rate of change (%)
1990–2000 2000–2013
Incidence Prevalence Mortality Incidence Prevalence Mortality Incidence Prevalence Mortality
Worldwide 98·65
(96·16 to 101·43)
159·00
(154·14 to 164·10)
19·24
(17·44 to 20·98)
0·03
(–0·17 to 0·25)
0·41
(0·23 to 0·58)
–3·29
(–4·07 to –2·58)
–0·60
(–0·73 to –0·50)
–1·31
(–1·41 to –1·20)
–3·72
(–4·42 to –2·99)
High-income 
Asia Paciﬁ c
34·36
(33·42 to 35·26)
62·80
(59·34 to 66·56)
2·14
(1·91 to 2·59)
–0·04
(–0·27 to 0·20)
–1·64
(–1·99 to –1·30)
–6·22
(–6·85 to –5·42)
0·11
(–0·06 to 0·27)
0·13
(–0·18 to 0·40)
–5·03
(–5·85 to –3·99)
Central Asia 122·11
(118·41 to 125·73)
179·30
(172·60 to 186·59)
11·08
(7·89 to 12·68)
1·03
(0·77 to 1·32)
1·03
(0·82 to 1·26)
5·50
(0·65 to 6·52)
–0·76
(–0·92 to –0·58)
–0·68
(–0·85 to –0·50)
–4·97
(–5·83 to –4·07)
East Asia 74·16
(71·90 to 76·54)
130·70
(125·21 to 136·66)
3·44
(3·00 to 3·99)
0·23
(–0·09 to 0·60)
0·68
(0·34 to 1·00)
–6·70
(–7·93 to –5·73)
–2·08
(–2·36 to –1·85)
–3·16
(–3·44 to –2·86)
–7·54
(–8·53 to –6·63)
South Asia 166·45
(160·83 to 172·18)
265·95
(256·77 to 275·37)
51·54
(43·79 to 59·81)
–0·77
(–1·10 to –0·41)
0·02
(–0·27 to 0·31)
–4·96
(–6·26 to –3·69)
–1·06
(–1·30 to –0·80)
–2·43
(–2·65 to –2·20)
–4·22
(–5·64 to –2·89)
Southeast Asia 145·16
(140·54 to 148·79)
300·95
(289·61 to 311·88)
41·83
(34·22 to 47·27)
1·59
(1·34 to 1·83)
1·42
(1·17 to 1·63)
–4·10
(–4·95 to –3·23)
–0·54
(–0·68 to –0·42)
0·12
(–0·03 to 0·28)
–3·61
(–4·42 to –2·82)
Australasia 6·38
(6·17 to 6·58)
11·11
(10·48 to 11·79)
0·24
(0·20 to 0·27)
–0·23
(–0·61 to 0·16)
–1·00
(–1·37 to –0·60)
–4·13
(–5·09 to –3·21)
–0·22
(–0·41 to –0·03)
–0·36
(–0·66 to –0·08)
–3·63
(–4·62 to –2·62)
Caribbean 55·36
(53·72 to 57·02)
70·84
(68·52 to 73·41)
7·19
(6·17 to 9·38)
1·89
(1·56 to 2·19)
0·87
(0·62 to 1·08)
–6·30
(–7·35 to –4·92)
–0·20
(–0·35 to –0·05)
–1·15
(–1·32 to –0·98)
–3·93
(–4·93 to –2·50)
Central Europe 26·72
(25·97 to 27·46)
41·97
(40·52 to 43·45)
1·69
(1·57 to 1·97)
1·58
(1·40 to 1·75)
0·40
(0·26 to 0·56)
–2·77
(–3·18 to –1·98)
–1·61
(–1·74 to –1·50)
–0·29
(–0·42 to –0·17)
–5·95
(–6·43 to –5·27)
Eastern Europe 79·27
(76·34 to 82·09)
118·55
(113·61 to 123·59)
7·89
(5·14 to 8·64)
1·33
(0·99 to 1·69)
1·73
(1·40 to 2·03)
8·28
(5·46 to 9·09)
–0·58
(–0·80 to –0·39)
–0·75
(–0·97 to –0·53)
–4·80
(–7·62 to –3·91)
Western Europe 10·84
(10·52 to 11·15)
17·25
(16·56 to 17·93)
0·54
(0·50 to 0·64)
–0·23
(–0·39 to –0·03)
–0·72
(–0·88 to –0·56)
–4·22
(–4·67 to –3·81)
–1·18
(–1·28 to –1·08)
–0·64
(–0·78 to –0·52)
–4·88
(–5·53 to –3·78)
Andean 
Latin America
117·89
(113·83 to 122·14)
161·10
(153·28 to 168·91)
9·37
(8·16 to 11·90)
0·00
(–0·30 to 0·33)
–0·89
(–1·18 to –0·60)
–8·25
(–9·07 to –5·88)
–0·81
(–1·04 to –0·54)
–0·78
(–1·06 to –0·52)
–4·86
(–5·88 to –3·78)
Central
Latin America
32·53
(31·73 to 33·35)
49·40
(48·00 to 50·99)
3·38
(3·12 to 4·19)
0·75
(0·52 to 0·93)
–0·39
(–0·61 to –0·19)
–7·53
(–7·85 to –6·72)
–1·69
(–1·83 to –1·55)
–1·51
(–1·67 to –1·35)
–4·21
(–4·74 to –3·03)
Southern 
Latin America
26·56
(25·80 to 27·32)
38·76
(37·10 to 40·48)
2·05
(1·85 to 2·30)
1·43
(1·06 to 1·78)
–0·06
(–0·35 to 0·23)
–4·77
(–5·78 to –4·23)
–2·56
(–2·75 to –2·39)
–1·56
(–1·78 to –1·32)
–3·35
(–4·03 to –2·70)
Tropical 
Latin America
52·99
(51·17 to 54·75)
92·22
(86·87 to 97·63)
3·24
(2·40 to 3·64)
0·51
(0·07 to 0·95)
–0·12
(–0·50 to 0·30)
–2·46
(–6·28 to –1·55)
–1·27
(–1·50 to –1·08)
–0·68
(–1·04 to –0·36)
–4·33
(–5·36 to –3·47)
North Africa and 
Middle East
34·45
(33·65 to 35·29)
48·00
(46·50 to 49·55)
4·56
(4·10 to 5·37)
1·07
(0·85 to 1·30)
–0·32
(–0·50 to –0·12)
–3·72
(–4·35 to –3·07)
–1·10
(–1·18 to –1·03)
–1·26
(–1·35 to –1·16)
–4·58
(–5·34 to –3·89)
High–income 
North America
5·03
(4·84 to 5·20)
10·05
(9·49 to 10·63)
0·23
(0·19 to 0·38)
–0·75
(–0·99 to –0·52)
–2·29
(–2·60 to –1·99)
–6·84
(–7·96 to –1·42)
–3·32
(–3·55 to –3·10)
–2·28
(–2·57 to –1·97)
–4·14
(–5·14 to –1·90)
Oceania 109·58
(106·38 to 112·83)
174·93
(167·73 to 182·77)
20·21
(12·67 to 40·27)
–0·73
(–1·12 to –0·36)
–0·85
(–1·20 to –0·52)
–6·29
(–8·55 to –2·59)
0·77
(0·60 to 0·98)
0·14
(–0·09 to 0·37)
–2·96
(–4·58 to –0·91)
Central sub-
Saharan Africa
285·76
(271·43 to 299·93)
485·43
(453·81 to 520·51)
100·60
(79·63 to 118·71)
0·63
(0·14 to 1·09)
0·31
(–0·12 to 0·74)
–0·12
(–1·35 to 1·27)
0·07
(–0·12 to 0·28)
–0·17
(–0·41 to 0·06)
–3·41
(–4·67 to –1·99)
Eastern sub-
Saharan Africa
203·95
(191·93 to 217·39)
311·05
(290·44 to 333·89)
96·61
(82·38 to 104·22)
–0·99
(–1·42 to –0·54)
–1·00
(–1·43 to –0·54)
–0·67
(–1·82 to 0·09)
–0·34
(–0·52 to –0·16)
–0·38
(–0·57 to –0·20)
–3·08
(–4·12 to –2·40)
Southern sub-
Saharan Africa
719·33
(642·13 to 823·58)
942·17
(834·80 to 1,079·88)
62·50
(53·16 to 71·44)
–4·74
(–5·78 to –3·50)
–3·70
(–4·66 to –2·54)
1·34
(–0·22 to 2·77)
0·14
(–0·26 to 0·54)
–0·09
(–0·41 to 0·28)
–4·12
(–5·91 to –2·91)
Western sub-
Saharan Africa
153·58
(146·18 to 161·45)
262·32
(248·20 to 277·02)
48·48
(41·75 to 55·30)
–0·33
(–0·79 to 0·14)
–0·45
(–0·89 to –0·01)
–0·84
(–1·71 to –0·07)
–0·57
(–0·73 to –0·39)
–0·69
(–0·86 to –0·49)
–3·09
(–3·84 to –2·17)
Data in parentheses are 95% uncertainty intervals.
Table 4: Age-standardised tuberculosis without HIV incidence, prevalence, and mortality rates and annualised rates of change for both sexes for 21 Global Burden of Disease regions
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diﬀ erent countries, comparisons of intervention scale-up 
are confounded by the timing of incidence. Nevertheless, 
the appendix (p 22) shows a crude comparison of years of 
life saved over the age of 15 years divided by prevalent cases 
in people older than 15 years in 2013. This ratio ranges 
from less than 0·07 in countries with minimal intervention 
to more than 0·49 in many high-income countries. In 
developing countries, Brazil stands out with a ratio of 0·37. 
In the next tier, with ratios between 0·28 and 0·35 includes 
many countries in Latin America and Botswana, Namibia, 
Thailand, Cambodia, South Korea, and some countries in 
central Europe. In eastern and southern Africa, Ethiopia, 
Rwanda, and Burundi we saw higher ratios than in many 
of their neighbouring countries. Pronounced variation 
within regions points to the historical variation in the 
timing of the epidemic response.
Figure 12 shows a comparison of our estimated 
prevalence for country-age-sex groups against national 
population prevalence surveys. This comparison provides 
a rough check that at the end of the modelling process our 
assessment remains consistent with population-based 
prevalence measurements as well as being consistent with 
data for all-cause mortality. In general, there is a strong 
correlation (0·96) of our country-age-sex estimates with 
survey prevalence—UNAIDS prevalence is also correlated 
(0·96) with survey data. However, in 21% of cases, there is 
a statistically signiﬁ cant diﬀ erence (19% for UNAIDS). 
The coeﬃ  cients obtained by regressing both GBD and 
UNAIDS estimates on survey estimates showed that both 
methods tended to be slightly higher than the surveys; 
however, only the UNAIDS coeﬃ  cient was a statistically 
signiﬁ cantly larger than one: UNAIDS, 1·08 (1·03 to 1·13); 
GBD, 1·02 (0·98 to 1·06). Country-speciﬁ c graphs 
comparing GBD, UNAIDS, and survey prevalences by age 
and sex are shown in the appendix (p 24).
Figure 13 shows the temporal changes of tuberculosis 
incident case numbers, the number of prevalent cases, 
and the number of deaths from 1990 to 2013. Total 
tuberculosis numbers are shown as well as numbers for 
tuberculosis in individuals who are HIV-negative. The 
number of incident cases for tuberculosis in individuals 
who are HIV-negative has increased from 5·0 million 
(4·8 million to 5·1 million) in 1990 to 7·1 million 
(6·9 million to 7·3 million) in 2013—a 1·5% (1·4 to 1·6) 
annual change. Prevalence in 1990 and 2013 was 1·6 
times higher than incidence, implying a duration of 20 
months on average for a case. Prevalence rates increased 
slightly between 1990 and 2000 (ARC 0·4% [0·2 to 0·6]) 
but decreased by 1·3% (1·4 to 1·2) per year from 2000 to 
2013. Deaths from tuberculosis in individuals who are 
HIV-negative are decreasing at a faster rate, from 
1·8 million (1·7 million to 1·9 million) in 1990 to 
1·3 million (1·2 million to 1·4 million) in 2013—a –1·4% 
(–1·9 to –1·0) annual change. Decreases in death 
numbers and increases in incidence numbers implies 
that the case-fatality rate has been falling over the period; 
the ratio of deaths to incidence overall went from 
0·36 (0·33 to 0·39) in 1990 to 0·18 (0·16 to 0·20) in 
2013—a –2·9% (–3·4 to –2·5) per year rate of change. 
Most global tuberculosis incidence cases and deaths in 
individuals who are HIV-negative are in men and boys, 
64·0% (63·6 to 64·3) for incidence and 64·7% (60·8 to 70·3) 
for mortality (ﬁ gure 14). Although age-speciﬁ c rates rise 
with age up to 70 years, in view of the comparatively 
young age-structure of countries with substantial burden 
of tuberculosis in individuals who are HIV-negative, 
83·2% (82·6 to 83·8) of cases and 58·8% (56·7 to 60·6) 
of deaths were in people younger than 60 years in 2013.
Table 4 shows a summary at the global and regional 
level of the ARCs for age-standardised rates of incidence, 
prevalence, and deaths for tuberculosis in individuals 
who are HIV-negative (see the appendix p 203 for 
tuberculosis including HIV-positive individuals). At the 
global level, age-standardised mortality rates decreased by 
3·3% (4·1 to 2·6), whereas incidence remained stable 
(0·0% [–0·2 to 0·2]) and prevalence rates increased by 
0·4% (0·2 to 0·6) during the period 1990 to 2000. Global 
decreases continued in the period 2000 to 2013 for 
mortality (–3·7% [–4·4 to –3·0]) whereas incidence 
decreased by 0·6% (0·7 to 0·5) and prevalence decreased 
by 1·3% (1·4 to 1·2). Across regions, in the period 2000 to 
2013, incidence rate ARCs in individuals who are HIV-
negative ranged from 0·8% (0·6 to 1·0) in Oceania to 
–3·3% (–3·6 to –3·1) in high-income North America. 
16 of 21 regions had a greater decrease (or at least a 
smaller increase) in the incidence rate from 2000 to 2013 
than for 1990 to 2000. Mortality rate decreases in HIV-
negative individuals were greater in the period 2000 to 
2013 than the decreases in prevalence in all 21 regions. 
The global decline in prevalence from 2000 to 2013 is 
largely accounted for by the large decreases in just two 
regions: east and south Asia. In south Asia, which 
accounts for 34·8% (33·9 to 35·6) of incident cases and 
47·7% (43·5 to 51·8) of deaths in 2013, the ARCs for 
2000 to 2013 were –1·1% (–1·3 to –0·8) for incidence, 
–2·4% (–2·7 to –2·2) for prevalence, and –4·2% 
(–5·6 to –2·9) for mortality. Accelerated decreases in 
prevalence, incidence and mortality occurred in east Asia 
from 2000 to 2013: –3·2% (–3·4 to –2·9) for prevalence, 
–2·1% (–2·4 to –1·9) for incidence, and –7·5% 
(–8·5 to –6·6) for mortality. The tuberculosis trend in 
eastern Europe has reversed: in the 1990s, mortality, 
incidence, and prevalence rates were all increasing, with 
ARCs of 8·3% (5·5 to 9·1), 1·3% (1·0 to 1·7), and 
1·7% (1·4 to 2·0), respectively. However, in the period 
2000 to 2013 the trends for all three of these indicators 
have improved, with ARCs of –4·8% (–7·6 to –3·9), 
–0·6% (–0·8 to –0·4), and –0·7% (–1·0 to –0·5). Table 5 
shows incidence and deaths by country in 2013 along with 
ARCs for age-standardised rates.
Figure 15 shows maps of age-standardised incidence 
rates and death rates for tuberculosis in individuals who 
are HIV-negative in 2013. Age-standardised incidence of 
tuberculosis in individuals who are HIV-negative is more 
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All ages incidence and deaths (2013) Annualised rate of change (%)
Male population Female population Total 1990–2000 2000–13
Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths
Worldwide 4 517 530
(4 398 104 to 
4 647 059)
835 602
(739 280 to 
958 088)
2 545 138
(2 472 904 to 
2 621 788)
454 659
(356 953 to 
511 449)
7 062 668
(6 885 472 to 
7 270 226)
1 290 260
(1 167 284 to 
1 406 183)
0·03
(–0·17 to 
0·25)
–3·29 
(–4·07 to 
–2·58)
–0·60 
(–0·73 to 
–0·50)
–3·72 
(–4·42 to 
–2·99)
Developed countries 252 990
(245 783 to 
260 127)
28 495
(23 320 to 
30 615)
123 333
(120 187 to 
125 954)
10 667
(7961 to 
12 027)
376 323
(367 117 to 
385 671)
39 162
(33 106 to 
41 646)
0·55
(0·34 to 
0·76)
1·61
(0·82 to 
2·05)
–1·18
(–1·30 to 
–1·07)
–4·94
(–6·29 to 
–4·37)
Developing 
countries
4 264 541
(4 146 317 to 
4 392 574)
807 106
(711 182 to 
928 549)
2 421 804
(2 351 014 to 
2 497 867)
443 992
(349 210 to 
500 700)
6 686 345
(6 511 240 to 
6 894 801)
1 251 098
(1 131 865 to 
1 366 785)
–0·38
(–0·59 to 
–0·17)
–3·93
(–4·69 to 
–3·23)
–0·91
(–1·04 to 
–0·80)
–4·01
(–4·70 to 
–3·29)
High-income Asia 
Paciﬁ c
51 867
(50 096 to 
53 703)
5443
(4666 to
7069)
29 463
(28 593 to 
30 398)
3551
(2701 to
4417)
81 331
(78 818 to 
83 863)
8994
(7907 to
10 611)
–0·04
(–0·27 to 
0·20)
–6·22
(–6·85 to 
–5·42)
0·11
(–0·06 to 
0·27)
–5·03
(–5·85 to 
–3·99)
Brunei 22
(20 to 23)
8
(6 to 10)
15
(14 to 17)
3
(2 to 4)
37
(34 to 40)
11
(9 to 13)
–0·28
(–0·80 to 
0·18)
–1·84
(–3·80 to 
0·30)
–1·23
(–1·74 to 
–0·68)
–3·65
(–5·51 to 
–1·69)
Japan 17 594
(16 435 to 
18 685)
2906
(2327 to
3961)
10 227
(9679 to
10 881)
1915
(1301 to
2618)
27 820
(26 331 to
29 468)
4821
(3987 to
5888)
–0·64
(–1·01 to 
–0·28)
–3·86
(–5·02 to 
–2·79)
–2·73
(–3·02 to 
–2·43)
–4·61
(–5·98 to 
–2·71)
Singapore 1262
(1195 to 1331)
71
(57 to 96)
569
(542 to 595)
27
(20 to 37)
1831
(1746 to 1918)
98
(82 to 124)
–0·58
(–0·95 to 
–0·21)
–6·42
(–7·76 to 
–5·23)
–1·24
(–1·54 to 
–0·93)
–5·48
(–6·99 to 
–3·82)
South Korea 32 990
(31 527 to 
34 332)
2458
(2089 to
3220)
18 653
(17 970 to
19 309)
1606
(1164 to
2115)
51 643
(49 712 to
53 364)
4064
(3512 to
4889)
–0·32
(–0·62 to 
0·06)
–8·27
(–9·24 to 
–6·67)
0·90
(0·68 to 
1·10)
–5·53
(–6·78 to 
–4·31)
Central Asia 63 244
(61 027 to 
65 347)
6644
(4595 to
7743)
40 455
(39 133 to
41 763
2138
(1317 to
2568)
103 698
(100 303 to 
106 922)
8782
(6094 to 
10 048)
1·03
(0·77 to 
1·32)
5·50
(0·65 to 
6·52)
–0·76
(–0·92 to 
–0·58)
–4·97
(–5·83 to 
–4·07)
Armenia 1353
(1298 to 1402)
118
(73 to 139)
425
(408 to 442)
16
(8 to 20)
1778
(1713 to 1840)
134
(83 to 156)
–1·31
(–1·81 to 
–0·72)
4·34
(–0·73 to 
6·06)
0·98
(0·75 to 
1·20)
–2·15
(–4·25 to 
–0·86)
Azerbaijan 6617
(6269 to 6969)
595
(418 to 757)
2767
(2622 to 2917)
121
(86 to 160)
9383
(8942 to 9850)
716
(525 to 874)
1·00
(0·57 to 
1·43)
3·62
(–1·43 to 
5·12)
–1·88
(–2·24 to 
–1·50)
–7·12
(–8·57 to 
–5·54)
Georgia 3740
(3595 to 3887)
163
(132 to 222)
1694
(1634 to 1765)
32
(24 to 39)
5434
(5259 to 5619)
195
(164 to 249)
–0·17
(–0·68 to 
0·26)
–1·21
(–2·65 to 
0·05)
0·34
(0·07 to 
0·62)
–3·49
(–4·94 to 
–1·20)
Kazakhstan 15 156
(14 432 to 
15 855)
2009
(1542 to
2570)
10 657
(10 282 to
11 060)
474
(317 to
612)
25 813
(24 838 to
26 776)
2482
(1979 to
3028)
1·32
(0·92 to 
1·83)
7·82
(2·74 to 
9·40)
–0·72
(–0·95 to 
–0·44)
–6·38
(–8·04 to 
–4·45)
Kyrgyzstan 3958
(3790 to 4131)
495
(292 to 612)
2988
(2873 to 3109)
142
(71 to 180)
6946
(6709 to 7179)
637
(391 to 760)
0·93
(0·44 to 
1·35)
7·99
(0·61 to 
9·71)
0·50
(0·26 to 
0·74)
–4·42
(–5·81 to 
–3·13)
Mongolia 2456
(2347 to 2564)
364
(265 to 470)
1753
(1688 to 1808)
141
(90 to 183)
4208
(4053 to 4355)
505
(380 to 624)
0·40
(0·03 to 
0·83)
0·55
(–0·85 to 
2·03)
–0·27
(–0·45 to 
–0·07)
–3·36
(–5·16 to 
–1·66)
Tajikistan 6765
(6436 to
7088)
420
(239 to
557)
4827
(4570 to
5083)
259
(167 to
351)
11 593
(11 079 to
12 122)
679
(436 to
856)
1·58
(0·89 to 
2·17)
7·07
(0·76 to 
8·76)
0·27
(–0·04 to 
0·55)
–3·95
(–5·58 to 
–2·32)
Turkmenistan 2929
(2765 to 3107)
433
(265 to 605)
1675
(1586 to 1759)
132
(84 to 193)
4604
(4391 to 4839)
565
(368 to 746)
–0·44
(–0·84 to 
–0·05)
3·89
(1·36 to 
5·53)
–1·68
(–2·04 to 
–1·32)
–4·99
(–7·19 to 
–3·02)
Uzbekistan 20 271
(19 309 to 
21 224)
2048
(1002 to
2829)
13 669
(13 054 to 
14 289)
821
(420 to
1147)
33 940
(32 505 to
35 238)
2870
(1486 to
3757)
1·62
(1·16 to 
2·16)
4·43
(–1·89 to 
5·94)
–1·17
(–1·48 to 
–0·83)
–3·90
(–6·12 to 
–1·90)
East Asia 791 190
(762 944 to 
818 962)
35 550
(29 728 to 
43 445)
371 698
(358 536 to 
386 706)
13 158
(11 150 to 
16 040)
1 162 888
(1 126 383 to 
1 201 277)
48 708
(42 203 to 
56 411)
0·23
(–0·09 to 
0·60)
–6·70
(–7·93 to 
–5·73)
–2·08
(–2·36 to 
–1·85)
–7·54
(–8·53 to 
–6·63)
China 732 136
(703 787 to 
759 995)
33 391
(27 605 to 
39 691)
335 017
(322 040 to 
350 436)
11 794
(9908 to 
14 032)
1 067 153
(1 031 846 to 
1 104 841)
45 185
(39 015 to 
50 882)
0·17
(–0·16 to 
0·56)
–6·85
(–8·22 to 
–5·83)
–2·32
(–2·62 to 
–2·07)
–7·77
(–8·79 to 
–6·88)
(Table 5 continues on next page)
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All ages incidence and deaths (2013) Annualised rate of change (% )
Male population Female population Total 1990–2000 2000–13
Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths
(Continued from previous page)
North Korea 50 156
(48 217 to 
52 190)
1442
(791 to
3100)
31 827
(30 744 to 
32 904)
1117
(625 to
2029)
81 983
(79 533 to
84 781)
2559
(1576 to
5051)
1·49
(0·64 to 
2·56)
–1·38
(–3·78 to 
0·90)
1·74
(1·42 to 
2·07)
–3·11
(–5·25 to 
–0·71)
Taiwan 
(Province of China)
8899
(8465 to
9340)
717
(598 to
899)
4853
(4603 to
5129)
247
(188 to
314)
13 752
(13 142 to
14 394)
964
(836 to
1140)
–0·11
(–0·54 to 
0·39)
–6·31
(–8·33 to 
–4·24)
0·05
(–0·23 to 
0·29)
–6·30
(–8·07 to 
–4·41)
South Asia 1 633 772
(1 569 448 to 
1 702 317)
400 912
(312 339 to 
503 463)
804 753
(774 985 to 
836 828)
215 086
(166 711 to 
264 425)
2 438 524
(2 353 624 to 
2 531 209)
615 998
(519 374 to 
719 825)
–0·77
(–1·10 to 
–0·41)
–4·96
(–6·26 to 
–3·69)
–1·06
(–1·30 to 
–0·80)
–4·22
(–5·64 to 
–2·89)
Afghanistan 7570
(7322 to
7874)
2876
(1666 to
5065)
9127
(8771 to
9459)
6312
(3402 to 
10 689)
16 697
(16 178 to
17 247)
9188
(5771 to
14 906)
3·97
(3·43 to 
4·51)
–0·65
(–2·98 to 
1·86)
0·56
(0·30 to 
0·82)
–5·18
(–7·46 to 
–2·99)
Bangladesh 161 542
(153 701 to 
169 490)
12 257
(9086 to 
16 868)
102 951
(97 116 to 
107 928)
3288
(2214 to
4983)
264 493
(253 273 to 
276 373)
15 545
(12 078 to 
20 443)
1·36
(0·86 to 
1·86)
–5·55
(–8·41 to 
–3·31)
–0·36
(–0·66 to 
–0·07)
–6·73
(–8·99 to 
–3·68)
Bhutan 544
(517 to 574)
68
(31 to 109)
445
(424 to 468)
19
(9 to 33)
990
(948 to 1033)
87
(42 to 139)
0·25
(–0·09 to 
0·61)
–5·97
(–8·66 to 
–3·31)
–2·26
(–2·51 to 
–2·03)
–6·31
(–9·09 to 
–3·32)
India 1 334 126
(1 276 181 to 
1 395 002)
356 940
(271 034 to 
454 519)
581 851
(556 873 to 
607 765)
188 577
(141 824 to 
238 149)
1 915 977
(1 843 861 to 
1 993 731)
545 516
(450 129 to 
650 735)
–1·10
(–1·50 to 
–0·67)
–5·21
(–6·68 to 
–3·77)
–1·13
(–1·42 to 
–0·82)
–4·01
(–5·56 to 
–2·53)
Nepal 20 479
(19 384 to 
21 535)
5460
(3794 to
7301)
11 092
(10 611 to
11 594)
2702
(1700 to
4062)
31 571
(30 084 to 
32 938)
8162
(6007 to
10 639)
–0·03
(–0·63 to 
0·58)
–4·24
(–5·88 to 
–2·53)
–0·51
(–0·74 to 
–0·29)
–5·03
(–6·72 to 
–3·33)
Pakistan 117 080
(111 322 to 
122 526)
23 311
(16 082 to 
32 229)
108 413
(103 577 to 
113 108)
14 188
(8804 to 
19 462)
225 493
(216 308 to 
234 231)
37 499
(27 926 to 
47 069)
0·27
(–0·12 to 
0·65)
–1·27
(–3·28 to 
0·78)
–1·31
(–1·55 to 
–1·07)
–5·31
(–7·55 to 
–3·08)
Southeast Asia 541 691
(520 045 to 
558 187)
130 046
(109 419 to 
150 362)
321 035
(311 259 to 
330 942)
63 824
(40 144 to 
75 348)
862 726
(833 162 to 
886 678)
193 870
(158 363 to 
219 911)
1·59
(1·34 to 
1·83)
–4·10
(–4·95 to 
–3·23)
–0·54
(–0·68 to 
–0·42)
–3·61
(–4·42 to 
–2·82)
Cambodia 16 661
(15 170 to
17 531)
2545
(1709 to
3420)
12 926
(12 358 to
13 427)
1213
(867 to
1704)
29 587
(27 838 to
30 741)
3758
(2878 to
4773)
1·36
(–0·01 to 
1·87)
–3·77
(–5·90 to 
–1·71)
–1·45
(–1·78 to 
–0·60)
–5·59
(–7·45 to 
–3·59)
Indonesia 186 734
(175 949 to 
195 308)
71 151
(53 474 to 
85 108)
154 066
(147 342 to 
160 217)
37 572
(15 822 to 
47 009)
340 799
(325 302 to 
352 949)
108 723
(73 764 to 
127 293)
3·13
(2·71 to 
3·53)
–3·86
(–5·13 to 
–2·57)
0·43
(0·11 to 
0·71)
–2·62
(–3·94 to 
–1·47)
Laos 7204
(6684 to
7594)
859
(489 to
1466)
3955
(3715 to
4163)
832
(393 to
1448)
11 160
(10 442 to
11 715)
1691
(987 to
2779)
3·06
(2·35 to 
3·71)
–3·02
(–5·76 to 
–0·36)
–0·75
(–1·02 to 
–0·44)
–4·16
(–6·44 to 
–1·55)
Malaysia 17 498
(16 676 to 
18 406)
1334
(1016 to
1599)
9246
(8850 to
9667)
389
(236 to
483)
26 744
(25 651 to
27 926)
1723
(1311 to
1991)
–0·36
(–0·79 to 
0·05)
–4·32
(–8·27 to 
–2·52)
–1·40
(–1·70 to 
–1·07)
–2·48
(–4·41 to 
–1·15)
Maldives 85
(82 to 89)
6
(4 to 8)
63
(60 to 65)
2
(1 to 2)
148
(143 to 153)
8
(6 to 9)
–1·83
(–2·21 to 
–1·43)
–7·65
(–9·08 to 
–6·02)
–3·25
(–3·56 to 
–2·98)
–4·85
(–9·44 to 
–2·97)
Myanmar 59 000
(53 067 to 
61 680)
17 233
(9964 to
26 771)
30 437
(29 213 to
31 605)
6523
(3695 to 
10 706)
89 437
(83 011 to
92 987)
23 756
(13 957 to 
37 308)
0·62
(–0·55 to 
1·12)
–2·87
(–5·51 to 
–0·43)
–1·09
(–1·41 to 
–0·65)
–4·84
(–7·09 to 
–2·53)
Philippines 114 611
(110 488 to 
119 351)
21 116
(16 010 to 
28 500)
51 534
(49 589 to 
53 349)
8162
(5945 to 
10 868)
166 145
(160 384 to 
172 007)
29 278
(23 891 to 
38 089)
0·35
(–0·07 to 
0·69)
–1·62
(–2·39 to 
–0·77)
–0·96
(–1·23 to 
–0·68)
–3·39
(–4·86 to 
–1·86)
Sri Lanka 10 106
(9609 to
10 617)
942
(734 to
1334)
5059
(4814 to
5330)
319
(231 to
430)
15 166
(14 454 to
15 881)
1261
(1036 to
1624)
–0·52
(–1·09 to 
0·02)
–2·87
(–3·90 to 
–1·90)
–1·01
(–1·35 to 
–0·69)
–4·76
(–6·19 to 
–3·23)
Thailand 46 721
(44 411 to 
49 189)
5688
(4374 to
8927)
23 885
(22 833 to 
24 943)
3464
(2555 to
4696)
70 607
(67 488 to
73 756)
9152
(7399 to
12 480)
–0·03
(–0·49 to 
0·40)
–8·31
(–9·62 to 
–4·61)
–1·90
(–2·20 to 
–1·59)
–4·04
(–5·60 to 
–2·51)
(Table 5 continues on next page)
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Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths
(Continued from previous page)
Timor-Leste 942
(902 to 985)
91
(60 to 138)
654
(627 to 678)
58
(35 to 83)
1595
(1534 to 1657)
150
(108 to 209)
1·57
(0·94 to 
2·19)
–3·62
(–5·28 to 
–1·92)
0·27
(0·01 to 
0·50)
–4·37
(–6·29 to 
–2·47)
Vietnam 81 050
(77 670 to 
84 298)
8851
(6374 to
12 124)
28 599
(27 468 to 
29 768)
5170
(3727 to
6860)
109 649
(105 506 to 
113 534)
14 021
(11 297 to 
17 789)
2·52
(2·07 to 
3·02)
–6·25
(–8·26 to 
–4·40)
–1·16
(–1·42 to 
–0·91)
–6·21
(–8·09 to 
–4·22)
Australasia 1038
(1000 to 1076)
58
(47 to 71)
834
(807 to 863)
46
(34 to 57)
1873
(1810 to 1929)
103
(88 to 118)
–0·23
(–0·61 to 
0·16)
–4·13
(–5·09 to 
–3·21)
–0·22
(–0·41 to 
–0·03)
–3·63
(–4·62 to 
–2·62)
Australia 861
(828 to 896)
48
(37 to 60)
665
(641 to 690)
36
(26 to 47)
1526
(1473 to 1576)
84
(69 to 98)
–0·65
(–1·06 to 
–0·21)
–3·49
(–4·74 to 
–2·35)
0·19
(–0·01 to 
0·42)
–3·05
(–4·21 to 
–1·86)
New Zealand 177
(170 to 183)
10
(8 to 13)
170
(163 to 176)
9
(7 to 12)
346
(334 to 358)
19
(17 to 23)
1·24
(0·90 to 
1·60)
–5·98 
(–7·22 to 
–4·62)
–1·62
(–1·82 to 
–1·41)
–3·85 
(–4·99 to 
–2·58)
Caribbean 12 755
(12 352 to 13 183)
1948
(1572 to 2687)
8670
(8381 to 8955)
1118
(892 to 1450)
21 425
(20 766 to 22 080)
3067
(2621 to 4000)
1·89
(1·56 to 
2·19)
–6·30
(–7·35 to 
–4·92)
–0·20
(–0·35 to 
–0·05)
–3·93
(–4·93 to 
–2·50)
Antigua and 
Barbuda
23
(22 to 24)
2
(1 to 2)
16
(16 to 17)
1
(0 to 1)
40
(38 to 41)
2
(2 to 3)
–0·06
(–0·51 to 
0·32)
–1·38
(–4·33 to 
0·49)
0·41
(0·16 to 
0·68)
–0·50
(–3·19 to 
1·75)
Barbados 32
(30 to 33)
6
(4 to 8)
35
(33 to 36)
2
(1 to 3)
66
(64 to 69)
8
(5 to 10)
–0·52
(–0·90 to 
–0·13)
–1·47
(–3·46 to 
–0·10)
–0·01
(–0·25 to 
0·23)
–0·51
(–3·35 to 
1·44)
Belize 106
(101 to 110)
7
(5 to 10)
60
(58 to 62)
2
(1 to 3)
166
(160 to 171)
10
(6 to 12)
2·05
(1·45 to 
2·53)
3·70
(1·28 to 
5·23)
1·20
(0·97 to 
1·47)
–0·38
(–3·01 to 
1·58)
Cuba 1003
(941 to 1063)
32
(26 to 39)
309
(290 to 330)
13
(10 to 17)
1312
(1238 to 1383)
44
(38 to 52)
–0·43
(–0·72 to 
–0·07)
–2·31
(–3·73 to 
–1·16)
–4·97
(–5·35 to 
–4·63)
–5·01
(–6·19 to 
–3·79)
Dominica 18
(17 to 19)
2
(1 to 2)
12
(11 to 13)
0
(0 to 0)
30
(29 to 31)
2
(1 to 3)
1·02
(0·61 to 
1·47)
–1·40
(–5·37 to 
0·39)
–0·87
(–1·22 to 
–0·55)
–1·03
(–3·45 to 
1·20)
Dominican 
Republic
3194
(3073 to 3331)
303
(228 to 429)
2117
(2029 to 2196)
148
(109 to 199)
5311
(5129 to 5502)
451
(365 to 591)
0·92
(0·47 to 
1·29)
–6·10
(–7·24 to 
–4·56)
–1·31
(–1·53 to 
–1·06)
–5·33
(–7·05 to 
–2·88)
Grenada 25
(24 to 26)
3
(2 to 3)
17
(17 to 18)
0
(0 to 1)
42
(40 to 43)
3
(2 to 4)
1·64
(1·11 to 
2·14)
0·17
(–2·84 to 
1·57)
–1·54
(–1·80 to 
–1·29)
–1·26
(–3·60 to 
0·38)
Guyana 384
(356 to 406)
29
(19 to 39)
220
(211 to 229)
8
(6 to 12)
604
(568 to 632)
37
(25 to 47)
3·75
(3·12 to 
4·36)
1·19
(–3·95 to 
2·92)
0·57
(0·35 to 
0·84)
–0·72
(–2·93 to 
1·20)
Haiti 5770
(5514 to 6016)
1211
(900 to 1759)
4483
(4273 to 4691)
745
(564 to 1025)
10 253
(9848 to 10 657)
1956
(1598 to 2639)
3·36
(2·79 to 
3·90)
–7·06
(–8·45 to 
–5·27)
0·71
(0·40 to 
1·03)
–4·00
(–5·41 to 
–2·44)
Jamaica 168
(159 to 175)
24
(17 to 32)
66
(62 to 69)
11
(7 to 15)
233
(223 to 243)
35
(27 to 43)
–2·12
(–2·51 to 
–1·72)
0·99
(–1·16 to 
2·49)
–2·36
(–2·71 to 
–2·04)
–3·24
(–4·98 to 
–1·50)
Saint Lucia 27
(26 to 28)
4
(2 to 5)
23
(22 to 24)
1
(1 to 2)
50
(48 to 52)
5
(3 to 6)
1·06
(0·67 to 
1·48)
–0·59
(–3·89 to 
0·95)
–2·27
(–2·46 to 
–2·07)
–2·91
(–4·81 to 
–1·19)
Saint Vincent and 
the Grenadines
23
(21 to 24)
2
(1 to 3)
15
(14 to 15)
0
(0 to 1)
37
(36 to 39)
3
(2 to 3)
1·90
(1·43 to 
2·42)
0·06
(–3·46 to 
1·73)
–2·60
(–2·92 to 
–2·28)
–2·93
(–5·67 to 
–1·13)
Suriname 154
(145 to 163)
13
(8 to 19)
70
(67 to 74)
4
(3 to 5)
224
(213 to 235)
17
(11 to 23)
1·46
(0·92 to 
1·98)
0·49
(–1·83 to 
1·91)
–1·31
(–1·68 to 
–0·96)
–1·25
(–4·23 to 
0·96)
(Table 5 continues on next page)
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Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths
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The Bahamas 29
(27 to 30)
9
(6 to 12)
26
(25 to 27)
3
(2 to 4)
55
(52 to 57)
12
(8 to 15)
–0·74
(–1·10 to 
–0·45)
–1·41
(–3·31 to 
0·07)
–4·28
(–4·62 to 
–3·93)
–2·24
(–4·47 to 
–0·20)
Trinidad and 
Tobago
217
(207 to 227)
29
(17 to 36)
85
(82 to 89)
9
(5 to 12)
303
(291 to 315)
37
(23 to 45)
–0·57
(–0·93 to 
–0·19)
–0·20
(–3·02 to 
0·96)
–1·54
(–1·77 to 
–1·27)
–2·51
(–5·01 to 
–1·02)
Central Europe 25 157
(24 431 to 25 958)
2201
(2014 to 2708)
12 384
(12 026 to 12 741)
646
(566 to 795)
37 541
(36 487 to 38 632)
2846
(2642 to 3395)
1·58
(1·40 to 
1·75)
–2·77
(–3·18 to 
–1·98)
–1·61
(–1·74 to 
–1·50)
–5·95
(–6·43 to 
–5·27)
Albania 374
(358 to 390)
16
(11 to 23)
178
(170 to 184)
9
(6 to 13)
551
(531 to 571)
24
(19 to 33)
–0·46
(–0·84 to 
–0·11)
–5·23
(–6·94 to 
0·46)
–1·70
(–1·92 to 
–1·50)
–4·63
(–6·73 to 
–2·40)
Bosnia and 
Herzegovina
944
(902 to 984)
134
(73 to 160)
509
(489 to 532)
44
(34 to 56)
1453
(1398 to 1513)
178
(114 to 206)
0·75
(0·47 to 
1·07)
–5·94
(–8·01 to 
–4·44)
–1·84
(–2·07 to 
–1·60)
–4·75
(–7·31 to 
–3·34)
Bulgaria 1805
(1732 to 1878)
113
(98 to 150)
910
(876 to 944)
35
(28 to 47)
2714
(2627 to 2804)
148
(131 to 195)
2·87
(2·39 to 
3·40)
1·07
(0·26 to 
2·16)
–0·74
(–0·95 to 
–0·53)
–4·99
(–5·86 to 
–3·87)
Croatia 807
(757 to 857)
57
(47 to 95)
420
(396 to 446)
28
(22 to 36)
1227
(1165 to 1296)
85
(73 to 127)
1·05
(0·77 to 
1·33)
–8·22
(–9·51 to 
–3·50)
–4·64
(–5·03 to 
–4·26)
–6·92
(–8·02 to 
–4·79)
Czech Republic 592
(565 to 621)
40
(34 to 66)
269
(257 to 281)
22
(16 to 41)
861
(826 to 897)
62
(52 to 102)
–0·69
(–1·04 to 
–0·35)
–5·21
(–6·97 to 
3·07)
–2·93
(–3·19 to 
–2·68)
–6·46
(–7·64 to 
–4·26)
Hungary 1426
(1375 to 1483)
87
(69 to 196)
726
(697 to 757)
46
(35 to 93)
2152
(2080 to 2228)
134
(108 to 272)
–0·26
(–0·64 to 
0·13)
–7·59
(–9·00 to 
–0·99)
–1·32
(–1·55 to 
–1·10)
–8·16
(–9·37 to 
–4·51)
Macedonia 312
(299 to 325)
32
(26 to 47)
177
(171 to 183)
11
(8 to 16)
489
(473 to 506)
42
(36 to 61)
–0·71
(–1·05 to 
–0·41)
–2·79
(–3·88 to 
–1·46)
–2·30
(–2·52 to 
–2·10)
–7·49
(–8·87 to 
–4·16)
Montenegro 78
(75 to 81)
2
(1 to 3)
51
(49 to 53)
1
(1 to 1)
129
(125 to 133)
2
(2 to 4)
1·05
(0·65 to 
1·44)
0·29
(–2·32 to 
4·03)
–0·41
(–0·63 to 
–0·21)
–8·11
(–10·19 to 
–3·01)
Poland 6141
(5911 to 6350)
658
(556 to 1110)
2897
(2783 to 3001)
176
(133 to 313)
9038
(8735 to 9314)
834
(714 to 1394)
–0·38
(–0·66 to 
–0·04)
–6·98
(–8·00 to 
–2·87)
–1·33
(–1·56 to 
–1·13)
–5·35
(–6·26 to 
–3·86)
Romania 10 953
(10 478 to 
11 423)
919
(571 to
1059)
5250
(5082 to
5445)
202
(92 to
244)
16 203
(15 631 to
16 796)
1121
(692 to
1270)
3·94
(3·65 to 
4·29)
3·16
(–1·58 to 
4·24)
–1·43
(–1·66 to 
–1·23)
–6·18
(–7·43 to 
–5·23)
Serbia 1161
(1110 to 1213)
101
(88 to 132)
703
(681 to 728)
46
(37 to 56)
1864
(1804 to 1930)
148
(132 to 181)
0·40
(0·01 to 
0·86)
–0·61
(–3·10 to 
2·29)
–0·39
(–0·64 to 
–0·12)
–5·88
(–6·81 to 
–3·99)
Slovakia 410
(391 to 432)
31
(25 to 37)
203
(195 to 211)
14
(10 to 19)
614
(590 to 639)
45
(38 to 52)
–1·98
(–2·29 to 
–1·70)
–5·90
(–7·59 to 
–2·10)
–4·25
(–4·51 to 
–3·95)
–4·58
(–5·77 to 
–3·34)
Slovenia 155
(148 to 162)
12
(10 to 15)
91
(87 to 95)
11
(8 to 16)
247
(237 to 256)
23
(18 to 28)
–1·25
(–1·50 to 
–1·01)
–7·84
(–9·43 to 
–3·53)
–4·92
(–5·17 to 
–4·68)
–4·38
(–6·46 to 
–2·82)
Eastern Europe 133 535
(127 584 to 
139 310)
17 428
(11 652 to 
19 299)
54 525
(52 459 to 
56 300)
3944
(1987 to
4564)
188 061
(181 006 to 
194 926)
21 372
(14 337 to 
23 390)
1·33
(0·99 to 
1·69)
8·28
(5·46 to 
9·09)
–0·58
(–0·80 to 
–0·39)
–4·80
(–7·62 to 
–3·91)
Belarus 4600
(4412 to 4804)
612
(340 to 743)
1778
(1713 to 1842)
110
(73 to 138)
6378
(6156 to 6624)
722
(427 to 852)
0·64
(0·14 to 
1·09)
5·98
(3·66 to 
6·97)
0·20
(–0·09 to 
0·50)
–1·48
(–5·03 to 
–0·04)
Estonia 314
(301 to 328)
35
(28 to 40)
115
(110 to 120)
8
(6 to 10)
429
(414 to 445)
44
(35 to 49)
0·29
(–0·20 to 
0·75)
4·25
(0·02 to 
5·59)
–3·42
(–3·70 to 
–3·14)
–8·24
(–9·26 to 
–7·23)
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Latvia 780
(747 to 816)
60
(50 to 77)
368
(352 to 383)
17
(14 to 21)
1148
(1106 to 1192)
78
(67 to 95)
0·27
(–0·10 to 
0·69)
5·20
(2·90 to 
6·18)
–2·43
(–2·67 to 
–2·16)
–8·97
(–10·32 to 
–6·96)
Lithuania 1457
(1394 to 1523)
176
(137 to 205)
594
(572 to 615)
41
(29 to 52)
2051
(1982 to 2127)
217
(168 to 246)
0·15
(–0·23 to 
0·54)
3·17
(0·55 to 
4·20)
–0·73
(–0·96 to 
–0·49)
–4·09
(–5·19 to 
–3·09)
Moldova 3218
(3092 to 3354)
328
(218 to 369)
1245
(1200 to 1290)
56
(32 to 67)
4463
(4316 to 4623)
384
(258 to 429)
3·21
(2·66 to 
3·69)
7·60
(1·92 to 
8·92)
1·64
(1·40 to 
1·88)
–1·41
(–2·87 to 
–0·50)
Russia 99 009
(94 194 to 
103 393)
12 075
(8364 to
13 569)
41 613
(39 823 to 
43 098)
2754
(1332 to
3200)
140 622
(135 057 to 
146 053)
14 829
(10 158 to 
16 436)
1·37
(0·95 to 
1·82)
8·72
(5·42 to 
9·70)
–0·53
(–0·84 to 
–0·28)
–5·19
(–7·85 to 
–4·21)
Ukraine 24 157
(22 734 to 25 531)
4141
(2591 to 4870)
8812
(8381 to 9239)
958
(501 to 1222)
32 969
(31 207 to 34 714)
5099
(3140 to 5841)
1·16
(0·77 to 
1·60)
7·75
(5·80 to 
8·66)
–1·18
(–1·51 to 
–0·84)
–3·34
(–7·29 to 
–1·87)
Western Europe 29 517
(28 659 to 30 370)
2660
(2396 to 3516)
19 185
(18 599 to19 725)
2011
(1640 to 2357)
48 702
(47 293 to 50 021)
4670
(4234 to 5466)
–0·23
(–0·39 to 
–0·03)
–4·22
(–4·67 to 
–3·81)
–1·18
(–1·28 to 
–1·08)
–4·88
(–5·53 to 
–3·78)
Andorra 10
(9 to 10)
0
(0 to 0)
8
(7 to 8)
0
(0 to 0)
18
(17 to 18)
0
(0 to 1)
5·20
(4·59 to 
5·86)
–4·60
(–7·70 to 
–1·71)
–2·13
(–2·37 to 
–1·89)
–3·14
(–5·50 to 
–0·78)
Austria 615
(591 to 641)
35
(28 to 62)
342
(329 to 355)
24
(19 to 35)
958
(922 to 992)
60
(49 to 93)
0·31
(–0·05 to 
0·72)
–9·56
(–11·01 to 
–3·71)
–1·57
(–1·83 to 
–1·35)
–3·97
(–5·15 to 
–2·71)
Belgium 737
(706 to 764)
71
(56 to 88)
438
(420 to 455)
48
(34 to 64)
1175
(1133 to 1214)
118
(96 to 141)
–0·85
(–1·16 to 
–0·58)
–1·72
(–3·80 to 
–0·52)
–0·61
(–0·82 to 
–0·41)
–3·70
(–5·02 to 
–2·34)
Cyprus 36
(35 to 38)
2
(2 to 3)
40
(38 to 41)
1
(1 to 1)
76
(74 to 79)
3
(2 to 4)
0·23
(–0·12 to 
0·58)
–4·05
(–6·10 to 
–2·04)
0·59
(0·39 to 
0·80)
–5·37
(–7·18 to 
–3·24)
Denmark 256
(245 to 267)
23
(19 to 29)
185
(177 to 193)
16
(12 to 21)
441
(425 to 456)
39
(34 to 46)
0·57
(0·25 to 
0·93)
–2·51
(–3·80 to 
–1·35)
–1·71
(–1·95 to 
–1·48)
–3·43
(–4·68 to 
–2·17)
Finland 256
(246 to 265)
39
(31 to 59)
149
(144 to 154)
42
(31 to 60)
405
(392 to 417)
81
(66 to 114)
–1·10
(–1·41 to 
–0·76)
–4·29
(–5·52 to 
–2·81)
–1·10
(–1·31 to 
–0·88)
–5·56
(–7·09 to 
–3·12)
France 4558
(4354 to 4760)
722
(577 to 977)
3077
(2944 to 3227)
697
(485 to 967)
7635
(7329 to 7949)
1419
(1151 to 1762)
–1·28
(–1·54 to 
–0·98)
–2·71
(–4·40 to 
–1·52)
–0·88
(–1·13 to 
–0·64)
–5·65
(–7·12 to 
–3·43)
Germany 4554
(4353 to 4769)
312
(258 to 565)
2754
(2636 to 2874)
196
(152 to 273)
7309
(7018 to 7608)
508
(430 to 808)
–1·13
(–1·39 to 
–0·88)
–5·97
(–6·86 to 
–4·32)
–3·39
(–3·63 to 
–3·14)
–6·22
(–7·41 to 
–3·22)
Greece 525
(499 to 548)
124
(89 to 150)
232
(221 to 244)
110
(48 to 152)
757
(725 to 788)
234
(150 to 283)
–1·05
(–1·42 to 
–0·65)
–8·68
(–9·95 to 
–4·50)
–2·04
(–2·31 to 
–1·79)
1·37
(–4·37 to 
3·08)
Iceland 19
(18 to 20)
0
(0 to 1)
20
(19 to 21)
2
(1 to 2)
39
(38 to 41)
2
(1 to 3)
1·74
(1·29 to 
2·20)
–5·07
(–7·26 to 
–1·85)
–1·18
(–1·45 to 
–0·91)
–0·74
(–5·01 to 
1·85)
Ireland 307
(293 to 320)
22
(17 to 27)
181
(173 to 189)
16
(12 to 21)
488
(468 to 507)
38
(31 to 45)
–0·88
(–1·27 to 
–0·49)
–4·71
(–5·90 to 
–3·54)
0·51
(0·29 to 
0·74)
–4·49
(–5·94 to 
–3·16)
Israel 352
(339 to 364)
25
(20 to 31)
188
(180 to 195)
14
(10 to 20)
539
(521 to 557)
39
(32 to 48)
–0·04
(–0·48 to 
0·42)
–0·11
(–5·05 to 
1·53)
–1·46
(–1·65 to 
–1·26)
–7·11
(–8·72 to 
–3·21)
Italy 2868
(2726 to 2999)
295
(238 to 389)
1942
(1858 to 2026)
203
(144 to 271)
4810
(4609 to 4999)
498
(415 to 600)
–0·76 
(–1·05 to 
–0·42)
–5·22 
(–6·26 to 
–4·32)
–1·43
(–1·70 to 
–1·19)
–4·53 
(–5·78 to 
–3·13)
(Table 5 continues on next page)
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Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths
(Continued from previous page)
Luxembourg 30
(28 to 31)
1
(1 to 1)
21
(20 to 22)
1
(1 to 2)
51
(49 to 53)
2
(2 to 2)
0·97
(0·54 to 
1·43)
2·98
(–6·36 to 
5·42)
–2·48
(–2·76 to 
–2·22)
–8·56
(–10·73 to 
–4·48)
Malta 29
(28 to 30)
0
(0 to 1)
20
(19 to 21)
0
(0 to 0)
49
(47 to 51)
1
(1 to 1)
3·82
(3·35 to 
4·33)
–2·94
(–5·44 to 
–1·15)
–2·74
(–3·00 to 
–2·50)
–6·24
(–7·80 to 
–3·55)
Netherlands 781
(751 to 812)
65
(53 to 84)
553
(534 to 571)
57
(43 to 78)
1334
(1291 to 1378)
123
(103 to 154)
–1·01
(–1·24 to 
–0·76)
–2·75
(–4·06 to 
–1·60)
–1·73
(–1·92 to 
–1·54)
–4·28
(–5·58 to 
–2·52)
Norway 205
(196 to 213)
25
(20 to 31)
196
(189 to 203)
25
(18 to 33)
401
(387 to 414)
50
(41 to 60)
–1·75
(–2·01 to 
–1·46)
–1·83
(–4·50 to 
–0·46)
–0·25
(–0·46 to 
–0·05)
–3·95
(–5·29 to 
–2·55)
Portugal 1672
(1603 to 1731)
191
(161 to 223)
889
(860 to 921)
78
(50 to 98)
2561
(2470 to 2639)
269
(223 to 305)
2·38
(2·07 to 
2·72)
–3·13
(–5·91 to 
–2·19)
–2·29
(–2·51 to 
–2·10)
–5·45
(–6·38 to 
–4·27)
Spain 4983
(4804 to 5160)
324
(270 to 475)
2959
(2846 to 3080)
205
(155 to 270)
7942
(7683 to 8198)
529
(451 to 680)
1·09
(0·80 to 
1·40)
–6·41
(–7·41 to 
–3·70)
–1·70
(–1·88 to 
–1·52)
–4·78
(–5·74 to 
–3·77)
Sweden 378
(364 to 392)
53
(41 to 68)
311
(299 to 323)
60
(41 to 83)
689
(666 to 711)
113
(91 to 143)
–0·83
(–1·11 to 
–0·54)
–1·17
(–3·35 to 
0·05)
–0·14
(–0·32 to 
0·06)
–3·51
(–5·14 to 
–1·56)
Switzerland 515
(493 to 536)
42
(34 to 59)
353
(339 to 368)
25
(18 to 39)
868
(834 to 900)
68
(55 to 95)
0·05
(–0·39 to 
0·52)
–2·72
(–4·00 to 
–1·27)
–0·41
(–0·65 to 
–0·21)
–4·58
(–6·05 to 
–2·63)
UK 5798
(5602 to 5988)
285
(210 to 331)
4306
(4166 to 4446)
186
(142 to 213)
10 104
(9811 to 10 382)
471
(367 to 530)
0·42
(0·08 to 
0·81)
–3·57
(–4·51 to 
–3·16)
1·04
(0·86 to 
1·23)
–2·66
(–3·91 to 
–1·71)
Andean Latin 
America
36 216
(34 796 to 37 724)
2556
(2128 to 3594)
26 385
(25 388 to 27 420)
1441
(1197 to 1753)
62 601
(60 306 to 64 967)
3997
(3456 to 5090)
0·00
(–0·30 to 
0·33)
–8·25
(–9·07 to 
–5·88)
–0·81
(–1·04 to 
–0·54)
–4·86
(–5·88 to 
–3·78)
Bolivia 7516
(7087 to 7915)
410
(293 to 571)
5200
(4952 to 5409)
316
(223 to 447)
12 716
(12 140 to 13 247)
726
(565 to 923)
1·15
(0·44 to 
1·72)
–7·16
(–9·13 to 
–5·10)
–0·87
(–1·16 to 
–0·56)
–4·80
(–6·69 to 
–2·93)
Ecuador 8555
(8105 to 9016)
711
(562 to 992)
5711
(5444 to 5981)
324
(239 to 416)
14 266
(13 639 to 14 930)
1035
(863 to 1329)
–0·32
(–0·77 to 
0·20)
–4·72
(–5·59 to 
–3·86)
–1·06
(–1·38 to 
–0·69)
–5·13
(–6·60 to 
–3·45)
Peru 20 145
(19 215 to 21 153)
1435
(1100 to 2157)
15 475
(14 761 to 16 181)
801
(619 to 1074)
35 619
(34 227 to 37 172)
2236
(1825 to 3032)
–0·20
(–0·57 to 
0·17)
–9·77
(–10·94 to 
–6·02)
–0·67
(–0·95 to 
–0·33)
–4·67
(–6·14 to 
–3·14)
Central 
Latin America
43 749
(42 613 to 44 861)
4446
(4041 to 5766)
28 824
(28 022 to 29 525)
1800
(1614 to 2107)
72 573
(70 783 to 74 324)
6245
(5761 to 7658)
0·75
(0·52 to 
0·93)
–7·53
(–7·85 to 
–6·72)
–1·69
(–1·83 to 
–1·55)
–4·21
(–4·74 to 
–3·03)
Colombia 9703
(9371 to 10 025)
1009
(765 to 1259)
6397
(6152 to 6646)
389
(304 to 504)
16 099
(15 579 to 16 618)
1398
(1130 to 1664)
0·62
(0·20 to 
1·07)
–4·70
(–5·68 to 
–3·86)
0·14
(–0·12 to 
0·40)
–3·28
(–4·63 to 
–1·97)
Costa Rica 581
(556 to 607)
46
(39 to 67)
278
(266 to 291)
20
(16 to 27)
859
(827 to 891)
67
(58 to 91)
2·72
(2·24 to 
3·20)
–4·16
(–5·40 to 
–1·82)
–4·85
(–5·10 to 
–4·61)
–5·35
(–6·60 to 
–3·31)
El Salvador 1058
(1021 to 1091)
75
(58 to 121)
676
(653 to 700)
35
(26 to 51)
1734
(1682 to 1783)
110
(89 to 166)
3·22
(2·65 to 
3·76)
–8·40
(–9·59 to 
–5·49)
–2·71
(–2·92 to 
–2·50)
–4·25
(–5·74 to 
–1·83)
Guatemala 3210
(3023 to 3404)
281
(231 to 447)
2289
(2138 to 2420)
162
(132 to 220)
5500
(5193 to 5787)
444
(384 to 647)
1·96
(1·60 to 
2·33)
–8·36
(–9·30 to 
–5·06)
–2·93
(–3·28 to 
–2·46)
–4·87
(–5·90 to 
–3·15)
Honduras 1871
(1737 to 1973)
163
(111 to 245)
1202
(1115 to 1267)
71
(45 to 104)
3073
(2868 to 3219)
234
(170 to 317)
2·15
(1·26 to 
2·69)
–3·08
(–5·53 to 
–0·88)
–1·71
(–2·13 to 
–0·60)
–3·17
(–5·35 to 
–0·69)
(Table 5 continues on next page)
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Male population Female population Total 1990–2000 2000–13
Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths
(Continued from previous page)
Mexico 18 799
(18 137 to 19 577)
2067
(1900 to 2795)
12 333
(11 807 to 12 760)
742
(665 to 934)
31 132
(30 075 to 32 230)
2808
(2607 to 3614)
0·21
(–0·19 to 
0·49)
–9·45
(–9·77 to 
–8·61)
–2·54
(–2·76 to 
–2·33)
–4·83
(–5·38 to 
–2·74)
Nicaragua 1308
(1256 to 1356)
131
(110 to 186)
984
(950 to 1023)
64
(53 to 79)
2292
(2216 to 2364)
195
(170 to 252)
1·80
(1·45 to 
2·17)
–4·76
(–5·85 to 
–3·06)
–2·64
(–2·84 to 
–2·43)
–5·94
(–7·06 to 
–3·97)
Panama 1108
(1067 to 1149)
147
(117 to 182)
623
(602 to 645)
74
(52 to 94)
1731
(1681 to 1784)
221
(178 to 257)
0·46
(0·14 to 
0·80)
–3·18
(–4·29 to 
–2·00)
–0·70
(–0·93 to 
–0·48)
–2·08
(–3·44 to 
–0·78)
Venezuela 6112
(5864 to 6352)
527
(440 to 672)
4043
(3900 to 4196)
242
(193 to 301)
10 154
(9802 to 10 512)
769
(671 to 953)
1·30
(0·80 to 
1·78)
–4·11
(–5·00 to 
–3·28)
–0·49
(–0·76 to 
–0·26)
–3·44
(–4·56 to 
–2·09)
Southern 
Latin America
9688
(9376 to 10 011)
903
(801 to 1083)
7399
(7165 to 7652)
478
(376 to 569)
17 086
(16 596 to 17 583)
1381
(1245 to 1552)
1·43
(1·06 to 
1·78)
–4·77
(–5·78 to 
–4·23)
–2·56
(–2·75 to 
–2·39)
–3·35
(–4·03 to 
–2·70)
Argentina 7099
(6824 to 7376)
483
(417 to 641)
6036
(5827 to 6272)
243
(203 to 301)
13 135
(12 732 to 13 551)
726
(650 to 901)
2·19
(1·71 to 
2·64)
–4·75
(–5·44 to 
–3·87)
–2·52
(–2·74 to 
–2·31)
–3·84
(–4·64 to 
–2·91)
Chile 2030
(1945 to 2112)
378
(307 to 445)
1087
(1045 to 1128)
214
(125 to 279)
3117
(3000 to 3222)
592
(462 to 682)
–0·95
(–1·24 to 
–0·66)
–4·67
(–8·82 to 
–3·54)
–3·04
(–3·30 to 
–2·80)
–3·09
(–4·21 to 
–2·00)
Uruguay 559
(538 to 585)
42
(34 to 53)
275
(265 to 285)
21
(16 to 28)
834
(809 to 864)
63
(54 to 75)
0·24 
(–0·09 to 
0·54)
–6·04 
(–7·31 to 
–2·82)
–1·64
(–1·82 to 
–1·44)
–3·69 
(–4·84 to 
–2·50)
Tropical 
Latin America
73 306
(70 470 to 
76 015)
4403
(3323 to
5088)
38 108
(36 706 to 
39 505)
1680
(1019 to
2013)
111 414
(107 496 to 
115 183)
6083
(4538 to
6844)
0·51
(0·07 to 
0·95)
–2·46
(–6·28 to 
–1·55)
–1·27
(–1·50 to 
–1·08)
–4·33
(–5·36 to 
–3·47)
Brazil 70 916
(68 130 to 
73 599)
4184
(3070 to
4864)
36 902
(35 531 to
38 259)
1604
(954 to 1934)
107 818
(103 978 to 
111 454)
5788
(4226 to
6524)
0·51
(0·06 to 
0·96)
–2·48
(–6·52 to 
–1·54)
–1·25
(–1·48 to 
–1·05)
–4·45
(–5·55 to 
–3·58)
Paraguay 2390
(2303 to 2479)
219
(174 to 284)
1206
(1159 to 1255)
75
(57 to 96)
3596
(3475 to 3717)
295
(243 to 359)
0·31
(–0·09 to 
0·64)
–1·86
(–3·01 to 
0·40)
–1·95
(–2·18 to 
–1·71)
–1·00
(–2·49 to 
0·33)
North Africa and 
Middle East
86 141
(83 903 to 
88 660)
8299
(7259 to
10 104)
68 242
(66 546 to 
69 943)
6920
(5792 to
8585)
154 383
(150 668 to 
158 377)
15 219
(13 553 to 
18 407)
1·07
(0·85 to 
1·30)
–3·72
(–4·35 to 
–3·07)
–1·10
(–1·18 to 
–1·03)
–4·58
(–5·34 to 
–3·89)
Algeria 11 691
(11 189 to 12 162)
955
(739 to 1181)
8879
(8507 to 9238)
773
(435 to 988)
20 570
(19 806 to 21 341)
1728
(1282 to 2038)
2·37
(1·91 to 
2·84)
–4·03
(–6·09 to 
–2·11)
–0·39
(–0·61 to 
–0·19)
–4·59
(–6·49 to 
–2·96)
Bahrain 213
(203 to 224)
6
(5 to 9)
103
(98 to 107)
3
(2 to 3)
316
(303 to 329)
9
(7 to 11)
3·34
(2·94 to 
3·74)
0·16
(–4·67 to 
2·36)
–1·11
(–1·33 to 
–0·88)
–7·09
(–9·11 to 
–5·05)
Egypt 9949
(9524 to 10 386)
566
(461 to 812)
6400
(6127 to 6676)
271
(222 to 342)
16 349
(15 790 to 16 971)
837
(715 to 1107)
–0·59
(–0·98 to 
–0·24)
–6·15
(–7·43 to 
–4·74)
–1·99
(–2·23 to 
–1·73)
–5·27
(–6·55 to 
–3·58)
Iran 8393
(8006 to 8818)
829
(373 to 1060)
8093
(7739 to 8472)
573
(203 to 757)
16 485
(15 864 to 17 177)
1402
(601 to 1689)
0·38
(–0·05 to 
0·80)
–1·99
(–8·10 to 
0·16)
–1·58
(–1·83 to 
–1·32)
–3·67
(–8·62 to 
–1·85)
Iraq 6817
(6557 to 7089)
531
(359 to 767)
5875
(5640 to 6102)
518
(344 to 741)
12 693
(12 244 to 13 108)
1050
(791 to 1352)
2·10
(1·61 to 
2·66)
–0·06
(–2·54 to 
2·43)
0·34
(0·14 to 
0·52)
–2·74
(–4·90 to 
–0·53)
Jordan 233
(223 to 243)
14
(10 to 19)
294
(283 to 306)
9
(7 to 12)
527
(508 to 545)
23
(19 to 27)
–1·51
(–1·82 to 
–1·19)
–4·05
(–6·24 to 
–1·60)
–2·61
(–2·85 to 
–2·38)
–6·29
(–8·15 to 
–4·24)
Kuwait 543
(519 to 569)
16
(14 to 20)
399
(383 to 414)
12
(8 to 15)
943
(906 to 980)
28
(24 to 32)
–0·93
(–1·26 to 
–0·59)
–4·24
(–7·68 to 
–2·34)
0·02
(–0·16 to 
0·19)
–4·47
(–6·08 to 
–2·88)
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Male population Female population Total 1990–2000 2000–13
Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths
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Lebanon 297
(284 to 308)
27
(18 to 39)
351
(339 to 364)
18
(10 to 31)
647
(627 to 667)
45
(30 to 61)
–2·56
(–2·92 to 
–2·15)
–6·13
(–8·30 to 
–3·44)
0·08
(–0·11 to 
0·25)
–3·76
(–5·73 to 
–1·72)
Libya 1159
(1107 to 1205)
47
(34 to 62)
773
(738 to 808)
27
(20 to 36)
1932
(1858 to 1999)
74
(59 to 90)
–0·17
(–0·48 to 
0·14)
–3·92
(–6·37 to 
–1·01)
–0·29
(–0·51 to 
–0·09)
–2·09
(–4·07 to 
–0·11)
Morocco 13 415
(13 005 to 13 883)
1945
(1447 to 2587)
10 017
(9667 to 10 323)
1191
(772 to 1555)
23 432
(22 701 to 24 090)
3135
(2448 to 3831)
2·10
(1·76 to 
2·45)
–4·26
(–5·86 to 
–2·60)
–0·35
(–0·56 to 
–0·18)
–3·98
(–5·54 to 
–2·43)
Oman 324
(308 to 341)
21
(15 to 29)
212
(205 to 221)
11
(8 to 15)
537
(517 to 558)
32
(25 to 40)
0·07
(–0·26 to 
0·39)
–4·07
(–7·49 to 
–1·27)
–0·93
(–1·13 to 
–0·72)
–1·32
(–4·47 to 
1·22)
Palestine 212
(198 to 227)
3
(2 to 6)
101
(93 to 109)
2
(1 to 3)
314
(294 to 334)
4
(3 to 8)
–1·13
(–1·49 to 
–0·74)
–9·54
(–11·95 to 
–6·97)
–0·81
(–1·12 to 
–0·54)
–6·67
(–9·40 to 
0·66)
Qatar 628
(599 to 655)
4
(3 to 5)
136
(131 to 142)
1
(1 to 1)
764
(730 to 794)
5
(4 to 6)
–1·07
(–1·39 to 
–0·69)
–10·71
(–13·40 to 
–1·51)
–0·21
(–0·44 to 
0·04)
–6·72
(–8·60 to 
–4·88)
Saudi Arabia 3326
(3194 to 3457)
515
(405 to 678)
2121
(2035 to 2200)
378
(287 to 464)
5447
(5253 to 5623)
894
(760 to 1066)
–0·24
(–0·61 to 
0·17)
–4·01
(–6·99 to 
–1·46)
–1·36
(–1·57 to 
–1·15)
–5·23
(–6·74 to 
–3·50)
Sudan 12 035
(11 497 to 12 546)
1041
(619 to 1638)
9052
(8705 to 9391)
1260
(688 to 2041)
21 086
(20 354 to 21 845)
2301
(1596 to 3312)
3·49
(3·02 to 
3·95)
–1·53
(–3·42 to 
0·50)
–1·42
(–1·67 to 
–1·20)
–4·66
(–6·36 to 
–3·02)
Syria 2301
(2203 to 2391)
34
(22 to 76)
2229
(2149 to 2311)
22
(16 to 39)
4530
(4378 to 4678)
56
(42 to 109)
–0·81
(–1·17 to 
–0·47)
–17·86
(–22·06 to 
–7·72)
–1·32
(–1·55 to 
–1·09)
–4·47
(–6·76 to 
–2·18)
Tunisia 1962
(1888 to 2037)
108
(69 to 150)
1247
(1201 to 1290)
50
(28 to 75)
3209
(3099 to 3306)
158
(108 to 204)
–0·12
(–0·56 to 
0·33)
–6·73
(–8·86 to 
–4·62)
–0·18
(–0·37 to 
0·01)
–3·17
(–5·22 to 
–1·07)
Turkey 12 762
(12 296 to 13 256)
769
(600 to 1000)
8146
(7902 to 8442)
310
(199 to 374)
20 908
(20 284 to 21 577)
1079
(894 to 1303)
–0·13
(–0·52 to 
0·25)
–7·47
(–8·63 to 
–6·29)
–0·63
(–0·85 to 
–0·40)
–6·89
(–8·50 to 
–5·40)
United Arab 
Emirates
182
(160 to 205)
41
(23 to 73)
132
(122 to 144)
11
(6 to 20)
314
(284 to 348)
52
(33 to 88)
–2·06
(–2·49 to 
–1·61)
–5·67
(–9·36 to 
–2·35)
–2·43
(–2·70 to 
–2·14)
–3·48
(–5·91 to 
–1·39)
Yemen 4060
(3889 to 4231)
818
(454 to 1807)
3532
(3386 to 3664)
1473
(797 to 3012)
7592
(7305 to 7839)
2291
(1316 to 4607)
1·76
(1·44 to 
2·11)
–2·58
(–5·41 to 
0·43)
–2·88
(–3·15 to 
–2·65)
–3·23
(–5·60 to 
–0·46)
High-income 
North America
11 875
(11 372 to 12 364)
707
(586 to 1241)
6941
(6674 to 7204)
471
(369 to 816)
18 816
(18 130 to 19 491)
1177
(998 to 1966)
–0·75
(–0·99 to 
–0·52)
–6·84
(–7·96 to 
–1·42)
–3·32
(–3·55 to 
–3·10)
–4·14
(–5·14 to 
–1·90)
Canada 1100
(1058 to 1143)
76
(62 to 95)
825
(793 to 860)
68
(51 to 89)
1925
(1856 to 1997)
144
(121 to 173)
–0·16
(–0·40 to 
0·09)
–4·31
(–5·58 to 
–3·26)
–2·78
(–3·01 to 
–2·58)
–3·95
(–5·23 to 
–2·44)
USA 10 773
(10 289 to 11 246)
630
(513 to 1154)
6115
(5872 to 6358)
403
(304 to 747)
16 888
(16 246 to 17 509)
1033
(862 to 1814)
–0·81
(–1·06 to 
–0·55)
–7·17
(–8·41 to 
–1·17)
–3·39
(–3·64 to 
–3·16)
–3·97
(–5·06 to 
–1·57)
Oceania 4645
(4489 to 4814)
704
(400 to 1623)
4218
(4075 to 4362)
446
(267 to 1000)
8864
(8595 to 9143)
1150
(683 to 2513)
–0·73
(–1·12 to 
–0·36)
–6·29
(–8·55 to 
–2·59)
0·77
(0·60 to 
0·98)
–2·96
(–4·58 to 
–0·91)
Federated States 
of Micronesia
43
(39 to 48)
7
(4 to 11)
40
(35 to 44)
5
(3 to 9)
83
(75 to 93)
12
(8 to 19)
–0·67
(–1·17 to 
–0·17)
–3·90
(–6·15 to 
–1·42)
–0·43
(–0·85 to 
0·00)
–4·15
(–6·50 to 
–1·65)
Fiji 153
(146 to 159)
22
(17 to 33)
122
(117 to 127)
13
(10 to 18)
275
(266 to 284)
36
(29 to 46)
0·06
(–0·27 to 
0·40)
–4·59
(–6·81 to 
–2·51)
–3·38
(–3·61 to 
–3·14)
–7·39
(–9·55 to 
–3·01)
(Table 5 continues on next page)
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Kiribati 142
(137 to 146)
10
(7 to 15)
123
(119 to 127)
8
(5 to 13)
265
(258 to 272)
18
(13 to 25)
3·44
(2·90 to 
3·98)
–5·99
(–8·49 to 
–2·65)
1·77
(1·49 to 
1·96)
–4·42
(–6·74 to 
–2·12)
Marshall Islands 44
(42 to 47)
3
(2 to 4)
45
(42 to 48)
2
(1 to 4)
89
(85 to 94)
5
(4 to 7)
1·13
(0·54 to 
1·75)
–0·90
(–3·42 to 
1·88)
0·18
(–0·15 to 
0·45)
–4·86
(–7·59 to 
–1·77)
Papua New 
Guinea
3343
(3217 to 3481)
475
(241 to 1242)
3067
(2954 to 3184)
258
(134 to 765)
6409
(6196 to 6628)
733
(387 to 1938)
–1·30
(–1·80 to 
–0·81)
–7·41
(–10·18 to 
–2·60)
1·36
(1·14 to 
1·64)
–2·15
(–4·02 to 
0·10)
Samoa 38
(37 to 40)
3
(1 to 7)
28
(26 to 29)
6
(1 to 17)
66
(64 to 69)
10
(2 to 20)
0·12
(–0·18 to 
0·39)
–5·63
(–8·20 to 
–3·08)
–0·65
(–0·91 to 
–0·41)
–3·72
(–6·24 to 
–0·78)
Solomon Islands 285
(274 to 294)
51
(32 to 77)
279
(267 to 289)
64
(31 to 106)
563
(545 to 580)
115
(67 to 176)
0·65
(0·19 to 
1·01)
–3·63
(–5·86 to 
–1·37)
–0·79
(–0·98 to 
–0·56)
–3·98
(–6·07 to 
–1·56)
Tonga 20
(19 to 21)
2
(1 to 2)
16
(15 to 17)
2
(1 to 4)
36
(34 to 38)
4
(3 to 5)
–0·44
(–0·75 to 
–0·14)
–3·64
(–6·23 to 
–1·28)
–1·91
(–2·21 to 
–1·64)
–5·15
(–7·36 to 
–2·38)
Vanuatu 63
(60 to 65)
19
(12 to 29)
68
(66 to 71)
23
(11 to 39)
131
(127 to 136)
42
(25 to 66)
–1·10
(–1·41 to 
–0·79)
–2·90
(–5·22 to 
–0·49)
–0·78
(–1·03 to 
–0·53)
–4·56
(–6·71 to 
–1·95)
Central sub-Saharan 
Africa
114 571
(107 911 to 
120 891)
33 525
(25 993 to 
41 648)
87 499
(82 703 to 
92 494)
17 485
(13 887 to 
21 598)
202 070
(191 398 to 
212 432)
51 009
(41 734 to 
60 076)
0·63
(0·14 to 
1·09)
–0·12
(–1·35 to 
1·27)
0·07
(–0·12 to 
0·28)
–3·41
(–4·67 to 
–1·99)
Angola 19 588
(18 242 to 20 956)
5969
(3248 to 9477)
15 174
(14 016 to 16 231)
2863
(1863 to 4366)
34 762
(32 403 to 37 070)
8832
(5359 to 13 612)
–1·42
(–2·07 to 
–0·79)
–1·98
(–4·23 to 
0·51)
–0·13
(–0·46 to 
0·17)
–5·32
(–8·13 to 
–2·53)
Central African 
Republic
7034
(6346 to 7738)
2236
(1447 to 2967)
5389
(4875 to 5960)
1637
(1103 to 2296)
12 423
(11 309 to 13 628)
3873
(2704 to 4851)
1·04
(0·02 to 
1·95)
0·03
(–1·58 to 
1·56)
–0·65
(–1·20 to 
–0·17)
–1·87
(–3·39 to 
–0·30)
Congo 4248
(3927 to 4561)
986
(463 to 1355)
3486
(3234 to 3753)
354
(179 to 488)
7734
(7204 to 8267)
1340
(665 to 1727)
–0·31
(–0·90 to 
0·25)
–0·56
(–2·25 to 
1·06)
0·32
(–0·11 to 
0·78)
–3·13
(–4·78 to 
–1·42)
DR Congo 79 732
(74 757 to 
84 369)
23 672
(17 122 to 
31 677)
60 129
(56 560 to 
63 798)
12 414
(9525 to 
15 979)
139 861
(132 598 to 
147 281)
36 085
(28 514 to 
45 093)
1·27
(0·71 to 
1·77)
0·54
(–1·12 to 
2·69)
0·16
(–0·10 to 
0·43)
–3·04
(–4·69 to 
–1·29)
Equatorial Guinea 518
(455 to 575)
164
(49 to 278)
389
(339 to 433)
93
(29 to 178)
907
(803 to 1007)
257
(84 to 422)
–0·71
(–1·43 to 
–0·14)
–3·80
(–7·15 to 
–1·08)
0·43
(–0·14 to 
0·92)
–5·54
(–9·39 to 
–2·50)
Gabon 3450
(3120 to 3833)
497
(218 to 697)
2932
(2730 to 3148)
125
(62 to 179)
6383
(5896 to 6882)
623
(299 to 826)
–0·69
(–1·63 to 
0·31)
1·59
(–0·73 to 
3·64)
1·41
(1·01 to 
1·84)
–2·13
(–3·86 to 
–0·45)
Eastern sub-Saharan 
Africa
326 105
(307 524 to 
347 855)
100 724
(81 254 to 
111 357)
227 786
(214 817 to 
242 641)
70 740
(56 858 to 
78 604)
553 891
(522 812 to 
589 662)
171 464
(145 647 to 
185 375)
–0·99
(–1·42 to 
–0·54)
–0·67
(–1·82 to 
0·09)
–0·34
(–0·52 to 
–0·16)
–3·08
(–4·12 to 
–2·40)
Burundi 8469
(7891 to 8974)
5140
(3037 to 7242)
5083
(4729 to 5420)
2432
(1539 to 3512)
13 553
(12 704 to 14 335)
7572
(5442 to 10 002)
–1·75
(–2·51 to 
–1·01)
0·90
(–0·79 to 
2·79)
–0·71
(–1·22 to 
–0·20)
–3·35
(–5·09 to 
–1·71)
Comoros 274
(249 to 298)
252
(140 to 388)
163
(147 to 179)
130
(77 to 212)
437
(400 to 475)
382
(251 to 530)
–1·51
(–1·93 to 
–1·07)
1·82
(–0·60 to 
4·34)
–0·99
(–1·46 to 
–0·53)
–1·21
(–3·38 to 
0·75)
Djibouti 1238
(1160 to 1318)
249
(131 to 455)
681
(638 to 722)
124
(49 to 246)
1919
(1808 to 2027)
372
(213 to 649)
2·29
(1·36 to 
3·33)
4·84
(1·85 to 
7·69)
–1·35
(–1·74 to 
–0·91)
–2·05
(–4·46 to 
0·41)
Eritrea 2443
(2265 to 2637)
1862
(1218 to 2781)
2138
(1986 to 2301)
1275
(768 to 1967)
4582
(4280 to 4895)
3137
(2364 to 4419)
–2·54
(–3·18 to 
–1·95)
–3·50
(–7·18 to 
–0·29)
–0·46
(–0·98 to 
0·04)
–0·44
(–2·52 to 
2·32)
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Ethiopia 65 303
(60 948 to 
69 848)
29 593
(23 362 to 
36 203)
51 751
(48 490 to 
54 753)
20 595
(16 355 to 
25 142)
117 053
(110 158 to 
124 123)
50 188
(42 276 to 
58 367)
–1·43
(–2·14 to 
–0·80)
–2·97
(–4·42 to 
–1·56)
–0·34
(–0·78 to 
0·13)
–3·43
(–5·14 to 
–2·08)
Kenya 61 605
(56 119 to 
67 928)
11 395
(8667 to
14 118)
44 251
(40 340 to 
48 438)
6502
(4931 to
8374)
105 856
(96 915 to 
115 666)
17 898
(14 693 to 
20 861)
–3·01
(–3·82 to 
–2·14)
0·11
(–1·61 to 
1·83)
0·91
(0·47 to 
1·32)
–3·18
(–4·75 to 
–1·69)
Madagascar 28 720
(26 533 to 
30 590)
2500
(1536 to
3896)
19 627
(18 101 to 
20 984)
1208
(722 to
1901)
48 347
(44 889 to 
51 382)
3707
(2528 to
5317)
3·48
(2·31 to 
4·56)
–1·68
(–3·78 to 
0·22)
–0·11
(–0·46 to 
0·34)
–2·58
(–4·97 to 
–0·15)
Malawi 7370
(6519 to 8387)
4849
(3792 to 6091)
6187
(5510 to 7018)
3453
(2663 to 4329)
13 558
(12 132 to 15 242)
8302
(6970 to 9744)
–1·14
(–2·02 to 
–0·53)
1·45
(–0·12 to 
2·81)
–0·56
(–0·93 to 
–0·19)
–3·87
(–5·49 to 
–2·42)
Mauritius 230
(215 to 246)
12
(9 to 15)
100
(94 to 106)
2
(2 to 3)
330
(312 to 349)
14
(12 to 17)
–0·94
(–1·36 to 
–0·46)
–7·88
(–9·06 to 
–6·43)
–4·31
(–4·68 to 
–3·94)
–3·18
(–4·76 to 
–1·55)
Mozambique 29 668
(25 448 to 
34 673)
9214
(7203 to
11 545)
16 854
(14 214 to 
19 640)
5735
(4380 to
7257)
46 522
(39 804 to
53 743)
14 950
(12 303 to 
17 475)
–3·04
(–3·98 to 
–1·98)
–0·97
(–2·56 to 
0·60)
–1·81
(–2·31 to 
–1·17)
–1·94
(–3·39 to 
–0·57)
Rwanda 6636
(6158 to
7123)
2827
(1698 to
4085)
4032
(3767 to
4311)
1228
(801 to
1779)
10 668
(10 014 to
11 354)
4055
(2621 to
5504)
1·43
(0·77 to 
2·11)
0·81
(–2·22 to 
2·74)
0·22
(–0·19 to 
0·59)
–6·62
(–8·51 to 
–5·03)
Seychelles 45
(41 to 48)
1
(1 to 2)
32
(30 to 34)
0
(0 to 0)
77
(72 to 82)
2
(1 to 2)
–0·07
(–0·55 to 
0·52)
8·54
(–5·51 to 
11·90)
–2·18
(–2·58 to 
–1·75)
–2·85
(–4·74 to 
–1·02)
Somalia 12 912
(12 172 to
13 747)
3702
(2227 to
6112)
7816
(7323 to
8227)
4964
(2942 to
7757)
20 728
(19 605 to
21 824)
8667
(5501 to
13 266)
0·00
(–0·67 to 
0·73)
3·50
(0·65 to 
6·21)
–0·24
(–0·57 to 
0·08)
–0·04
(–2·14 to 
2·61)
South Sudan 10 187
(9231 to
11 115)
5002
(3165 to
6780)
5276
(4768 to
5726)
3376
(2373 to
4474)
15 463
(14 087 to
16 764)
8378
(6420 to
10 484)
–0·26
(–1·43 to 
0·72)
2·66
(–1·35 to 
5·22)
–1·21
(–2·13 to 
–0·55)
–1·72
(–4·17 to 
0·41)
Tanzania 23 582
(21 502 to
25 681)
10 942
(7615 to
14 080)
16 759
(15 183 to
18 327)
9099
(6309 to 
11 620)
40 341
(36 939 to
43 710)
20 041
(14 575 to 
24 332)
–0·91
(–1·47 to 
–0·32)
0·84
(–0·52 to 
2·22)
–0·34
(–0·66 to 
0·00)
–2·57
(–4·76 to 
–1·04)
Uganda 28 674
(25 605 to
31 944)
8923
(5823 to
11 569)
18 418
(16 646 to
20 441)
5815
(3394 to
7326)
47 092
(42 791 to
52 231)
14 738
(9637 to
18 062)
0·90
(0·16 to 
1·58)
0·46
(–1·22 to 
2·04)
–1·26
(–1·61 to 
–0·94)
–3·76
(–5·20 to 
–2·24)
Zambia 26 785
(23 118 to
31 050)
4197
(3120 to
5379)
19 554
(17 143 to
22 604)
4760
(3545 to
5975)
46 339
(40 875 to
53 310)
8957
(7242 to
10 668)
0·05
(–0·60 to 
0·63)
3·72
(2·18 to 
5·32)
0·40
(–0·13 to 
0·86)
–2·56
(–4·03 to 
–0·99)
Southern sub–
Saharan Africa
272 261
(241 833 to 
311 989)
23 357
(19 033 to 
27 878)
237 413
(209 522 to 
273 154)
13 252
(10 527 to 
16 642)
509 674
(455 681 to 
580 571)
36 609
(31 228 to 
41 720)
–4·74
(–5·78 to 
–3·50)
1·34
(–0·22 to 
2·77)
0·14
(–0·26 to 
0·54)
–4·12
(–5·91 to 
–2·91)
Botswana 4934
(4205 to 5877)
636
(351 to 996)
4455
(3757 to 5248)
319
(167 to 509)
9389
(8127 to 10 938)
956
(588 to 1428)
–4·85
(–5·75 to 
–3·67)
4·74
(1·54 to 
8·02)
–0·50
(–1·00 to 
0·08)
–6·62
(–9·80 to 
–3·70)
Lesotho 3723
(3283 to 4338)
1887
(1426 to 2373)
2712
(2373 to 3188)
1539
(979 to 2165)
6435
(5692 to 7474)
3425
(2662 to 4196)
–4·01
(–5·27 to 
–2·51)
5·45
(3·63 to 
7·17)
4·05
(3·77 to 
4·32)
–1·52
(–2·68 to 
–0·46)
Namibia 5530
(4773 to 6358)
1419
(1050 to 1840)
4716
(4055 to 5397)
771
(580 to 976)
10 246
(8987 to 11 696)
2189
(1775 to 2654)
–2·07
(–3·18 to 
–0·80)
2·91
(1·43 to 
4·46)
0·74
(0·38 to 
1·15)
–3·39
(–4·78 to 
–2·01)
South Africa 217 545
(192 039 to 
249 900)
13 138
(10 056 to 
16 480)
190 831
(166 974 to 
221 264)
6779
(4934 to 9016)
408 376
(363 668 to 
466 379)
19 918
(16 269 to 
23 639)
–5·44
(–6·61 to 
–4·11)
0·93
(–1·12 to 
2·79)
–0·08
(–0·53 to 
0·40)
–6·08
(–8·53 to 
–4·44)
Swaziland 3426
(2949 to 4025)
652
(395 to 865)
3086
(2639 to 3705)
563
(304 to 828)
6512
(5645 to 7658)
1215
(752 to 1536)
–4·20
(–5·44 to 
–2·71)
6·31
(4·21 to 
8·34)
3·04
(2·62 to 
3·46)
–3·49
(–4·98 to 
–1·90)
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Zimbabwe 37 104
(32 309 to 42 857)
5625
(3921 to 8124)
31 613
(27 725 to 36 707)
3280
(2078 to 4815)
68 717
(60 653 to 78 743)
8905
(6790 to 11 779)
–4·38
(–5·13 to 
–3·64)
1·73
(–0·26 to 
3·54)
2·64
(2·11 to 
3·17)
1·30
(–0·94 to 
3·71)
Western sub-
Saharan Africa
255 207
(242 139 to 
268 854)
53 088
(43 739 to 
65 410)
149 320
(141 150 to 
157 043)
34 426
(29 093 to 
40 604)
404 527
(384 745 to 
425 437)
87 515
(77 221 to 
101 345)
–0·33
(–0·79 to 
0·14)
–0·84
(–1·71 to 
–0·07)
–0·57
(–0·73 to 
–0·39)
–3·09
(–3·84 to 
–2·17)
Benin 6698
(6330 to 7098)
1521
(1102 to 2066)
3663
(3461 to 3858)
661
(455 to 855)
10 361
(9842 to 10 892)
2181
(1687 to 2775)
–0·81
(–1·41 to 
–0·29)
–0·89
(–2·59 to 
0·70)
–0·60
(–0·90 to 
–0·27)
–1·17
(–2·68 to 
0·27)
Burkina Faso 8129
(7660 to 8652)
2690
(1939 to 3409)
4308
(4084 to 4545)
2248
(1603 to 2909)
12 437
(11 811 to 13 118)
4938
(3773 to 5839)
–0·68
(–1·27 to 
–0·12)
–0·62
(–2·08 to 
0·81)
–0·14
(–0·64 to 
0·37)
–0·27
(–3·18 to 
1·27)
Cameroon 22 407
(20 502 to 24 548)
2837
(2162 to 3887)
14 476
(13 221 to 15 747)
1748
(1132 to 2228)
36 883
(33 889 to 40 082)
4585
(3672 to 5728)
–0·60
(–1·61 to 
0·37)
1·33
(–0·23 to 
2·86)
–0·58
(–0·85 to 
–0·34)
–2·55
(–3·99 to 
–0·96)
Cape Verde 534
(498 to 573)
30
(16 to 48)
238
(222 to 255)
12
(4 to 19)
772
(725 to 822)
41
(23 to 63)
–0·19
(–0·72 to 
0·42)
–2·22
(–5·07 to 
0·79)
–0·61
(–0·95 to 
–0·25)
–5·03
(–7·79 to 
–2·43)
Chad 11 187
(10 264 to 12 122)
2390
(1692 to 3397)
6101
(5677 to 6570)
2690
(1739 to 3764)
17 288
(16 059 to 18 602)
5079
(3874 to 6266)
–1·62
(–2·29 to 
–0·99)
0·88
(–0·73 to 
2·45)
0·60
(0·21 to 
1·00)
–1·31
(–2·73 to 
0·12)
Côte d’Ivoire 17 640
(16 340 to 19 048)
4389
(3289 to 5529)
11 389
(10 512 to 12 294)
2138
(1379 to 2701)
29 029
(27 031 to 31 250)
6526
(4937 to 7802)
–0·47
(–1·24 to 
0·28)
0·76
(–1·02 to 
2·61)
–0·74
(–1·15 to 
–0·32)
–1·35
(–2·69 to 
0·02)
Ghana 12 926
(12 176 to 13 666)
2359
(1804 to 3219)
7499
(7080 to 7894)
1270
(945 to 1681)
20 426
(19 330 to 21 464)
3629
(2962 to 4525)
–0·55
(–1·25 to 
0·07)
–5·66
(–7·58 to 
–3·76)
–2·16
(–2·49 to 
–1·85)
–5·38
(–6·98 to 
–3·21)
Guinea 10 887
(10 170 to 11 592)
1874
(1374 to 2509)
5891
(5511 to 6272)
1605
(1072 to 2321)
16 778
(15 772 to 17 779)
3479
(2696 to 4378)
0·73
(0·14 to 
1·33)
–0·74
(–2·32 to 
1·01)
–1·44
(–1·79 to 
–1·10)
–0·68
(–2·04 to 
0·69)
Guinea–Bissau 1887
(1707 to 2058)
406
(286 to 591)
1244
(1131 to 1356)
284
(189 to 402)
3131
(2855 to 3399)
690
(497 to 984)
–0·86
(–1·53 to 
–0·16)
1·40
(–1·17 to 
4·00)
0·15
(–0·41 to 
0·69)
–1·20
(–3·81 to 
1·42)
Liberia 5762
(5418 to 6140)
837
(595 to 1212)
4623
(4347 to 4890)
557
(388 to 742)
10 384
(9849 to 10 944)
1394
(1081 to 1843)
–0·29
(–1·17 to 
0·61)
0·72
(–1·11 to 
2·93)
1·76
(1·38 to 
2·16)
–1·69
(–3·23 to 
–0·22)
Mali 7940
(7504 to 8410)
2682
(1849 to 3673)
4349
(4132 to 4591)
1368
(972 to 1939)
12 289
(11 653 to 12 912)
4050
(3212 to 5232)
–1·06
(–1·68 to 
–0·50)
–2·09
(–3·54 to 
–0·47)
–0·24
(–0·55 to 
0·14)
–1·21
(–2·69 to 
0·27)
Mauritania 7172
(6635 to 7684)
503
(329 to 759)
3234
(2976 to 3463)
321
(200 to 483)
10 406
(9667 to 11 067)
824
(589 to 1108)
–0·01
(–0·69 to 
0·59)
–2·63
(–5·32 to 
–0·46)
0·42
(0·08 to 
0·75)
–2·27
(–3·86 to 
–0·95)
Niger 13 239
(12 554 to 13 971)
3151
(2391 to 4336)
5498
(5251 to 5759)
2218
(1695 to 2844)
18 737
(17 926 to 19 676)
5369
(4389 to 6650)
0·32
(–0·27 to 
0·90)
–0·81
(–2·45 to 
0·62)
–0·33
(–0·71 to 
0·00)
–1·95
(–3·43 to 
–0·45)
Nigeria 97 302
(89 158 to 
105 772)
22 730
(15 211 to 
31 509)
59 901
(54 701 to
65 227)
14 719
(10 135 to 
20 468)
157 203
(145 193 to 
169 957)
37 449
(28 903 to 
48 392)
–0·24
(–0·94 to 
0·42)
–0·64
(–2·26 to 
0·79)
–0·84
(–1·21 to 
–0·44)
–4·22
(–5·82 to 
–2·52)
Sâo Tomé 
and Príncipe
111
(89 to 120)
9
(5 to 15)
75
(67 to 79)
4
(2 to 6)
186
(157 to 199)
13
(8 to 19)
0·50
(–0·74 to 
1·40)
–1·80
(–4·37 to 
0·61)
–0·59
(–1·18 to 
–0·24)
–2·70
(–5·55 to 
–0·04)
Senegal 12 866
(12 178 to 13 535)
2252
(1492 to 3041)
6142
(5851 to 6455)
1369
(824 to 1953)
19 008
(18 120 to 19 896)
3621
(2596 to 4579)
–0·07
(–0·50 to 
0·33)
–1·79
(–3·53 to 
–0·06)
–0·81
(–1·10 to 
–0·48)
–2·28
(–3·62 to 
–0·86)
Sierra Leone 13 131
(12 244 to 14 006)
1393
(964 to 1976)
7366
(6836 to 7836)
593
(435 to 778)
20 497
(19 213 to 21 774)
1986
(1522 to 2579)
0·99
(0·35 to 
1·62)
1·67
(–0·21 to 
3·51)
1·09
(0·69 to 
1·48)
–2·20
(–3·70 to 
–0·55)
(Table 5 continues on next page)
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than 200 per 100 000 population in 24 countries in sub-
Saharan Africa as well as in North Korea, Timor-Leste, 
Cambodia, Laos, Philippines, and Kiribati (ﬁ gure 15). 
There are an additional 16 countries with rates of more 
than 150 per 100 000 population that include Bangladesh, 
Myanmar, India, Pakistan, Ethiopia, and Malawi. Figure 15 
also shows tuberculosis death rates in individuals who are 
HIV-negative which are above 10 per 100 000 population in 
all countries in sub-Saharan Africa and increase to more 
than 50 per 100 000 population in 40 countries. Among 
middle-income countries outside of sub-Saharan Africa, 
Afghanistan, Indonesia, India, Myanmar, and the 
Philippines stand out as countries with death rates higher 
than 50 per 100 000 population. The highest age-
standardised death rates in Latin America and the 
Caribbean are in Haiti followed by Bolivia and Peru. Death 
rates per 100 000 population are highly variable in north 
Africa and the Middle East, ranging from very low in Syria 
(0·5 [0·3 to 0·9]) and Jordan (0·8 [0·6 to 1·0]) to high in 
Morocco [14·3 [11·2 to 17·5]) and Yemen (19·9 [11·5 to 41·5]) 
in 2013. Eastern Europe and central Asia stand out with 
death rates that are substantially higher than western or 
central Europe. China has lower rates of death than 
eastern Europe and central Asia. Our ﬁ ndings are mostly 
consistent with the list of high-burden countries used by 
WHO; however, our top 22 countries in terms of case 
numbers or death numbers that are not on the WHO 
high-burden list include South Korea, North Korea, and 
Madagascar for case numbers and Angola and Zambia for 
mortality. WHO high-burden countries that did not make 
our top 22 list for case numbers include Afghanistan, 
Cambodia, and Tanzania, and the WHO high-burden 
countries that did not make our top 22 list for mortality 
include Brazil and Cambodia.
Trends in the annual number of new cases of malaria, 
and annual deaths from malaria, are shown in ﬁ gure 16 for 
the period since 1990. Global incidence seems to have 
peaked in 2003 at 232 million cases (143 million to 
387 million) and has since fallen by about 29% to 165 million 
new cases (95 million to 284 million) in 2013. There is 
massive uncertainty around these estimates: the 2013 
estimate, for example, could be anywhere between 
95 million and 284 million. The estimates of new malaria 
cases in the World Malaria Report fall within the uncertainty 
intervals of the GBD estimates with a mean number of new 
cases in 2012 of 207 million (135 million to 287 million). By 
contrast with incidence data, the World Malaria Report 
estimates of malaria deaths are slightly lower (ﬁ gure 16). 
There are also some important diﬀ erences in the timing of 
the peak and decline in malaria mortality. Annual malaria 
deaths began to decline from a peak of 1·2 million 
(1·1 million to 1·4 million) in 2004 to about 855 000 (703 000 
to 1 032 000) in 2013, having increased from 888 000 
(793 000 to 993 000) in 1990. According to the World Malaria 
Report,110 malaria caused about 627 000 deaths in 2012, 
having reached a peak of about 900 000 around the turn of 
the century. The age-sex pattern of global malaria incident 
cases and deaths in 2013 is shown in ﬁ gure 17. The largest 
number of cases is in people younger than 15 years. Malaria 
deaths, by contrast, are concentrated in children younger 
than 5 years, although malaria caused between 10 000 and 
25 000 deaths in each 5-year age group beyond age 15 years, 
so that the cumulative fraction of malaria deaths in adults 
reaches 33·75%.
Globally, age-standardised malaria incidence and death 
rates were increasing in the period 1990–2000 (table 6), 
but many regions outside of sub-Saharan Africa and north 
Africa and the Middle East had decreases in age-
standardised incidence, death rates, or both. In the period 
since 2000, all regions including sub-Saharan Africa had 
decreases in age-standardised incidence and death rates. 
Incidence decreased by 38% (37 to 40) in central Asia since 
2000, a result of increased malaria elimination eﬀ orts in 
the region. Figure 18 shows the geographical distribution 
of the age-standardised incidence rate in 2013. The 
geographical distribution of the age-standardised mortality 
rate (ﬁ gure 18) shows a similar pattern with the highest 
rates in Mozambique, Burkina Faso, Guinea-Bissau, Mali, 
Sierra Leone, The Gambia, and Guinea. Rwanda stands 
out as having low rates compared with its neighbouring 
countries. Outside of Africa, Yemen, India, Myanmar, and 
Papua New Guinea have death rates higher than 7·5 per 
100 000 population. In southeast Asia, Thailand and 
Malaysia have achieved very low death rates. Table 7 shows 
All ages incidence and deaths (2013) Annualised rate of change (% )
Male population Female population Total 1990–2000 2000–13
Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths
(Continued from previous page)
The Gambia 2059
(1941 to 2172)
204
(111 to 334)
1088
(1024 to 1151)
88
(49 to 141)
3147
(2978 to 3308)
292
(161 to 474)
–0·13
(–0·53 to 
0·31)
–0·23
(–2·91 to 
2·39)
0·32
(0·08 to 
0·55)
–2·19
(–4·47 to 
0·28)
Togo 3325
(3074 to 3607)
832
(562 to 1231)
2232
(2060 to 2388)
534
(388 to 718)
5558
(5161 to 5966)
1366
(1038 to 1789)
–1·42
(–2·23 to 
–0·63)
–0·83
(–2·41 to 
0·83)
0·51
(0·22 to 
0·81)
–2·43
(–4·10 to 
–0·63)
Data in parentheses are 95% uncertainty intervals.
Table 5: Tuberculosis without HIV incidence and deaths for all ages by sex and annualised rates of change for 21 Global Burden of Disease regions and 188 countries
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Figure 15: Age-standardised tuberculosis incidence (A) and death rates (B) in HIV-negative individuals in 2013, both sexes
ATG=Antigua and Barbuda. VCT=Saint Vincent and the Grenadines. Isl=Islands. FSM=Federated States of Micronesia. LCA=Saint Lucia. TTO=Trinidad and Tobago. TLS=Timor-Leste.
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incidence and death numbers by country in 2013 along 
with ARCs for age-standardised rates. Four countries have 
over 5 million cases a year including India with over 
60 million cases, Nigeria (30 million), DR Congo (with 
6 million), and Mozambique (6 million). Three 
countries—Nigeria, DR Congo, and India—account for 
roughly 50% of all malaria deaths in 2013.
Discussion
HIV, tuberculosis, and malaria remain major health 
challenges in 2013. The mean age of death diﬀ ers 
substantially between them, at 15·3 years for malaria, 
38·6 years for HIV, and 52·9 years for tuberculosis in 
HIV-negative individuals, which means that the burden 
in terms of years of life lost varies across the diseases. 
Tuberculosis deaths have decreased globally since 1990, 
and after 2000 incidence, prevalence, and death have all 
decreased. HIV incidence peaked in 1997 and mortality 
peaked in 2005 with substantial declines since the peak in 
each. Malaria incidence and mortality peaked and began 
declining in 2004 with substantial drops in the number of 
child deaths in sub-Saharan Africa over the past 5 years. 
There is substantial variation both in levels and trends for 
all three diseases across countries. HIV and malaria 
incidence and death are concentrated in sub-Saharan 
Africa whereas tuberculosis burden is more widespread 
but most pronounced in south and southeast Asia.
From our analysis of HIV data, our ﬁ ndings show that 
the HIV epidemic is smaller than estimated by UNAIDS. 
Our global epidemic curve for mortality ranges was lower 
than estimated by UNAIDS for every year; at the peak in 
2005 our estimates are 27·0% lower and in 2012 are 
14·5% lower. Our estimates of global prevalence diﬀ er 
from UNAIDS’s by 17·1% in 2005 and 18·7% in 2012. 
The substantial diﬀ erences in the number of deaths stem 
from two key diﬀ erences in these analyses. First, in the 
125 concentrated epidemics with some cause of death 
data for mortality due to HIV, our estimated mortality is 
52·2% lower in 2000 and 58·4% lower in 2012 than 
UNAIDS’s estimates. Our prevalence estimates are, for 
example, 36·3% lower for Panama, 52·2% lower for 
Colombia, and 58·4% lower in Russia. Second, in the 
large generalised epidemics, selecting epidemic curves 
that are consistent with prevalence data, all-cause 
mortality, and available studies on survival with and 
without ART shifted median survival up. For example, in 
southern Africa, median survival oﬀ  ART for the age-
group 25–34 years increased from 10·5 years to 
11·5 years. Longer or shorter survival oﬀ  ART in some 
countries could be explained by genetic factors,111–115 co-
factors such as the presence of other diseases like 
malaria,116–118 diﬀ erential access to treatments for 
opportunistic infections, or other co-factors that have not 
been described. These ﬁ ndings are important in terms of 
identifying the magnitude and comparative burden of 
HIV. Table 8 outlines the diﬀ erences between our HIV/
AIDS estimation strategy and that of UNAIDS.
Comparison of population-based surveys with our 
estimates of prevalence suggest reasonable alignment and 
the regression analysis of estimated prevalence on 
measured prevalence suggest there is not systematic 
tendency in our estimates to overestimate or under estimate 
prevalence. However, much variation exists by age and sex 
with nearly one in ﬁ ve of our age-sex speciﬁ c prevalence 
estimates statistically diﬀ erent than the survey prevalences. 
Several potential explanations for this variation exist. Our 
assumptions about the relative incidence pattern by country 
might not be true at the local level. Diﬀ erential non-
response in the surveys by age and sex is also a potential 
factor. The adjustments made through the demographic 
matching and CoDCorrect algorithm could contribute to 
the diﬀ erences. More analysis on a country-by-country basis 
will be helpful in exploring these issues in future research.
Revisions of the global epidemiology of HIV of this 
magnitude—in view of the weakness of direct 
measurement of incidence and death—should not be 
surprising. As prevalence surveys became more widely 
available, UNAIDS revised downward their global 
prevalence estimates by 18% in 2007 and their global 
mortality estimates by nearly 24%.119 Taking into account 
more data for survival on and oﬀ  ART and incorporating 
all-cause mortality data has led to revisions of a similar 
Figure 16: Global malaria incidence (A) and deaths (B), 1990–2013, for all ages and both sexes combined
Shaded areas are 95% uncertainty intervals.
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magnitude. Our revisions also suggests that there is 
greater uncertainty for incidence, prevalence, and death 
than previously estimated. Irrespective of the speciﬁ c 
estimates generated from imperfect data, however, our 
assessment of prevalence continues to point to the very 
large and steadily growing numbers of infected individuals, 
many of whom are in need of antiretroviral therapy. Great 
progress has been achieved reducing infections in children 
(62·4% reduction since the incidence peak in 2002) due to 
the scale-up of interventions. The continued 1·7 million 
new infections per year in adults, down 32·7% from the 
peak of the epidemic at the global scale, however, is a stark 
reminder of the continuing epidemic.
A key ﬁ nding that conﬁ rms many local, regional, and 
global studies120–125 is that interventions, especially ART, 
PMTCT, and co-trimoxazole, have had a profound eﬀ ect. 
Cumulatively, 19·1 million years of life have been saved 
since 1996, 5·7 million in developed countries and 
13·4 million in developing countries, where the ratio of 
DAH to years of life saved is less than $4500 for the 
average of the period 2000–11. In view of the very rapid 
increase in years of life saved in 2012 and 2013, the ratio 
for the period 2000–13 when DAH ﬁ gures are available 
will probably be much lower. The scale-up, number of 
lives saved, and comparatively low price per year of life 
saved is one of the major achievements in global health in 
the past decade. Many groups—local, national, and 
global—deserve credit for this accomplishment. DAH 
does not count national contributions to the cost of HIV 
programmes; real variation in the ratio of the total cost per 
year of life saved is probably much smaller because many 
middle-income countries receive little DAH and fund 
most HIV interventions from their own resources. Micro-
economic studies of the cost per years of life saved have 
also reported wide variation across locations.126–128 We 
would expect, given investments in initial programme 
start-up including capital equipment investments, that the 
ratio of DAH to life-years saved will decrease over time. 
With prevalence growing 5·8% per year over the past 
5 years, the need to learn from more eﬃ  cient programmes 
is paramount. Our analysis of survival on ART shows 
wide variation in programme outcomes within sub-
Saharan Africa. Counterfactual analysis of what might 
happen if all programmes achieved the levels of mortality 
seen in the programmes with the best outcomes or even 
what would happen if high-income country on-ART death 
rates were achieved would help shed further light on the 
importance of quality improvement for future HIV death 
reductions. Improving cost-eﬀ ectiveness of ART 
programmes will require a process of continuously 
documenting costs, outcomes, and eﬃ  ciency along with a 
mechanism for shared learning across programmes on 
improving quality. HIV infected intravenous drug users 
have not beneﬁ ted as much from treatment as those 
infected through sexual transmission. Regions with an 
ongoing increase in mortality from HIV in the 2000–13 
period are high-income Asia Paciﬁ c, central and eastern 
Asia, eastern and central Europe, north Africa and the 
Middle East, Oceania, and southern and western sub-
Saharan. In a number of these regions large proportions 
of HIV cases are in intravenous drug users for whom 
countries might be less inclined to provide treatment 
services. Even in countries with a greater emphasis on 
harm-reduction strategies, drug users might still be a 
more diﬃ  cult group for health services to reach.129
Age-standardised tuberculosis mortality rates including 
tuberculosis in HIV-positive individuals at the global level 
changed at –2·8% (–3·6 to –2·2) per year from 1990 to 
2000 and around a percentage point faster from 2000 to 
2013 (–3·7% [–4·4 to –3·0%]) per year. When examining 
tuberculosis mortality in individuals who are HIV-negative, 
the acceleration was smaller, from –3·3 (–4·1 to –2·6) to 
–3·7% (–4·4 to –3·0) change per year but still statistically 
signiﬁ cant. There has been comparatively little decrease in 
Figure 17: Global age-sex distribution of malaria incidence (A) and deaths (B) in 2013
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the global age-standardised tuberculosis incidence rates in 
HIV-negative individuals although some regions such as 
south Asia and east Asia have seen accelerated declines 
since 2000. Prevalence has decreased much faster than 
incidence, which is consistent with earlier and more 
eﬀ ective treatment-shortening durations. In addition to 
shorter duration, the death to incidence ratio changed 
from 0·36 in 1990 to 0·18 in 2013, also a likely consequence 
of treatment. There has been much regional and country 
variation in progress on tuberculosis with the ARC for 
mortality ranging from –10·3% to 2·5% from 1990 to 2013 
and the ARC for incidence ranging from –3·3% to 2·5% 
over the same period. This variation implies that more 
rapid progress is possible at the global scale if lessons can 
be learned from countries with more rapid achievement. 
Since 2000, as for HIV and malaria, global progress in 
terms of prevalence and mortality has accelerated. We are 
unable to compute the extra years of life saved for 
tuberculosis as we can for HIV; but the comparatively 
small DAH for tuberculosis over the period 2000–11 
($8·3 billion) has been associated over this time period 
with greater reductions in incidence, prevalence, and death 
rates. Tuberculosis is diﬀ erent from HIV and malaria in 
that the rising incidence and death rates with age mean 
that demographic ageing of the world’s population in the 
absence of other changes will naturally lead to higher 
numbers of cases and deaths. Demographic changes in 
essence slow the progress of tuberculosis control; a factor 
that should be built into considerations of funding and 
programme strategy. The established links between 
alcohol, diabetes, tobacco smoking and tuberculosis also 
mean that trends in these risk factors can modulate trends 
in tuberculosis.131–133 In this analysis, we have not separately 
examined the incidence, prevalence, and mortality related 
Age-standardised rates in 2003 
(per 100 000 population)
Annualised rate of change (%)
Incidence Mortality 1990–2000 2000–13
Incidence Mortality Incidence Mortality
Worldwide 2360·42
(1373·81 to 4051·98)
11·78
(9·69 to 14·21)
0·26
(–1·02 to 1·12)
1·96
(0·84 to 3·06)
–3·27
(–4·99 to –1·18)
–3·11
(–4·72 to –1·60)
High-income 
Asia Paciﬁ c
0·40
(0·34 to 0·47)
0·00
(0·00 to 0·00)
–8·48
(–9·93 to –7·09)
–18·55
(–19·35 to –17·73)
–1·67
(–2·28 to –1·18)
–16·79
(–17·75 to –15·86)
Central Asia 0·19
(0·16 to 0·21)
0·02
(0·01 to 0·03)
16·77
(15·48 to 18·21)
–4·84
(–9·03 to –0·29)
–38·41
(–39·92 to –37·09)
–7·32
(–10·76 to –3·15)
East Asia 0·23
(0·20 to 0·25)
0·01
(0·01 to 0·01)
–0·60
(–1·44 to 0·36)
–7·67
(–9·34 to –6·02)
–19·91
(–20·96 to –18·98)
–10·95
(–13·09 to –8·36)
South Asia 4428·64
(1639·86 to 10 388·82)
9·08
(7·00 to 11·73)
–2·00
(–3·78 to –0·81)
–2·65
(–4·27 to –0·91)
–3·33
(–4·67 to –1·81)
–3·39
(–5·45 to –1·31)
Southeast Asia 1231·49
(556·12 to 2635·04)
2·28
(1·68 to 3·15)
–3·89
(–5·56 to –2·16)
–4·54
(–6·53 to –2·65)
–5·88
(–8·59 to –3·01)
–6·89
(–9·01 to –4·25)
Caribbean 245·54
(227·17 to 263·02)
0·91
(0·51 to 1·47)
–3·35
(–3·63 to –3·05)
–4·52
(–6·90 to –1·78)
–4·08
(–4·64 to –3·53)
–7·48
(–11·51 to –3·38)
Andean
Latin America
49·36
(42·60 to 55·80)
0·04
(0·03 to 0·05)
–2·53
(–3·04 to –2·04)
–5·70
(–7·28 to –4·09)
–2·79
(–3·64 to –2·05)
–13·80
(–15·92 to –11·45)
Central
Latin America
46·12
(40·32 to 51·63)
0·05
(0·04 to 0·07)
–2·29
(–2·75 to –1·85)
–5·58
(–7·13 to –4·18)
–2·10
(–2·76 to –1·51)
–10·06
(–12·13 to –7·34)
Southern
Latin America
0·95
(0·81 to 1·08)
0·00
(0·00 to 0·00)
–9·52
(–10·71 to –8·32)
–16·26
(–17·13 to –15·40)
–3·21
(–4·06 to –2·48)
–16·29
(–17·17 to –15·43)
Tropical
Latin America
62·80
(53·39 to 71·76)
0·03
(0·02 to 0·05)
–6·49
(–7·87 to –5·20)
–17·58
(–19·80 to –15·41)
–0·11
(–0·50 to 0·21)
–9·20
(–12·22 to –5·86)
North Africa and 
Middle East
396·71 
(122·46 to 1028·80)
1·97
(1·07 to 3·48)
2·14
(1·31 to 3·18)
3·88
(0·73 to 7·01)
–5·74
(–9·08 to –2·40)
–7·07
(–10·62 to –3·04)
Oceania 10 452·65
(3908·47 to 25 253·80)
20·54
(11·95 to 33·16)
–0·02
(–0·25 to 0·19)
–0·30
(–3·70 to 2·75)
–2·14
(–3·14 to –1·05)
–2·61
(–5·49 to 0·65)
Central 
sub-Saharan Africa
6628·47
(3171·03 to 13 240·91)
43·15
(28·36 to 63·55)
–2·74
(–4·45 to –1·39)
–1·59
(–4·08 to 1·08)
–5·13
(–7·81 to –2·43)
–5·73
(–9·03 to –2·28)
Eastern 
sub-Saharan Africa
6411·66
(3214·47 to 12 802·02)
39·58
(33·03 to 49·36)
0·41
(–0·29 to 1·52)
0·77
(–0·82 to 2·33)
–6·68
(–8·94 to –3·58)
–6·76
(–8·47 to –4·40)
Southern 
sub-Saharan Africa
766·01
(315·25 to 1807·70)
4·21
(3·22 to 5·76)
2·84
(1·28 to 4·19)
2·85
(–0·40 to 5·45)
–5·63
(–8·37 to –2·64)
–7·30
(–9·74 to –4·10)
Western 
sub-Saharan Africa
11 874·88
(6907·10 to 20 684·35)
85·89
(68·14 to 105·95)
0·90
(0·26 to 1·72)
1·45
(–0·24 to 3·18)
–3·79
(–5·33 to –2·00)
–3·40
(–5·15 to –1·56)
Data in parentheses are 95% uncertainty intervals.
Table 6: Age-standardised malaria incidence and mortality rates and annualised rates of change for both sexes for 16 Global Burden of Disease regions
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Figure 18: Age-standardised malaria incidence (A) and death (B) rates in 2013, both sexes
ATG=Antigua and Barbuda. VCT=Saint Vincent and the Grenadines. Isl=Islands. FSM=Federated States of Micronesia. LCA=Saint Lucia. TTO=Trinidad and Tobago. TLS=Timor-Leste.
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All ages incidence and deaths (2013) Annualised rate of change (%)
Male population Female population Total 1990–2000 2000–13
Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths
Worldwide 80 442 176
(46 673 036 to 
138 440 048)
434 792
(337 311 to 
564 653)
84 487 696
(48 637 128 to 
145 153 824)
419 777
(341 821 to 
517 091)
164 929 872
(95 399 904 to 
284 354 624)
854 568
(702 884 to 
1 032 471)
0·26
(–1·02 to 
1·12)
1·96
(0·84 to 
3·06)
–3·27
(–4·99 to 
–1·18)
–3·11
(–4·72 to 
–1·60)
Developed countries 357
(305 to 405)
0
(0 to 1)
357
(304 to 407)
0
(0 to 1)
713
(609 to 812)
0
(0 to 2)
–8·36
(–9·74 to 
–7·03)
–17·90
(–18·68 to 
–17·07)
–2·13
(–1·63 to 
–2·74)
–16·22
(–15·27 to 
–17·20)
Developing countries 80 441 816
(46 672 684 to 
138 439 696)
434 792
(337 311 to 
564 653)
84 487 336
(48 636 776 to 
145 153 472)
419 776
(341 820 to 
517 091)
164 929 152
(95 399 192 to 
284 353 920)
854 568
(702 884 to 
1 032 470)
–0·21
(–1·75 to 
0·75)
1·49
(0·43 to 
2·53)
–3·45
(–1·35 to 
–5·15)
–3·29
(–1·84 to 
–4·85)
High-income Asia Paciﬁ c 357
(305 to 405)
0
(0 to 1)
357
(304 to 407)
0
(0 to 1)
713
(609 to 812)
0
(0 to 2)
–8·48
(–9·93 to 
–7·09)
–18·55
(–19·35 to 
–17·73)
–1·67
(–2·28 to 
–1·18)
–16·79
(–17·75 to 
–15·86)
South Korea 357
(305 to 405)
0
(0 to 1)
357
(304 to 407)
0
(0 to 1)
713
(609 to 812)
0
(0 to 2)
–10·95
(–12·29 to 
–9·59)
–18·68
(–19·49 to 
–17·87)
–3·08
(–2·37 to 
–3·92)
–18·02
(–17·09–
18·94)
Central Asia 78
(68 to 87)
8
(4 to 16)
77
(67 to 87)
9
(5 to 15)
155
(135 to 174)
17
(12 to 28)
16·77
(15·48 to 
18·21)
–4·84
(–9·03 to 
–0·29)
–38·41
(–39·92 to 
–37·09)
–7·32
(–10·76 to 
–3·15)
Armenia 0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
–9·57
(–10·69 to 
–8·41)
–15·72
(–16·70 to 
–14·75)
0·00
(0·00 to 
0·00)
0·00
(0·00 to 
0·00)
Azerbaijan 69
(59 to 78)
0
(0 to 0)
68
(58 to 78)
0
(0 to 0)
137
(117 to 156)
0
(0 to 0)
–10·20
(–11·30 to 
–9·07)
–15·90
(–16·85 to 
–15·01)
–3·97
(–4·94 to 
–3·13)
–16·58
(–17·75 to 
–15·39)
Georgia 0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
–9·75
(–10·91 to 
–8·56)
–16·20
(–17·20 to 
–15·16)
0·00
(0·00 to 
0·00)
0·00
(0·00 to 
0·00)
Kyrgyzstan 0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
–41·62
(–42·09 to 
–41·15)
–14·46
(–15·47 to 
–13·49)
0·00
(0·00 to 
0·00)
0·00
(0·00 to 
0·00)
Tajikistan 9
(9 to 9)
8
(4 to 16)
9
(9 to 9)
9
(5 to 15)
18
(18 to 18)
17
(12 to 28)
35·20
(34·62 to 
35·73)
–3·24
(–6·10 to 
–0·23)
–55·80
(–56·25 to 
–55·19)
–7·05
(–9·62 to 
–3·93)
Turkmenistan 0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
–10·02
(–10·94 to 
–9·05)
–14·45
(–15·79 to 
–13·17)
0·00
(0·00 to 
0·00)
0·00
(0·00 to 
0·00)
Uzbekistan 0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
–9·49
(–10·49 to 
–8·45)
–14·63
(–15·54 to 
–13·68)
0·00
(0·00 to 
0·00)
0·00
(0·00 to 
0·00)
East Asia 1215
(1110 to 1313)
88
(73 to 108)
1283
(1178 to 1379)
56
(45 to 73)
2498
(2299 to 2666)
144
(124 to 168)
–0·60
(–1·44 to 
0·36)
–7·67
(–9·34 to 
–6·02)
–19·91
(–20·96 to 
–18·98)
–10·95
(–13·09 to 
–8·36)
China 1029
(928 to 1124)
88
(73 to 108)
1091
(987 to 1187)
56
(45 to 72)
2121
(1925 to 2281)
144
(123 to 168)
–0·04
(–0·98 to 
1·06)
–7·61
(–9·30 to 
–5·96)
–21·42
(–22·66 to 
–20·35)
–10·94
(–13·10 to 
–8·27)
North Korea 185
(161 to 209)
0
(0 to 1)
192
(167 to 217)
0
(0 to 1)
377
(328 to 425)
0
(0 to 1)
–10·69
(–11·70 to 
–9·61)
–15·7
(–17·42 to 
–13·95)
–4·45
(–5·46 to 
–3·55)
–15·81
(–17·48 to 
–13·96)
South Asia 28 475 300
(10 587 800 to 
67 635 616)
56 349
(37 151 to 
77 226)
33 373 982
(13 386 620 to 
76 448 012)
65 428
(48 800 to 
88 397)
61 849 284
(24 099 755 to 
145 007 704)
121 777
(95 871 to 
155 492)
–2·00
(–3·78 to 
–0·81)
–2·65
(–4·27 to 
–0·91)
–3·33
(–4·67 to 
–1·81)
–3·39
(–5·45 to 
–1·31)
Afghanistan 61 979
(52 009 to 
72 293)
490
(191 to 1019)
156 053
(129 086 to 
184 258)
1292
(436 to 
3052)
218 032
(181 117 to 
256 551)
1783
(821 to 
3659)
0·03
(0·03 to 
0·04)
0·09
(–3·60 to 
3·74)
–2·00
(–2·01 to 
–1·97)
–1·99
(–5·69 to 
1·90)
Bangladesh 98 380
(82 421 to 
113 840)
19
(10 to 29)
95 500
(79 870 to 
110 636)
13
(9 to 19)
193 880
(162 292 to 
224 476)
32
(23 to 43)
–0·24
(–0·39 to 
–0·12)
–4·19
(–7·61 to 
–0·47)
–0·30
(–0·47 to 
–0·17)
–11·10
(–14·43 to 
–8·04)
Bhutan 2330
(2095 to 2541)
5
(2 to 12)
1901
(1693 to 2091)
4
(2 to 9)
4231
(3783 to 4628)
9
(4 to 18)
–3·19
(–3·50 to 
–2·86)
–4·68
(–8·00 to 
–1·25)
–5·35
(–6·25 to 
–4·49)
–12·08
(–16·81 to 
–6·86)
(Table 7 continues on next page)
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All ages incidence and deaths (2013) Annualised rate of change (%)
Male population Female population Total 1990–2000 2000–13
Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths
(Continued from previous page)
India 27 961 284
(10 074 561 to 
67 098 740)
54 179
(35 494 to 
74 975)
32 739 706
(12 716 841 to 
75 811 540)
62 143
(45 048 to 
85 171)
60 700 992
(22 931 083 to 
143 871 240)
116 322
(90 658 to 
149 612)
–1·89
(–3·64 to 
–0·62)
–2·53
(–4·23 to 
–0·79)
–3·39
(–4·78 to 
–1·81)
–3·42
(–5·51 to 
–1·29)
Nepal 29 278
(24 657 to 
34 027)
228
(47 to 605)
31 161
(26 244 to 
36 214)
243
(48 to 725)
60 439
(50 901 to 
70 240)
471
(207 to 983)
–4·76
(–4·79 to 
–4·71)
–4·98
(–8·32 to 
–1·48)
–6·10
(–6·19 to 
–5·99)
–6·70
(–9·86 to 
–3·30)
Pakistan 322 049
(296 287 to 
347 753)
1427
(668 to 3316)
349 662
(319 168 to 
380 514)
1733
(1023 to 
2640)
671 710
(615 243 to 
727 902)
3159
(2008 to 
5012)
–2·78
(–3·00 to 
–2·54)
–3·39
(–10·99 to 
1·24)
-2·88
(-3·20 to 
-2·54)
-4·57
(-7·27 to 
-1·89)
Southeast Asia 4 132 009
(1 852 612 to 
8 988 789)
7763
(5510 to 
10 731)
3 646 243
(1 692 229 to 
7 606 561)
6454
(4571 to 
9267)
7 778 252
(3 535 079 to 
16 619 553)
14 217
(10 315 to 
19 781)
–3·89
(–5·56 to 
–2·16)
–4·54
(–6·53 to 
–2·65)
–5·88
(–8·59 to 
–3·01)
–6·89
(–9·01 to 
–4·25)
Cambodia 81 263
(68 959 to 
93 966)
616
(320 to 1034)
59 358
(50 948 to 
67 993)
426
(232 to 731)
140 621
(119 933 to 
161 846)
1043
(644 to 
1568)
–1·39
(–1·41 to 
–1·37)
–1·44
(–4·84 to 
1·64)
–7·65
(–7·83 to 
–7·42)
–8·39
(–10·95 to 
–5·47)
Indonesia 1 076 361
(191 105 to 
3 596 748)
1802
(1320 to 
2434)
927 470
(158 478 to 
3 289 462)
1341
(1002 to 
1749)
2 003 831
(354 339 to 
6 883 029)
3143
(2418 to 
4019)
–3·60
(–5·19 to 
–1·74)
–3·37
(–5·99 to 
–0·89)
–5·34
(–7·67 to 
–2·76)
–5·19
(–7·51 to 
–2·46)
Laos 19 132
(17 423 to 
20 734)
50
(16 to 104)
19 817
(18 099 to 
21 419)
55
(17 to 148)
38 949
(35 519 to 
42 170)
105
(47 to 227)
–3·07
(–3·54 to 
–2·62)
–5·53
(–10·64 to 
–1·69)
–1·71
(–1·99 to 
–1·45)
–3·57
(–8·86 to 
0·19)
Malaysia 63 361
(53 065 to 
73 334)
11
(8 to 19)
65 962
(55 033 to 
76 567)
3
(3 to 5)
129 323
(108 082 to 
149 901)
15
(10 to 23)
–0·16
(–0·36 to 
–0·01)
–7·42
(–10·01 to 
–4·96)
–0·01
(–0·11 to 
0·07)
–9·15
(–12·65 to 
–4·74)
Myanmar 2 459 973
(906 379 to 
5 902 743)
4834
(2817 to 
7915)
2 156 398
(835 746 to 
4 950 837)
4322
(2610 to 
7099)
4 616 371
(1 764 904 to 
10 796 693)
9155
(5590 to 
14 544)
–3·55
(–5·33 to 
–1·76)
–3·76
(–6·69 to 
–0·96)
–6·36
(–9·39 to 
–3·22)
–6·61
(–9·46 to 
–3·31)
Philippines 283 519
(241 103 to 
323 938)
155
(105 to 233)
273 023
(229 455 to 
315 173)
75
(50 to 105)
556 542
(470 324 to 
639 165)
230
(166 to 326)
–2·47
(–3·22 to 
–1·83)
–12·12
(–13·41 to 
–10·84)
–0·29
(–0·49 to 
–0·12)
–6·69
(–9·40 to 
–3·80)
Sri Lanka 1475
(1246 to 1710)
11
(7 to 21)
1259
(1070 to 1453)
9
(6 to 16)
2734
(2316 to 3165)
21
(14 to 34)
–10·46
(–10·49 to 
–10·42)
–10·62
(–14·16 to 
–7·17)
–14·14
(–14·34 to 
–13·90)
–14·99
(–18·77 to 
–10·59)
Thailand 83 572
(72 401 to 
94 358)
78
(45 to 136)
82 312
(69 822 to 
94 242)
41
(29 to 58)
165 884
(142 197 to 
188 453)
118
(78 to 184)
–8·27
(–9·64 to 
–6·94)
–17·72
(–19·18 to 
–16·20)
–1·64
(–2·15 to 
–1·21)
–11·32
(–14·38 to 
–7·50)
Timor-Leste 9968
(8560 to 11 314)
7
(0 to 70)
10 356
(9075 to 
11 576)
13
(0 to 69)
20 324
(17 664 to 
22 892)
21
(3 to 108)
–4·39
(–5·00 to 
–3·78)
–7·90
(–13·71 to 
–2·64)
–4·15
(–5·12 to 
–3·30)
–15·40
(–32·58 to 
–3·97)
Vietnam 47 663
(44 070 to 
51 177)
187
(119 to 275)
45 016
(41 641 to 
48 218)
159
(106 to 237)
92 679
(85 719 to 
99 315)
345
(248 to 460)
–4·58
(–4·87 to 
–4·25)
–5·75
(–8·86 to 
–2·80)
–5·99
(–6·74 to 
–5·23)
–10·07
(–12·95 to 
–6·79)
Caribbean 50 098
(46 165 to 
53 745)
165
(18 to 371)
59 643
(55 171 to 
64 155)
239
(67 to 548)
109 741
(101 549 to 
117 526)
404
(227 to 643)
–3·35
(–3·63 to 
–3·05)
–4·52
(–6·90 to 
–1·78)
–4·08
(–4·64 to 
–3·53)
–7·48
(–11·51 to 
–3·38)
Belize 18
(18 to 19)
1
(1 to 2)
19
(18 to 19)
0
(0 to 1)
37
(37 to 37)
1
(1 to 2)
–9·26
(–9·66 to 
–8·83)
3·53
(0·26 to 
6·57)
–30·58
(–31·09 to 
–30·08)
–9·26
(–13·68 to 
–4·65)
Dominican Republic 5029
(4326 to 5699)
4
(2 to 7)
5075
(4382 to 5736)
4
(3 to 8)
10 104
(8707 to 
11 435)
8
(5 to 13)
–1·48
(–1·64 to 
–1·35)
–4·33
(–7·40 to 
–1·63)
–1·01
(–1·10 to 
–0·93)
–3·42
(–7·70 to 
0·73)
Guyana 2825
(2453 to 3184)
3
(1 to 5)
2559
(2166 to 
2934)
1
(1 to 2)
5383
(4619 to 6113)
4
(2 to 7)
–0·09
(–0·11 to 
–0·07)
–0·28
(–3·14 to 
2·67)
–2·56
(–3·25 to 
–1·98)
–13·19
(–18·97 to 
–8·69)
Haiti 36 035
(33 327 to 
38 617)
135
(6 to 317)
44 517
(40 927 to 
48 139)
203
(52 to 480)
80 552
(74 426 to 
86 878)
338
(183 to 551)
–3·92
(–4·15 to 
–3·66)
–4·91
(–7·20 to 
–2·41)
–4·78
(–5·24 to 
–4·30)
–7·39
(–11·97 to 
–3·59)
(Table 7 continues on next page)
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All ages incidence and deaths (2013) Annualised rate of change (%)
Male population Female population Total 1990–2000 2000–13
Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths
(Continued from previous page)
Suriname 348
(312 to 383)
2
(1 to 3)
183
(168 to 197)
1
(0 to 1)
530
(486 to 575)
2
(2 to 4)
–0·78
(–0·92 to 
–0·66)
–0·24
(–2·89 to 
2·65)
–7·55
(–8·08 to 
–7·00)
–10·29
(–13·99 to 
–5·90)
Western Europe 0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
3
(3 to 3)
0
(0 to 0)
0·00
(0·00 to 
0·00)
0·00
(0·00 to 
0·00)
0·00
(0·00 to 
0·00)
0·00
(0·00 to 
0·00)
Greece 0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
3
(3 to 3)
0
(0 to 0)
0·00
(0·00 to 
0·00)
0·00
(0·00 to 
0·00)
0·00
(0·00 to 
0·00)
0·00
(0·00 to 
0·00)
Andean Latin America 14 203
(12 281 to 
16 046)
13
(10 to 16)
13 873
(11 903 to 
15 753)
10
(8 to 14)
28 075
(24 173 to 
31 791)
23
(18 to 29)
–2·53
(–3·04 to 
–2·04)
–5·70
(–7·28 to 
–4·09)
–2·79
(–3·64 to 
–2·05)
–13·80
(–15·92 to 
–11·45)
Bolivia 756
(665 to 841)
1
(1 to 2)
749
(657 to 835)
1
(1 to 2)
1505
(1323 to 1676)
2
(2 to 3)
–3·23
(–3·91 to 
–2·58)
–7·80
(–11·61 to 
–4·50)
–1·48
(–1·97 to 
–1·06)
–7·30
(–9·75 to 
–4·81)
Ecuador 7617
(6556 to 8628)
6
(4 to 9)
7625
(6565 to 
8633)
6
(4 to 10)
15 242
(13 121 to 
17 261)
12
(9 to 17)
–2·97
(–3·42 to 
–2·52)
–5·63
(–7·68 to 
–3·48)
–3·94
(–4·91 to 
–3·10)
–16·00
(–18·85 to 
–13·03)
Peru 5829
(5052 to 6580)
5
(4 to 8)
5499
(4672 to 
6288)
3
(2 to 4)
11 328
(9724 to 
12 860)
8
(6 to 12)
–1·90
(–2·47 to 
–1·35)
–5·98
(–8·41 to 
–3·66)
–1·35
(–2·03 to 
–0·77)
–11·42
(–14·39 to 
–8·24)
Central Latin America 56 110
(49 168 to 
62 758)
69
(50 to 98)
55 170
(47 750 to 
62 283)
49
(38 to 68)
111 280
(96 932 to 
125 061)
118
(93 to 160)
–2·29
(–2·75 to 
–1·85)
–5·58
(–7·13 to 
–4·18)
–2·10
(–2·76 to 
–1·51)
–10·06
(–12·13 to 
–7·34)
Colombia 32 242
(28 091 to 
36 221)
35
(21 to 60)
31 681
(27 161 to 
35 989)
23
(14 to 37)
63 924
(55 318 to 
72 202)
58
(38 to 91)
2·72
(2·19 to 
3·33)
10·32
(8·38 to 
12·23)
–1·85
(–2·44 to 
–1·34)
–10·46
(–14·05 to 
–6·31)
Costa Rica 5
(4 to 5)
0
(0 to 0)
4
(4 to 4)
0
(0 to 0)
9
(8 to 9)
0
(0 to 0)
–14·75
(–15·01 to 
–14·44)
–15·71
(–16·55 to 
–14·88)
–10·54
(–11·69 to 
–9·35)
–16·41
(–17·25 to 
–15·51)
El Salvador 45
(39 to 51)
0
(0 to 0)
48
(41 to 55)
0
(0 to 0)
92
(79 to 105)
0
(0 to 0)
–10·30
(–11·52 to 
–9·06)
–17·04
(–17·93 to 
–16·11)
–3·27
(–4·11 to 
–2·55)
–15·13
(–16·27 to 
–13·97)
Guatemala 9936
(8732 to 11 057)
14
(10 to 21)
10 220
(8956 to 
11 422)
13
(9 to 19)
20 156
(17 688 to 
22 495)
27
(20 to 37)
–9·66
(–10·61 to 
–8·66)
–14·29
(–16·36 to 
–12·07)
–3·62
(–4·43 to 
–2·88)
–10·87
(–13·59 to 
–7·87)
Honduras 2998
(2669 to 3298)
6
(3 to 11)
3135
(2813 to 3423)
7
(4 to 12)
6133
(5476 to 6718)
12
(7 to 20)
–1·96
(–2·26 to 
–1·64)
–3·63
(–7·31 to 
–0·43)
–3·19
(–3·86 to 
–2·55)
–8·14
(–12·04 to 
–3·03)
Mexico 82
(71 to 94)
1
(0 to 2)
65
(57 to 74)
0
(0 to 2)
148
(128 to 167)
1
(0 to 4)
–16·51
(–16·58 to 
–16·43)
–16·86
(–17·61 to 
–16·06)
–13·47
(–13·84 to 
–13·04)
–15·00
(–15·78 to 
–14·18)
Nicaragua 2410
(2032 to 2776)
1
(1 to 1)
2463
(2076 to 
2836)
1
(1 to 1)
4873
(4108 to 5612)
2
(1 to 2)
–6·78
(–7·71 to 
–5·87)
–12·23
(–15·27 to 
–9·58)
–3·91
(–4·87 to 
–3·10)
–21·04
(–24·04 to 
–17·96)
Panama 409
(396 to 421)
0
(0 to 1)
427
(415 to 440)
0
(0 to 0)
836
(836 to 836)
1
(0 to 1)
7·72
(7·08 to 
8·30)
–6·42
(–9·63 to 
–3·40)
–3·16
(–3·90 to 
–2·59)
–5·84
(–9·33 to 
–1·91)
Venezuela 7983
(7025 to 8864)
12
(7 to 17)
7127
(6100 to 8102)
5
(3 to 7)
15 109
(13 168 to 
16 970)
17
(12 to 23)
–0·99
(–1·32 to 
–0·69)
–3·84
(–6·20 to 
–1·59)
–1·12
(–1·56 to 
–0·75)
–7·30
(–10·34 to 
–4·47)
Southern Latin America 301
(260 to 341)
0
(0 to 1)
308
(264 to 350)
0
(0 to 1)
609
(524 to 691)
0
(0 to 2)
–9·52
(–10·71 to 
–8·32)
–16·26
(–17·13 to 
–15·40)
–3·21
(–4·06 to 
–2·48)
–16·29
(–17·17 to 
–15·43)
Argentina 301
(260 to 341)
0
(0 to 1)
308
(264 to 350)
0
(0 to 1)
609
(524 to 691)
0
(0 to 2)
–9·26
(–10·45 to 
–8·06)
–16·11
(–16·96 to 
–15·24)
–3·14
(–3·97 to 
–2·43)
–16·03
(–16·90 to 
–15·16)
(Table 7 continues on next page)
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All ages incidence and deaths (2013) Annualised rate of change (%)
Male population Female population Total 1990–2000 2000–13
Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths
(Continued from previous page)
Tropical Latin America 66 015
(56 554 to 
75 020)
46
(30 to 68)
65 424
(55 196 to 
75 263)
24
(17 to 35)
131 439
(111 720 to 
150 238)
71
(50 to 99)
–6·49
(–7·87 to 
–5·20)
–17·58
(–19·80 to 
–15·41)
–0·11
(–0·50 to 
0·21)
–9·20
(–12·22 to 
–5·86)
Brazil 65 965
(56 511 to 
74 963)
46
(30 to 68)
65 376
(55 156 to 
75 209)
24
(17 to 35)
131 341
(111 637 to 
150 126)
71
(50 to 99)
–6·47
(–7·85 to 
–5·18)
–17·56
(–19·78 to 
–15·39)
–0·08
(–0·47 to 
0·24)
–9·17
(–12·18 to 
–5·80)
Paraguay 50
(43 to 57)
0
(0 to 0)
48
(41 to 55)
0
(0 to 0)
98
(83 to 112)
0
(0 to 0)
–8·20
(–9·31 to 
–7·08)
–14·75
(–15·77 to 
–13·77)
–2·98
(–3·76 to 
–2·31)
–14·55
(–15·76 to 
–13·32)
North Africa and 
Middle East
1 257 700
(382 396 to 
3 243 600)
5900
(2915 to 
11 443)
857 057
(252 567 to 
2 356 446)
4703
(2009 to 
9594)
2 114 756
(638 796 to 
5 569 750)
10 604
(5415 to 
19 759)
2·14
(1·31 to 
3·18)
3·88
(0·73 to 
7·01)
–5·74
(–9·08 to 
–2·40)
–7·07
(–10·62 to 
–3·04)
Algeria 0
(0 to 0)
6
(3 to 9)
0
(0 to 0)
4
(3 to 7)
0
(0 to 0)
10
(7 to 14)
0·00
(0·00 to 
0·00)
–2·69
(–5·57 to 
0·50)
0·00
(0·00 to 
0·00)
–7·46
(–11·11 to 
–3·07)
Iran 385
(372 to 396)
5
(3 to 7)
402
(391 to 415)
6
(3 to 9)
787
(787 to 787)
10
(8 to 14)
–18·17
(–19·47 to 
–16·77)
0·52
(–2·67 to 
3·62)
–22·32
(–23·57 to 
–21·08)
–7·92
(–10·80 to 
–4·64)
Iraq 0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
–9·60
(–10·60 to 
–8·55)
–14·67
(–16·70 to 
–12·66)
0·00
(0·00 to 
0·00)
0·00
(0·00 to 
0·00)
Morocco 0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
–0·27
(–0·29 to 
–0·25)
–0·33
(–2·73 to 
2·08)
0·00
(0·00 to 
0·00)
0·00
(0·00 to 
0·00)
Oman 0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
–2·61
(–2·83 to 
–2·38)
–3·48
(–7·28 to 
0·13)
0·00
(0·00 to 
0·00)
0·00
(0·00 to 
0·00)
Saudi Arabia 40
(39 to 41)
11
(7 to 15)
42
(41 to 43)
2
(1 to 3)
82
(82 to 82)
13
(9 to 18)
–13·85
(–14·36 to 
–13·25)
–3·99
(–9·06 to 
1·16)
–33·50
(–34·40 to 
–32·55)
–9·01
(–12·48 to 
–5·52)
Sudan 689 118
(190 185 to 
1 833 451)
3160
(1326 to 
6839)
366 931
(78 799 to 
1 177 901)
2203
(605 to 
5384)
1 056 050
(275 911 to 
2 940 472)
5363
(2274 to 
11 118)
0·34
(–0·31 to 
1·15)
1·19
(–2·43 to 
4·91)
–7·83
(–11·74 to 
–3·79)
–8·71
(–12·78 to 
–4·35)
Syria 0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
0
(0 to 0)
–6·57
(–6·65 to 
–6·48)
–6·84
(–11·33 to 
–2·88)
0·00
(0·00 to 
0·00)
0·00
(0·00 to 
0·00)
Turkey 534
(456 to 607)
0
(0 to 1)
540
(457 to 618)
0
(0 to 1)
1073
(913 to 1225)
1
(0 to 2)
–10·63
(–11·84 to 
–9·40)
–17·20
(–18·35 to 
–16·09)
–3·59
(–4·51 to 
–2·80)
–17·30
(–18·54 to 
–16·04)
Yemen 566 320
(192 251 to 
1 374 706)
2713
(1242 to 
5640)
488 281
(161 967 to 
1 225 111)
2483
(941 to 
5133)
1 054 601
(355 535 to 
2 646 959)
5196
(2471 to 
10 098)
0·14
(–0·78 to 
1·12)
1·55
(–2·57 to 
5·80)
–3·51
(–5·44 to 
–1·70)
–4·11
(–7·91 to 
–0·48)
Oceania 593 916
(232 012 to 
1 391 577)
1104
(485 to
1910)
492 920
(207 650 to 
1 088 266)
915
(493 to 
1565)
1 086 836
(441 330 to 
2 484 740)
2019
(1221 to 
3218)
–0·02
(–0·25 to 
0·19)
–0·30
(–3·70 to 
2·75)
–2·14
(–3·14 to 
–1·05)
–2·61
(–5·49 to 
0·65)
Papua New Guinea 523 910
(197 634 to 
1 243 454)
964
(419 to
1682)
434 724
(177 464 to 
965 172)
804
(432 to 
1383)
958 634
(376 486 to 
2 206 672)
1768
(1075 to 
2810)
–0·25
(–0·48 to 
–0·04)
–0·50
(–3·96 to 
2·65)
–2·14
(–3·44 to 
–1·31)
–2·72
(–5·65 to 
0·47)
Solomon Islands 9577
(8537 to 10 514)
19
(4 to 42)
8847
(7818 to 9787)
14
(5 to 33)
18 424
(16 358 to 
20 296)
33
(11 to 66)
–1·17
(–1·39 to 
–0·96)
–2·90
(–6·90 to 
0·69)
–1·83
(–2·26 to 
–1·45)
–6·15
(–9·61 to 
–1·88)
Vanuatu 3289
(2994 to 3565)
9
(2 to 21)
2990
(2687 to 3262)
7
(2 to 19)
6279
(5684 to 6820)
15
(5 to 33)
–0·73
(–0·86 to 
–0·61)
–1·70
(–5·70 to 
2·06)
–2·20
(–2·67 to 
–1·78)
–6·06
(–10·15 to 
–1·72)
Central sub-Saharan Africa 3 940 130
(1 939 904 to 
7 688 653)
28 851
(16 111 to 
49 729)
4 301 690
(2 303 019 to 
7 982 794)
31 817
(15 802 to 
64 045)
8 241 820
(4 297 149 to 
15 640 374)
60 667
(35 115 to 
99 000)
–2·74
(–4·45 to 
–1·39)
–1·59
(–4·08 to 
1·08)
–5·13
(–7·81 to 
–2·43)
–5·73
(–9·03 to 
–2·28)
(Table 7 continues on next page)
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Male population Female population Total 1990–2000 2000–13
Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths
(Continued from previous page)
Angola 778 653
(352 510 to 
1 612 440)
5421
(2082 to 
12 081)
638 443
(292 224 to 
1 338 115)
5240
(1083 to 
12 889)
1 417 096
(646 248 to 
2 901 702)
10 661
(4178 to 
21 870)
–0·62
(–2·10 to 
0·86)
1·22
(–3·40 to 
5·85)
–5·02
(–7·47 to 
–2·37)
–5·31
(–9·46 to 
–0·84)
Central African Republic 240 694
(129 143 to 
433 562)
1611
(876 to
2611)
297 972
(167 115 to 
517 369)
1964
(919 to 
3569)
538 666
(298 738 to 
947 709)
3575
(2032 to 
5659)
–1·49
(–2·76 to 
–0·56)
–0·24
(–4·56 to 
3·72)
–2·80
(–4·33 to 
–1·36)
–3·33
(–7·33 to 
0·58)
Congo 167 366
(72 013 to 
344 886)
977
(550 to
1804)
159 795
(72 976 to 
323 383)
991
(298 to 
2116)
327 162
(147 092 to 
665 882)
1968
(1004 to 
3472)
–0·01
(–0·62 to 
0·96)
0·73
(–2·21 to 
3·90)
–4·81
(–7·57 to 
–2·47)
–5·96
(–10·89 to 
–2·09)
DR Congo 2 641 315
(1 317 961 to 
5 137 603)
20 087
(9338 to 
38 586)
3 087 537
(1 663 453 to 
5 670 932)
22 827
(9178 to 
50 451)
5 728 853
(3 000 717 to 
10 790 512)
42 914
(21 336 to 
79 936)
–3·50
(–5·45 to 
–1·84)
–2·41
(–5·40 to 
0·76)
–5·42
(–8·43 to 
–2·51)
–6·12
(–10·11 to 
–1·77)
Equatorial Guinea 37 847
(22 135 to 
65 711)
298
(75 to
572)
45 073
(26 889 to 
76 106)
333
(106 to
625)
82 920
(49 005 to 
142 294)
631
(252 to 
1064)
0·51
(–0·35 to 
2·06)
1·47
(–2·65 to 
5·61)
–3·66
(–5·51 to 
–1·71)
–3·98
(–7·08 to 
–0·92)
Gabon 74 255
(35 105 to 
144 155)
457
(225 to
817)
72 869
(35 969 to 
139 716)
462
(200 to
864)
147 125
(71 124 to 
281 843)
919
(531 to 
1515)
–1·67
(–2·75 to 
–0·76)
–1·65
(–4·39 to 
1·27)
–5·94
(–8·51 to 
–2·95)
–6·00
(–9·47 to 
–2·26)
Eastern sub–Saharan Africa 12 520 054
(6 544 247 to 
24 090 664)
85 566
(65 168 to 
109 586)
13 377 215
(7 291 825 to 
24 578 200)
89 820
(66 224 to 
130 417)
25 897 270
(13 782 158 to 
48 529 276)
175 387
(140 361 to 
221 113)
0·41
(–0·29 to 
1·52)
0·77
(–0·82 to 
2·33)
–6·68
(–8·94 to 
–3·58)
–6·76
(–8·47 to 
–4·40)
Burundi 603 449
(369 625 to 
975 531)
5362
(2862 to 
8974)
710 930
(446 217 to 
1 124 371)
5920
(3022 to 
9518)
1 314 379
(807 412 to 
2 096 773)
11 282
(6353 to 
17 300)
0·99
(–0·10 to 
2·83)
1·93
(–1·04 to 
4·83)
–7·95
(–11·90 to 
–3·84)
–8·05
(–11·72 to 
–4·60)
Comoros 28 650
(26 480 to 
30 862)
117
(56 to
222)
26 067
(24 109 to 
27 935)
97
(16 to
246)
54 718
(50 588 to 
58 781)
215
(98 to
414)
0·05
(0·04 to 
0·05)
0·26
(–4·13 to 
4·99)
–2·90
(–3·27 to 
–2·52)
–5·16
(–10·58 to 
–1·32)
Djibouti 21 649
(17 792 to 
25 716)
184
(68 to
369)
19 021
(15 634 to 
22 592)
161
(49 to
297)
40 671
(33 427 to 
48 308)
345
(147 to
599)
2·61
(2·61 to 
2·61)
2·82
(–1·60 to 
7·69)
–4·90
(–4·91 to 
–4·90)
–4·96
(–9·86 to 
–0·39)
Eritrea 106 098
(89 697 to 
122 962)
815
(252 to
1836)
106 810
(90 294 to 
123 790)
821
(264 to 
1770)
212 908
(179 991 to 
246 752)
1636
(615 to 
3199)
1·01
(0·99 to 
1·03)
1·29
(–5·39 to 
7·27)
–5·79
(–5·95 to 
–5·59)
–6·71
(–12·59 to 
–1·24)
Ethiopia 1 638 589
(498 186 to 
4 270 533)
9877
(5029 to 
17 293)
1 182 333
(373 552 to 
3 267 067)
8510
(3506 to 
16 787)
2 820 922
(876 846 to 
7 716 426)
18 387
(9037 to 
32 209)
–2·03
(–2·86 to 
–1·05)
–1·98
(–9·18 to 
5·43)
–9·03
(–13·49 to 
–4·40)
–8·99
(–14·92 to 
–2·87)
Kenya 782 119
(236 917 to 
2 033 030)
4464
(2618 to 
7478)
627 587
(175 809 to 
1 772 853)
3896
(1826 to 
8102)
1 409 706
(412 893 to 
3 805 649)
8360
(4891 to 
14 436)
0·11
(–0·62 to 
0·92)
1·07
(–2·51 to 
4·74)
–10·47
(–15·44 to 
–5·08)
–10·98
(–15·32 to 
–6·72)
Madagascar 459 299
(131 674 to 
1 198 750)
2123
(986 to
4137)
612 453
(212 737 to 
1 430 807)
2783
(1420 to 
4868)
1 071 751
(352 252 to 
2 626 270)
4906
(2985 to 
7867)
–2·01
(–3·47 to 
–0·96)
–1·42
(–4·41 to 
1·43)
–5·02
(–7·63 to 
–2·26)
–4·54
(–8·19 to 
–0·46)
Malawi 347 806
(116 374 to 
858 925)
2147
(1094 to 
3889)
402 696
(148 948 to 
930 569)
2456
(1061 to 
4910)
750 502
(268 060 to 
1 769 176)
4603
(2546 to 
8195)
–5·03
(–9·46 to 
–1·71)
–6·52
(–10·60 to 
–2·72)
–6·86
(–10·48 to 
–3·26)
–7·02
(–11·10 to 
–2·31)
Mozambique 2 773 504
(1 582 152 to 
4 911 657)
19 196
(13 650 to 
25 948)
3 244 189
(1 684 669 to 
6 325 806)
20 473
(14 753 to 
26 654)
6 017 693
(3 266 015 to 
11 078 884)
39 669
(31 008 to 
49 712)
1·81
(0·66 to 
3·21)
2·46
(–0·06 to 
5·23)
–4·51
(–6·24 to 
–2·39)
–4·21
(–6·46 to 
–1·59)
Rwanda 237 157
(89 675 to 
564 253)
1806
(811 to
3293)
232 335
(89 900 to 
553 411)
1764
(700 to 
3613)
469 491
(179 942 to 
1 118 489)
3569
(1754 to 
6572)
1·80
(0·38 to 
4·16)
3·12
(–0·56 to 
6·87)
–13·32
(–19·57 to 
–6·60)
–13·13
(–18·69 to 
–7·48)
Somalia 474 870
(233 983 to 
899 300)
3314
(1561 to 
6276)
356 615
(172 956 to 
709 509)
2806
(1284 to 
5202)
831 485
(409 498 to 
1 610 977)
6120
(3066 to 
10 592)
1·08
(0·14 to 
2·50)
2·13
(–2·36 to 
6·49)
–3·90
(–6·14 to 
–1·78)
–4·22
(–8·54 to 
0·35)
South Sudan 301 308
(112 436 to 
702 216)
1703
(841 to
3414)
201 184
(72 449 to 
507 884)
1399
(430 to 
3252)
502 492
(186 803 to 
1 157 572)
3102
(1547 to 
5794)
0·48
(–0·36 to 
1·49)
1·58
(–2·83 to 
6·29)
–8·28
(–12·73 to 
–3·81)
–8·89
(–13·00 to 
–3·96)
(Table 7 continues on next page)
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All ages incidence and deaths (2013) Annualised rate of change (%)
Male population Female population Total 1990–2000 2000–13
Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths
(Continued from previous page)
Tanzania 1 873 958
(934 095 to 
3 672 184)
13 495
(7362 to 
22 215)
2 307 766
(1 239 301 to 
4 260 696)
16 242
(7989 to 
32 819)
4 181 724
(2 178 550 to 
7 920 536)
29 737
(17 572 to 
48 950)
0·43
(–0·49 to 
1·73)
0·35
(–2·63 to 
3·47)
–7·77
(–11·64 to 
–3·71)
–7·90
(–11·48 to 
–3·73)
Uganda 1 918 386
(1 036 770 to 
3 491 911)
14 247
(7967 to 
22 532)
2 262 354
(1 245 502 to 
4 007 412)
15 298
(8111 to 
25 181)
4 180 741
(2 285 851 to 
7 474 431)
29 545
(18 946 to 
45 298)
1·18
(0·28 to 
2·49)
2·41
(–0·76 to 
5·53)
–5·93
(–8·61 to 
–2·92)
–6·12
(–9·34 to 
–2·49)
Zambia 945 622
(525 219 to 
1 635 147)
6667
(4445 to 
9435)
1 077 049
(585 683 to 
1 925 781)
7145
(4894 to 
10 132)
2 022 671
(1 112 338 to 
3 551 130)
13 812
(10 076 to 
18 903)
1·58
(0·47 to 
2·82)
2·33
(–1·34 to 
5·52)
–7·24
(–10·69 to 
–3·45)
–7·00
(–9·68 to 
–3·94)
Southern sub-Saharan 
Africa
344 868
(147 187 to 
780 285)
1896
(1376 to 
2580)
275 985
(104 772 to 
678 471)
1374
(907 to 
2251)
620 853
(252 060 to 
1 471 492)
3270
(2462 to 
4543)
2·84
(1·28 to 
4·19)
2·85
(–0·40 to 
5·45)
–5·63
(–8·37 to 
–2·64)
–7·30
(–9·74 to 
–4·10)
Botswana 18 238
(16 153 to 
20 347)
112
(53 to 223)
9133
(8445 to 
9797)
35
(10 to 91)
27 371
(24 696 to 
30 025)
147
(79 to 264)
2·81
(2·54 to 
3·04)
3·53
(–3·49 to 
9·77)
–5·03
(–5·44 to 
–4·60)
–6·75
(–12·19 to 
0·12)
Namibia 33 857
(31 052 to 
36 663)
158
(97 to 267)
25 990
(23 915 to 
27 914)
83
(24 to 211)
59 847
(55 363 to 
64 383)
241
(142 to 420)
1·76
(1·54 to 
1·97)
2·62
(–1·56 to 
6·85)
–3·86
(–4·31 to 
–3·41)
–6·36
(–9·85 to 
–2·46)
South Africa 2755
(2663 to 2834)
245
(105 to 537)
2874
(2795 to 2966)
128
(86 to 249)
5629
(5629 to 5629)
374
(213 to 699)
0·25
(–0·49 to 
1·00)
2·53
(–0·30 to 
5·59)
0·08
(–0·96 to 
0·85)
–13·25
(–17·68 to 
–7·37)
Swaziland 12 878
(10 579 to 
15 305)
110
(29 to 241)
6411
(5268 to 7617)
54
(13 to 127)
19 290
(15 847 to 
22 922)
164
(68 to 335)
3·76
(3·75 to 
3·76)
3·44
(–2·65 to 
8·27)
–6·68
(–6·68 to 
–6·68)
–6·59
(–12·07 to 
–1·34)
Zimbabwe 277 139
(78 586 to 
717 290)
1272
(858 to
1885)
231 578
(60 882 to 
634 297)
1073
(595 to 
1857)
508 717
(140 095 to 
1 364 465)
2345
(1609 to 
3439)
3·02
(1·17 to 
4·87)
2·96
(–1·94 to 
6·75)
–5·96
(–9·71 to 
–2·38)
–3·40
(–9·25 to 
–1·72)
Western sub-Saharan Africa 28 989 748
(18 569 128 to 
44 034 576)
246 973
(179 298 to 
334 725)
27 966 300
(17 623 922 to 
43 268 248)
218 875
(160 016 to 
281 613)
56 956 048
(36 282 648 to 
86 449 152)
465 848
(356 750 to 
590 771)
0·90
(0·26 to 
1·72)
1·45
(–0·24 to 
3·18)
–3·79
(–5·33 to 
–2·00)
–3·40
(–5·15 to 
–1·56)
Benin  496 703
(272 131 to 
893 268)
3604
(1769 to 
6020)
589 179
(338 344 to 
1 013 545)
4085
(2429 to 
5968)
1 085 882
(607 392 to 
1 908 784)
7689
(4649 to 
11 064)
0·70
(–0·14 to 
1·81)
1·40
(–1·86 to 
4·67)
–5·23
(–7·29 to 
–2·73)
–5·17
(–8·32 to 
–1·64)
Burkina Faso 1 772 734
(1 091 493 to 
2 837 545)
12 942
(8142 to 
19 266)
2 068 269
(1 260 720 to 
3 396 651)
14 319
(9910 to 
19 631)
3 841 003
(2 364 116 to 
6 158 591)
27 261
(19 599 to 
36 230)
1·68
(0·72 to 
2·97)
2·68
(0·22 to 
5·22)
–3·54
(–5·11 to 
–1·90)
–3·85
(–6·24 to 
–1·62)
Cameroon 1 141 115
(640 140 to 
2 003 619)
8634
(4332 to 
14 541)
1 528 984
(911 130 to 
2 529 638)
10 703
(6168 to 
17 005)
2 670 100
(1 556 196 to 
4 539 860)
19 336
(11 574 to 
29 258)
2·64
(1·22 to 
4·14)
3·42
(0·19 to 
6·56)
–6·47
(–9·47 to 
–3·19)
–6·40
(–9·50 to 
–2·56)
Cape Verde 38
(32 to 44)
0
(0 to 1)
28
(24 to 32)
0
(0 to 0)
66
(56 to 77)
1
(0 to 1)
–3·60
(–3·62 to 
–3·57)
–3·39
(–8·78 to 
0·84)
–9·01
(–9·15 to 
–8·85)
–9·55
(–13·74 to 
–5·02)
Chad 638 516
(327 314 to 
1 182 104)
4372
(2095 to 
8178)
745 182
(425 863 to 
1 287 409)
5463
(2674 to 
9708)
1 383 698
(754 840 to 
2 472 300)
9835
(5004 to 
16 673)
2·43
(1·10 to
4·1)
3·70
(–0·41 to 
7·68)
–3·75
(–5·46 to 
–1·87)
–3·93
(–7·62 to 
–0·18)
CÔte d’Ivoire 1 116 108
(616 173 to 
1 965 682)
7931
(3796 to 
14 026)
1 270 614
(746 533 to 
2 117 101)
8849
(4705 to 
13 599)
2 386 722
(1 373 505 to 
4 113 535)
16 780
(9577 to 
25 660)
1·71
(0·73 to 
2·79)
2·29
(–0·63 to 
5·30)
–6·23
(–9·23 to 
–3·05)
–6·04
(–9·41 to 
–2·47)
Ghana 1 131 416
(597 366 to 
2 063 095)
7843
(4899 to 
11 682)
1 274 480
(700 996 to 
2 287 354)
8572
(5486 to 
12 246)
2 405 896
(1 293 177 to 
4 322 408)
16 415
(11 390 to 
22 881)
0·84
(0·18 to 
1·91)
1·12
(–1·55 to 
3·85)
–3·36
(–4·97 to 
–1·62)
–3·64
(–6·35 to 
–0·93)
Guinea 850 008
(528 198 to 
1 364 161)
6594
(3882 to 
9881)
1 070 541
(666 679 to 
1 678 739)
8003
(4779 to 
11 599)
1 920 549
(1 202 796 to 
3 033 236)
14 597
(9576 to 
20 495)
1·25
(0·42 to 
2·38)
1·68
(–2·23 to 
5·68)
–4·18
(–6·17 to 
–2·06)
–4·40
(–7·17 to 
–1·23)
Guinea-Bissau 188 651
(118 426 to 
302 109)
1747
(1155 to 
2514)
202 199
(125 656 to 
321 006)
1796
(1158 to 
2502)
390 850
(244 350 to 
622 761)
3543
(2481 to 
4805)
0·68
(0·07 to 
1·55)
1·26
(–1·71 to 
4·49)
–2·73
(–3·94 to 
–1·50)
–2·10
(–4·72 to 
0·53)
(Table 7 continues on next page)
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to multi-drug resistant tuberculosis (MDR-TB). There are 
concerns that even in places with substantial decreases in 
tuberculosis incidence, prevalence, and death such as in 
China, MDR-TB might be a substantial challenge.82,133–136 
Modelling studies have shown that under speciﬁ c 
circumstances MDR-TB could reverse important gains 
made in combatting tuberculosis.82,136,137 Future revisions of 
the burden of disease should examine more carefully the 
evidence on the levels and trends in MDR-TB.
Our results for tuberculosis diﬀ er from WHO estimates 
in some important ways. In general, we estimate higher 
mortality, lower prevalence and incidence, and a smaller 
fraction of tuberculosis related to HIV. Our estimates of 
prevalence are driven by the available prevalence surveys 
and are not back calculated from incidence. Our incidence 
estimates start with case-notiﬁ cations corrected for 
missing age-groups and case types such as smear-negative 
pulmonary or extrapulmonary and expert judgment of the 
case-detection rate. For some countries, with implausibly 
large numbers of smear-negative and extra-pulmonary 
cases notiﬁ ed in individuals younger than 15 years, we 
have excluded these data from the analysis. However, the 
Bayesian meta-regression identiﬁ es a solution for 
incidence that is consistent with prevalence data and 
estimates of cause-speciﬁ c mortality. Because this analysis 
is undertaken using age-speciﬁ c and sex-speciﬁ c rates, it 
also takes into account the changing relations between 
incidence, prevalence, remission, excess mortality, and 
cause-speciﬁ c mortality with age and sex. Because true 
incidence in any country is not known, our estimates as 
well as WHO’s depend on expert judgment on the case-
detection rate. Systematic bias in the estimated case-
detection rate, particularly for earlier time periods, will 
aﬀ ect not only the volume of estimated tuberculosis cases 
but also time trends. India accounts for 27·1% 
(26·3 to 27·9) of global incident cases in 2013; systematic 
errors in the estimated incidence in India in the 1990s 
would have a profound eﬀ ect on global trends. Perhaps 
more importantly, our assessment of global trends for 
death are similar to WHO but diﬀ er for prevalence and 
somewhat for incidence. Because total age-sex-speciﬁ c 
case notiﬁ cations reported to WHO for smear-positive 
pulmonary tuberculosis have continued to increase—by 
1·1 million in 2000, 2·3 million in 2005, and 2·5 million in 
All ages incidence and deaths (2013) Annualised rate of change (%)
Male population Female population Total 1990–2000 2000–13
Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths
(Continued from previous page)
Liberia 215 778
(119 173 to 
385 255)
1467
(765 to
2519)
254 770
(147 560 to 
431 784)
1686
(875 to 
2731)
470 548
(269 710 to 
826 308)
3154
(1799 to 
4992)
1·24
(0·14 to 
2·72)
2·28
(–2·18 to 
6·27)
–4·86
(–7·07 to 
–2·53)
–5·09
(–8·35 to 
–1·67)
Mali 1 812 025
(1 148 899 to 
2 815 056)
16 526
(9857 to 
24 875)
2 412 241
(1 441 912 to 
3 931 845)
19 164
(11 403 to 
27 092)
4 224 267
(2 612 582 to 
6 660 447)
35 690
(23 410 to 
50 450)
1·92
(0·85 to 
3·23)
2·76
(–0·57 to 
6·17)
–2·92
(–4·12 to 
–1·64)
–2·36
(–5·26 to 
0·56)
Mauritania 164 717
(77 085 to 
322 374)
974
(444 to
1838)
105 272
(49 402 to 
215 015)
820
(290 to 
1460)
269 989
(130 899 to 
534 343)
1795
(844 to 
3103)
4·56
(2·16 to 
7·12)
5·77
(1·59 to 
9·62)
–2·34
(–3·70 to 
–1·16)
–2·84
(–5·92 to 
0·18)
Niger 1 348 843
(837 303 to 
2 127 755)
11 564
(4559 to 
20 485)
1 608 928
(1 030 476 to 
2 443 363)
13 869
(6688 to 
21 584)
2 957 771
(1 877 757 to 
4 481 069)
25 433
(13 395 to 
40 453)
1·60
(0·44 to 
3·22)
3·06
(–1·34 to 
7·27)
–3·31
(–4·83 to 
–1·71)
–2·67
(–6·93 to 
1·33)
Nigeria 16 635 774
(10 707 174 to 
25 163 660)
151 794
(95 928 to 
223 806)
13 033 882
(8 224 059 to 
19 909 316)
108 611
(61 160 to 
158 184)
29 669 656
(19 004 200 to 
45 297 792)
260 405
(171 907 to 
361 607)
0·23
(–0·19 to 
0·67)
0·63
(–2·57 to 
3·99)
–2·93
(–4·21 to 
–1·58)
–2·36
(–5·34 to 
0·72)
São Tomé and PrÍncipe 5915
(5258 to 6577)
35
(16 to 65)
6027
(5360 to 6701)
36
(17 to 61)
11 942
(10 619 to 
13 278)
71
(37 to 119)
–0·48
(–0·50 to 
–0·44)
–0·49
(–4·15 to 
2·96)
–3·41
(–3·69 to 
–3·11)
–4·75
(–7·98 to 
–1·83)
Senegal 429 236
(185 098 to 
920 585)
2970
(1400 to 
5280)
500 762
(241 439 to 
992 049)
3600
(1687 to 
5828)
929 998
(430 550 to 
1 917 898)
6570
(3511 to 
10 420)
–0·43
(–1·31 to 
0·31)
0·65
(–1·92 to 
3·11)
–9·11
(–13·59 to 
–4·35)
–9·07
(–13·06 to 
–5·09)
Sierra Leone 519 098
(329 919 to 
801 942)
4106
(2244 to 
6714)
678 273
(416 276 to 
1 092 241)
4775
(2912 to 
6784)
1 197 371
(749 248 to 
1 872 567)
8882
(5691 to 
12 669)
0·58
(0·04 to 
1·27)
1·10
(–1·78 to 
3·98)
–5·95
(–8·84 to 
–2·89)
–5·91
(–8·77 to 
–2·86)
The Gambia 153 051
(92 298 to 
251 289)
1056
(648 to 
1604)
148 981
(90 176 to 
243 097)
1034
(644 to 
1510)
302 032
(182 698 to 
494 937)
2090
(1405 to 
3029)
–1·07
(–1·53 to 
–0·59)
–0·89
(–3·74 to 
1·98)
–3·64
(–5·28 to 
–1·84)
–3·78
(–6·35 to 
–0·95)
Togo 369 830
(214 148 to 
641 934)
2811
(1429 to 
5062)
467 452
(283 814 to 
760 578)
3488
(1900 to 
5575)
837 282
(499 488 to 
1 395 545)
6299
(3690 to 
9808)
–0·48
(–1·12 to 
–0·01)
0·07
(–2·97 to 
3·01)
–3·55
(–5·34 to 
–1·72)
–2·72
(–6·05 to 
0·32)
Data in parentheses are 95% uncertainty intervals.
Table 7: Malaria incidence and deaths for all ages by sex and annualised rates of change for 16 Global Burden of Disease regions and 105 countries
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2012—diﬀ erences in time trends stem from assumptions 
about the case-detection rate and, in our study, the 
incorporation of information from prevalence surveys and 
all-cause mortality. Table 9 outlines the diﬀ erences between 
our tuberculosis estimation strategy and that of WHO.
Malaria burden rose steadily until 2004 and has since 
decreased. The Global Fund, President’s Malaria Initiative, 
and other bilateral and private initiatives have spent 
$11·3 billion in DAH from 2000 to 2011. The hypothesis 
that global action has been an important factor in these 
declines is highly plausible.6,110,138–141 The decline in our 
assessment is driven by the statistical model ﬁ tted to the 
available but sparse verbal autopsy data. Key independent 
variables in the model that drive this estimated decline are 
resistance for ﬁ rst-line agents and ITN coverage. Noor and 
colleagues’142 assessment of trends in PfPR from 2000 to 
2010 indicate that some countries such as Malawi, Zambia, 
or DR Congo have had substantial scale-up of ITNs with 
minimal reduction or increases in PfPR. Explanations for 
the mismatch between ITN scale-up and changes in PfPR 
could lie in the estimation of any of PfPR, ITNs, or local 
factors that aﬀ ect who actually receives and uses ITNs, or 
it could be a function of other factors—eg, climatic 
changes over this period. There could also be important 
threshold or saturation eﬀ ects for ITNs on PfPR. While 
the substantial decline in child mortality in the past 5 years 
is welcome news, understanding the relative role of 
artemisinin combination treatment scale-up and vector 
control is challenging and might vary by country. The 
variability in the relation between ITNs and PfPR at the 
national level emphasises the risks of simply assuming 
that ITN scale-up at the national level will yield the 
percentage reduction in child deaths seen in the 
randomised trials; a strategy used by Child Health 
Epidemiology Reference Group (CHERG) in their child 
mortality estimates. It is also important to note that the 
CHERG models did not include a ﬁ rst-line drug resistance 
as a covariate. Our ﬁ ndings show this to be an important 
predictor in the Africa models in particular and a key 
driver of the temporal trend noted in this region. Table 10 
outlines the diﬀ erences between our malaria estimation 
strategy and that of WHO.
MDG6 brought global attention to these three diseases, 
ushering in an unprecedented focus on speciﬁ c diseases 
in the broader development agenda. Despite many who 
questioned the wisdom of a focus on speciﬁ c diseases, 
there has been accelerated progress on HIV, malaria, and 
tuberculosis since 2000. In the case of HIV, our 
estimation strategy allows for direct quantiﬁ cation of 
years of life saved, which have been substantial. For 
tuberculosis and malaria, we see accelerated reductions 
in deaths and cases compared with the decade before the 
Millennium Declaration. Rigorously assigning causality 
to these accelerations to the global collective action 
catalysed by the Millennium Declaration is beyond the 
scope of this paper and likely impossible in view of the 
data limitations. Nevertheless, as governments and the 
global community debate the nature, scope, and utility of 
setting new global targets post-2015, these ﬁ ndings 
should be taken into consideration.
Our comparative analysis of these three diseases shows 
pronounced diﬀ erences in data gaps and measurement 
challenges. Antenatal clinic serosurveillance and 
population surveys in generalised epidemics have been a 
powerful tool for tracking evolution of the HIV epidemic 
with real data collected on an annual basis. Cause of death 
data in many countries with concentrated epidemics also 
provide a timely way to examine the eﬀ ect of HIV. But, 
national data for the outcome of ART is weak. Measures 
such as retention in care and loss to follow-up are often 
incomplete and diﬃ  cult to compare across facilities, 
programmes, and countries. UNAIDS and our modelling 
do not routinely use national data for treatment outcomes 
and depend on cohort or published studies. In view of the 
huge eﬀ ect of ART on death and prevalence, more accurate 
and continuous monitoring of ART outcomes and costs 
must be a high priority. By contrast with HIV, tuberculosis 
treatment outcomes are highly standardised and reported 
to WHO at least through the end of treatment. However, 
real-time data for the time-trends of tuberculosis is hard to 
come by. Case notiﬁ cations can only be interpreted by 
resorting to expert opinion on the case detection rate, and 
prevalence surveys are infrequent and require large sample 
sizes. A system analogous to the antenatal clinic 
serosurveillance for tuberculosis would be possible if new 
diagnostics emerge that can quantitatively assess load of 
bacilli in an infected individual. Pending such a 
technological advance, more frequent prevalence surveys 
and perhaps capture-recapture studies82 are the only direct 
measurement available to track evolution of the epidemic. 
In our study, ARC for incidence and prevalence 2000 to 
2013 is correlated (0·93). Information about malaria 
clinical cases and deaths is much weaker than for HIV or 
tuberculosis. Case reports are very incomplete. Most 
deaths occur in places without vital registration systems. 
Verbal autopsy is widely believed to exaggerate malaria 
deaths, especially in adults,143–145 in view of the tendency to 
overdiagnose malaria in African hospital settings;146–149 our 
systematic review of validation studies, though, shows low 
sensitivity (33%) and low speciﬁ city (93%). Bias is a 
function of both sensitivity and speciﬁ city. If these 
validation studies that are published are correct we might 
be underestimating and not overestimating malaria deaths 
in adults and children in areas with substantial malaria 
and the reverse in areas with little malaria. The only 
comparatively easy-to-measure outcome related to malaria 
is the P falciparum parasite rate. Local surveys have been 
usefully collated and analysed by Noor and colleagues and 
the Malaria Atlas Project.142 These data provide hard 
evidence on the trends in a measurable outcome; the 
challenge is that there is a loose relation in the available 
data between PfPR and incidence or mortality. In view of 
how important malaria is, the state of monitoring systems 
for malaria burden is poor. Repeated verbal autopsy studies 
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GBD 2013 UNAIDS 201360,160
Incidence, prevalence, and mortality
Key data 
sources and 
inputs
• Vital registration (VR) data
• UNAIDS’ 1000 Estimation and Projection Package (EPP) incidence and prevalence curves
• GBD 2013 HIV-free life tables
• UNPOP World Population Prospects (WPP) 2012 population and fertility estimates
• Antiretroviral therapy (ART), prevention of mother-to-child transmission (PMTCT), 
and other intervention coverage data reported to UNAIDS
• HIV mortality rates on-ART from systematic literature review (102 studies)
• HIV mortality rates oﬀ -ART from systematic literature review (13 cohort studies)
• UNAIDS assumptions for other spectrum HIV inputs
• Population surveys of HIV prevalence
• Antenatal care (ANC) surveillance
• Surveillance data for high-risk groups
• UNPOP World Population Prospects 2010 population, fertility and HIV-free 
mortality estimates
• ART, PMTCT, and other intervention coverage data reported to UNAIDS by 
countries; UNAIDS states these are validated by UNAIDS, WHO, and UNICEF but no 
method for validation is provided
• Assumptions on the percent of the population in high-risk groups for each 
country with a concentrated epidemic; UNAIDS states that estimates are derived 
empirically, based on regional values or expert consensus but provides no detail 
by country on the empirical basis for the assumptions
• UNAIDS assumptions for other Spectrum HIV inputs based on a range of 
published studies and unpublished analyses
Key 
adjustments 
to data
• VR data adjusted for completeness
• VR data adjusted for garbage coding and misclassiﬁ cation HIV deaths
• None
Modelling 
strategy
All countries:
• Age-sex-CD4-speciﬁ c estimates of HIV mortality on-ART and oﬀ -ART based on 
meta-regression of studies from literature reviews
• Spectrum recoded in open-source language Python to facilitate uncertainty analysis
Generalised epidemics and populations with national surveys:
• 46 countries
• EPP outputs (15–49 years, both sexes) for generalised epidemics used as an input to 
modiﬁ ed Spectrum
• EPP ﬁ t to national prevalence data for India, Senegal, and Niger
• Spectrum (Python version) run with modiﬁ ed death rates on and oﬀ  ART, GBD HIV-free 
mortality, and WPP 2012 population estimates; intervention estimates for ART, PMTCT 
as reported by UNAIDS
• Sampling uncertainty distributions for all input parameters generate 10 000 year-age-sex 
speciﬁ c estimates of HIV mortality, incidence, and prevalence
• Selection of the 1000 epidemic curves that minimize the gap between GBD 2013 all-cause 
mortality estimates and Spectrum mortality outputs
Concentrated epidemics with VR:
• 125 countries
• Space-time Gaussian Process Regression (ST-GPR) on adjusted VR data to produce 
complete time series of age-sex-speciﬁ c mortality
• EPP outputs (15–49 years, both sexes) with Spectrum inputs, GBD 2013 demographic 
data, and updated on-ART and oﬀ -ART mortality analysis to run Spectrum and generate 
1000 year-age-sex speciﬁ c estimates of HIV mortality, incidence, and prevalence
• Adjusted incidence from Spectrum using the ratio of ST-GPR modelled mortality to 
Spectrum modelled mortality with six diﬀ erent assumptions of the lag from year of 
infection to year of death (10–15 years). This produced 6000 time series of incidence 
(15–49 years, both sexes)
• Adjusted incidence with GBD HIV-free life tables, WPP 2012 demographic data, and 
updated on-ART and oﬀ -ART mortality analysis to run Spectrum and generate 
6000 year-age-sex speciﬁ c estimates of HIV mortality, incidence, and prevalence
• Select 1000 with the smallest root mean squared error between model predictions of 
mortality and the vital registration data
Concentrated without VR:
• 17 countries
• Extrapolation of incidence and prevalence for countries where UNAIDS does not generate 
estimates by randomly selecting draws from countries in the region with estimates
• Regional average of all other Spectrum inputs for countries where UNAIDS does not 
generate estimates
• EPP outputs (15–49 years, both sexes) with Spectrum inputs, GBD 2013 demographic 
data, and updated on-ART and oﬀ -ART mortality analysis to run Spectrum and 
generate 1000 age-sex speciﬁ c estimates of HIV mortality, incidence, and prevalence
• Random selection of 1000 ratios used in the incidence adjustment process from 
countries with relatively high prevalence
• Use selected ratios to adjust incidence in the absence of ST-GPR results, producing 
1000 adjusted incidence curves (15–49 years, both sexes).
• Adjusted incidence with Spectrum inputs, GBD 2013 demographic data, and updated 
on-ART and oﬀ -ART mortality analysis to run Spectrum and generate 1000 year-age-
sex speciﬁ c estimates of HIV mortality, incidence, and prevalence
Generalised epidemics and countries with suﬃ  cient HIV prevalence data:
• 41 countries
• EPP (one of three variants) used to generate incidence and prevalence curves for 
urban and rural or regional breakdowns with survey and ANC surveillance data; 
aggregation to generate national curves for ages 15–49 years in both sexes 
combined. Fitting parameters including start year of the epidemic modiﬁ ed to 
eliminate unrealistic ﬁ ts from the statistical model. Incidence adjusted downward 
by 92% for the fraction of people on ART.
• EPP outputs with Spectrum inputs and WPP 2010 demographic data to generate 
year-age-sex speciﬁ c estimates of HIV mortality, incidence, and prevalence
• Selective modiﬁ cation of input parameters including ART survival based on 
country consultation process
Concentrated epidemics in populations greater than 250 000:
• 114 countries
• EPP used to generate incidence and prevalence curves for high-risk groups using 
surveillance data for these populations
• Aggregation to generate national curves (15–49 years, both sexes) based on 
assumptions about the fraction of the population in each high-risk group
• EPP outputs with Spectrum progression parameters, reported ART and PMTCT 
coverage, and WPP 2010 demographic data to generate year-age-sex speciﬁ c 
estimates of HIV mortality, incidence, and prevalence
• For some countries with insuﬃ  cient data on prevalence in high-risk groups, 
reported HIV diagnoses over time and assumptions about the fraction diagnosed 
used
• Selective modiﬁ cation of assumptions on the percentage of the population in 
each high-risk group and other Spectrum input assumptions through country 
consultation process
Countries with populations less than 250 000:
• No estimates constructed
(Table 8 continues on next page)
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combined with carefully designed validation studies would 
be helpful. Better data for the incidence of clinical episodes 
conﬁ rmed with rapid diagnostic tests and how it varies as a 
function of the PfPR would improve incidence estimation.
Findings for these three diseases draw attention to the 
diﬀ erence between ICD-assigned underlying cause of 
death and the total mortality attributable to a disease 
including pathways through which a disease aggravates 
other disorders. ICD rules treat disorders—not just these 
three diseases—in this regard in substantially diﬀ erent 
ways. All deaths directly related to pregnancy and childbirth 
and any deaths aggravated by pregnancy are counted as 
maternal deaths. For HIV, all deaths in individuals who are 
HIV-positive are assigned to HIV unless they are due to 
completely incidental causes such as a road traﬃ  c injury. 
Following this convention, tuberculosis deaths in HIV-
positive people are assigned to HIV not tuberculosis. In the 
case of malaria, there has long been the recognition that 
malaria might increase the risk of death in children and 
adults from other causes such as septicaemia or chronic 
kidney disease.150–152 Early studies after the country-by-
country elimination or rapid control of malaria documented 
rapid changes in deaths from pneumonia and chronic 
kidney disease,153,154 suggesting the full eﬀ ects of malaria on 
mortality are greater than the ICD-coded malaria deaths. 
The ITN randomised controlled trials based on verbal 
autopsy documented that about half of the declines in 
under-5 mortality were in causes other than malaria 
assigned through a verbal autopsy.155,156 Our understanding 
of the magnitude of each disease is aﬀ ected by the at-times 
arbitrary rules governing assigning causes of death.
There are two important general observations from our 
analysis of HIV compared with prior analyses that might 
be relevant to other diseases. First, we saw that concentrated 
epidemics have been systematically over estimated by a 
factor on average of more than two. Overestimation is 
most likely related to a tendency to overestimate the size of 
high-risk groups for which little information exists. Why 
would expert judgment be, on average, so wrong? The 
disconnect in many countries between expert judgment 
and the results emerging from the analysis of cause of 
death data should caution researchers in the future from 
too much dependence on expert judgment in descriptive 
epidemiology. Second, we saw a systematic under-
estimation of uncertainty in many countries in the 
UNAIDS analysis. Their assessment for South Africa, for 
example, had for 2010 an uncertainty interval with a 
coeﬃ  cient of variation of 0·03. Our assessment before 
matching on all-cause mortality had a coeﬃ  cient of 
variation about six times higher (0·19) in the same year. 
There is a general tendency, we believe, in many modelling 
eﬀ orts to underestimate uncertainty when arbitrary 
assumptions about parameters are made. For example, the 
default assumptions for uncertainty in the UNAIDS 
Spectrum model is a coeﬃ  cient of variation 0·05 for 
mortality on and oﬀ  ART. We ﬁ nd from our empirical 
analysis coeﬃ  cients of variation that range from 0·44 (in 
the age group 15–24 years and CD4 count greater than 500) 
to 1·00 (in people aged 45 years or older and a CD4 count 
greater than 500). In other words, uncertainty in these 
parameters seems to have been underestimated, with the 
real value approximately ten times larger. This is not a 
critique of the UNAIDS Spectrum modelling eﬀ ort, rather 
a reminder that statistical analysis of parameter uncertainty 
often shows that we know much less than we think.
Our analysis of HIV in India based on the 2005–06 
National Family Health Survey and antenatal clinic 
serosurveillance suggests that in 2002 there were 287 000 
GBD 2013 UNAIDS 201360,160
(Continued from previous page)
Uncertainty • Use the 1000 EPP incidence curves consistent with the available prevalence data
• Generated 1000 sets of CD4 progression and CD4 speciﬁ c mortality on and oﬀ  ART 
sampled from the meta-regression of published studies
• Sample a uniform distribution of –10% to +10% of the mean value for all other 
Spectrum parameters including numbers on ART and PMTCT
• The sex ratio of incidence was sampled from a uniform distribution of –20% to +20% 
of mean value
• Major limitation is that uncertainty intervals for many parameters are sampled from 
an arbitrary uncertainty interval
• EPP likelihood estimation of incidence reﬂ ects uncertainty in prevalence data
• Uncertainty in the percent of the population in high-risk groups or urban and 
rural breakdown not incorporated
• All uncertainty adjustments to non-EPP inputs are arbitrary and small compared 
with GBD
• Uncertainty propagated after point estimates generated—coeﬃ  cients of 
variation for parameters arbitrarily selected and only for selected variables (eg, for 
adults ratio of fertility of HIV-positive to HIV-negative women, ratio of male to 
female incidence, average number of years in each CD4 category, HIV mortality 
without ART, HIV mortality with ART)
• No uncertainty incorporated for CD4 progression overtime or distribution of CD4 
counts at seroconversion
GBD 2013 
diﬀ erences
• Recoded Spectrum in the Python programing language to enable the model to run 
more eﬃ  ciently and allow for full uncertainty analysis
• Expanded uncertainty in Spectrum estimates of mortality, incidence, and prevalence 
by sampling distributions around most Spectrum inputs
• Empirically estimated uncertainty for HIV mortality on-ART and oﬀ -ART
• Used VR data when available to inform estimates of mortality for concentrated epidemics
• Identify epidemic curves and all-cause mortality estimates in countries with large 
epidemics that are most consistent with each other
• Sum of cause-speciﬁ c mortality estimates for a country-year-age-sex group must 
equal all-cause mortality estimate at the draw level (CoDCorrect algorithm)
N/A
Table 8: Comparison between Global Burden of Disease 2013 verses UNAIDS 2013 HIV estimates
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(199 000 to 377 000) deaths. Cause of death data, however, 
are available from several sources all pointing to 
substantially lower numbers of deaths than UNAIDS 
high-risk group analysis. Using data for 2001–03, 
investigators in the Million Death Study reported an 
estimated 59 000–140 000 deaths in 2004. The urban 
Medical Certiﬁ cation of Causes of Death system recorded 
a peak age-standardised death rate in 6·3 per 
100 000 population, which is equivalent at the national 
level to 57 000 deaths. We did not use these sources in our 
assessment; the substantial mismatch between our 
estimates draws attention to the need for improved 
understanding of causes of death in India.
Some global health eﬀ orts to develop robust estimates 
of the burden of disease sometimes end up using both 
empirical measurement on incidence, prevalence, and 
cause-speciﬁ c mortality plus coverage of interventions 
and assumed eﬀ ectiveness of interventions. The blending 
of real measurement of outcome and assumed mapping 
of interventions to outcome is justiﬁ ed because recent 
 GBD 2013 WHO 201382
Mortality
Key data sources or inputs • Vital registration (VR) data (2731 country-years)
• Verbal autopsy (VA) data (166 site-years)
• Covariates
• VR data (2087 country-years)
• WHO 2013 tuberculosis incidence estimates
• WHO 2012 tuberculosis case fatality rate (CFR) estimates
• Covariates
Key adjustments to data • VR adjusted for estimated completeness in each country-year
• VR and VA data adjusted based on detailed analysis of garbage coding
• VR and VA data adjusted for misclassiﬁ cation of tuberculosis-HIV
• Excluded VR data for South Africa and Zimbabwe due to misclassiﬁ cation of 
tuberculosis-HIV
• VR data adjusted for senile and ill-deﬁ ned cause of death
• VR data interpolated for missing data and trailing or leading missing values 
with exponential smoothing
• VR data adjusted for estimated completeness in each country year
Modelling strategy All countries:
• Use the Cause of Death Ensemble Modeling strategy (CODEm) to generate 
mortality estimates from the VR and VA data for all countries; covariates 
informed the model; CODEm tests a wide range of models and constructs an 
ensemble model on the basis of performance of diﬀ erent models judged with 
data held-out from model -building
• Model fraction tuberculosis-HIV with the fraction of tuberculosis-HIV in 
HIV mortality from the VR data – HIV-mortality estimates used to generate 
TB-HIV deaths
Countries with VR:
• Tuberculosis mortality directly from VR data: 123 countries (45% estimated 
global deaths)
Countries without VR with ten covariates available:
• Negative binomial model estimated based on the 123 countries in the ﬁ rst 
group; predictions from the model used for 27 countries
Countries without VR without complete covariates:
• Mortality estimated by multiplying estimated incidence multiplied by an 
estimate of the case-fatality rate for all-ages combined (67 countries)
• Regional case-fatality rates (CFR; high-income, middle-income, and low-income 
countries) generated from case notiﬁ cations by type (notiﬁ ed and non-notiﬁ ed) 
and VR data (Bayesian linear modelling done separately by region)
All countries:
• HIV plus tuberculosis incidence from UNAIDS’ Spectrum model and estimated 
CFR of tuberculosis mortality in HIV-positive people (six CFRs corresponding to 
six CD4 cell-count groups and one CFR for cases on ART)
Uncertainty All countries:
• CODEm generates uncertainty intervals for predicted death rates by sampling 
the posterior distribution of each of the component models in proportion to 
the weight of each model in the ensemble; mixed eﬀ ects component model 
uncertainty includes uncertainty in the betas and the hierarchical random 
eﬀ ects; spatiotemporal Gaussian Process Regression component models 
include uncertainty from the mean prior and the data variance
• Uncertainty interval coverage evaluated objectively with out-of-sample 
predictive validity
• Each country-year-age-sex draw adjusted so it is consistent with the sum of 
all GBD 2013 causes and the all-cause mortality estimate for that country-
year-age-sex group
• Uncertainty distributions across countries were assumed to be independent
Countries with VR:
• Uncertainty was computed based on sampling uncertainty
Countries without VR with ten covariates available:
• Uncertainty estimated from the uncertainty in the regression coeﬃ  cients
Countries without VR without complete covariates:
• Mortality estimate uncertainty computed with posterior distributions of CFR 
(assumed time independent within respective case categories [notiﬁ ed or not, 
HIV positive or negative]) and country-year distributions of estimated incidence
All countries:
• Assumed uncertainty distribution correlation across countries unknown
GBD 2013 diﬀ erences • Tuberculosis mortality in all countries based on models constructed from VR 
and VA data
• VR and VA data corrected for garbage coding and misclassiﬁ cation of HIV 
deaths as tuberculosis deaths
• Fraction tuberculosis-HIV in HIV empirically estimated with VR data
• Out-of-sample predictive validity testing used to select the ensemble model 
for estimating mortality in all countries
• The same approach was used for all countries
• Sum of cause-speciﬁ c mortality estimates for a country-year-age-sex group must 
equal all-cause mortality estimate at the draw level (CoDCorrect algorithm)
• N/A
(Table 9 continues on next page)
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scale-up of interventions might not be accounted for in 
the sparse measurements that are available. We used the 
modiﬁ ed Spectrum model to map ART coverage into 
likely changes in mortality from HIV. These ﬁ ndings are 
lent support in some countries by measured declines in 
all-cause mortality or cause-speciﬁ c mortality but in other 
countries are based entirely on the presumed relation 
between intervention roll-out and mortality. Many 
examples of such blending of data for outcome and 
intervention coverage exist: CHERG estimates of 
 GBD 2013 WHO 201382
(Continued from previous page)
Incidence and prevalence
Key data sources and 
inputs
• WHO tuberculosis case notiﬁ cations (age-sex-country-year speciﬁ c)
• Tuberculosis prevalence surveys (27 national survey-years and 
24 subnational survey-years in 24 countries)
• Expert opinion and consultation on the case-detection rate as reported by WHO
• GBD 2013 tuberculosis mortality estimates
• Pre-1994, case notiﬁ cations for selected countries (Australia, Canada, 
Germany, UK, and Japan)
• GBD 2013 HIV prevalence estimates (CD4 and antiretroviral therapy 
[ART]-status speciﬁ c)
• Relative risks (RRs) of tuberculosis-HIV compared with tuberculosis-only 
from literature review (eight studies)
• WHO tuberculosis case notiﬁ cations (country-year speciﬁ c)
• Prevalence surveys (about 19 national years), adjusted for extra-pulmonary 
tuberculosis and childhood tuberculosis
• Expert opinion and consultation of case detection rate (CDR)
• Tuberculosis subnational surveillance data, programmatic data, and 
inventory studies
• Measure of access to health care and performance of health system 
derived from Demographic and Health Surveys
• RRs of tuberculosis-HIV compared with tuberculosis-only (three studies)
• Population surveys of prevalence of HIV in patients with tuberculosis, 
sentinel HIV data, routine HIV testing of reported tuberculosis cases
• UNAIDS estimates of HIV prevalence in children and in adults
Key adjustments to 
data
• Correction of case notiﬁ cations for missing age groups, smear-unknown 
and relapsed cases, and missing diagnostic categories
• Case notiﬁ cations adjusted upwards for underreporting with CDR
• Prevalence surveys adjusted for likely proportion extra-pulmonary 
tuberculosis missing in a survey with case notiﬁ cation data
• Triangulation of expert opinion on under-reporting CDR, subnational 
administration data, programmatic data, inventory studies, and DHS data
• Case notiﬁ cation data reviewed and cleaned for underreporting, 
misclassiﬁ cation and over-reporting
• Prevalence measurements reviewed and adjusted for childhood 
tuberculosis and extra-pulmonary tuberculosis
Modelling strategy All countries:
• Derivation of remission and excess mortality from incidence to prevalence 
ratio and CFR models with the adjusted and historic case notiﬁ cations, 
prevalence data, and VR data
• Bayesian internally consistent estimation of incidence, prevalence, excess 
mortality, remission and mortality estimates in DisMod-MR 2.0
• Estimation of the proportion of total tuberculosis incidence and prevalence 
that occurs in HIV-positive individuals with GBD 2013 CD4-speciﬁ c HIV 
prevalence and CD4-speciﬁ c RRs from a meta-analysis in a population 
attributable fraction calculation
Countries with regional workshops:
• Extrapolation of CDR estimates for 1997, 2003, and 2008–12 using a beta 
distribution of plausible CDRs on three data points per country
• Estimation of incidence from CDR and case notiﬁ cations for 96 countries. 
Trends based on tuberculin surveys (three countries) and mortality estimates 
(40 countries)
Countries with national prevalence surveys:
• Incidence from empirical measurements of disease prevalence and duration 
estimates for two countries
High-income countries:
• Incidence from case notiﬁ cations and expert opinion or capture-recapture 
modelling
All countries:
• Proportion of tuberculosis incidence that is due to tuberculosis-HIV in 
UNAIDS’ Spectrum model based on population surveys of HIV prevalence 
among tubeculosis cases, sentinel HIV data, and routine HIV testing of 
reported tuberculosis cases
• Prevalence directly estimated from national surveys adjusted for extra-
pulmonary and childhood tuberculosis or indirectly from estimates of 
tuberculosis incidence and duration
Uncertainty • Uncertainty in case notiﬁ cations based on expert reported upper and lower 
bounds of the case-detection rate adjusted so that the minimum interval is 
plus or minus 20 percentage points
• Uncertainty in corrected incidence, remission rates, and excess mortality 
rates estimated by use of draws from the regression variance-covariance 
matrix of the betas and draws from the random eﬀ ects distributions
• Prevalence survey uncertainty computed from the sample size and sample design
• DisMod-MR generates posterior distributions for incidence, prevalence, 
remission, and excess mortality that is a function of data variance and 
model parameter uncertainty
• Uncertainty distributions across countries assumed to be uncorrelated
• Uncertainty in incidence based on primarily on uncertainty in expert 
opinion on the case-detection rate
• Prevalence uncertainty based on either sampling uncertainty in surveys 
and assumptions about extra-pulmonary and childhood tuberculosis 
(derived from case notiﬁ cation data) or incidence uncertainty and an 
assumed duration
• Assumed uncertainty distribution are uncorrelated
• Estimates and their uncertainty are not based on analysis of age-speciﬁ c rates
GBD 2013 diﬀ erences • DisMod-MR 2.0 simultaneously synthesizes all available data for incidence, 
remission, excess mortality and prevalence ensuring internal consistency
• Estimation of incidence, prevalence, remission, and excess mortality is 
age-sex speciﬁ c
• All countries modelled with the same approach
• N/A
Table 9: Comparison between Global Burden of Disease 2013 verses WHO 2013 tuberculosis estimates
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decreases in child deaths due to ITNs and Hemophilus 
inﬂ uenza type B vaccine coverage are not based on any 
statistical relation but on the assumption that inter-
ventions will yield the decreases seen in randomised 
trials. These are reasonable assumptions but fundamental 
diﬀ erence exist between observing the change in outcome 
as opposed to assuming the outcome has changed; this 
diﬀ erence is not immediately evident in global health 
estimation eﬀ orts. It can yield circular analyses in which 
estimates are used by other authors to assess impact. In 
general, in the GBD 2013, we have sought to use largely 
empirical data and statistical associations seen in the data 
to make estimates. But for HIV in particular, we have 
used the approach embodied in Spectrum.
This analysis of data for HIV, tuberculosis, and malaria 
has many limitations in view of the ambition to track 
incidence, prevalence, and mortality for 188 countries 
from 1990 to 2013. First, ART estimates for 2013 are 
highly preliminary. Countries have reported ART scale-
up through 2012 and provided estimates for 2013. Many of 
GBD 2013 WHO110,162
Mortality
Country groupings 1 High malaria transmission countries in Africa
2 Countries outside of Africa and low malaria transmission African countries
3 Countries with mostly or only Plasmodium vivax malaria
1 High transmission countries in Africa
2 Countries outside Africa and low malaria transmission African countries
Key data sources • Verbal autopsy (VA) studies and vital registration (VR) data • For countries outside Africa and low transmission African countries: NMCP 
reports for case estimates, as described below, as well as clinic records and 
reported malaria case fatality data
• For high malaria transmission countries in Africa: verbal autopsy studies, vital 
registration data, and clinical malaria mortality data
Key adjustments to data • VR adjusted for completeness
• Adjustments for child deaths in VA and VR for garbage coding
• None
Modelling strategy • Separate CODEM models for high malaria transmission countries in Africa 
and countries outside of Africa and low malaria transmission African 
countries; separate models for under 5 and ≥5 years
• CODEm covariates: Plasmodium falciparum parasite rate (PfPr) from the 
Malaria Atlas Project (2010), Lysenko endemicity, WHO population-at-risk, 
prevalence-weighted ﬁ rst-line drug resistance, health-system access, 
indoor residual spraying (IRS) and insecticide-treated nets (ITN) coverage, 
rainfall, education, and lagged gross domestic product (GDP).
• Deaths for countries with mostly or only P vivax malaria estimated with a 
negative binomial model
For countries outside Africa and low transmission African countries:
• Deaths estimated by multiplying malaria case estimates by ﬁ xed case fatality 
ratios (0·45% in Africa; 0·3% outside of Africa), based on clinical malaria 
mortality and reported malaria case fatality data
For high-transmission countries in Africa:
• Child deaths estimated using a verbal autopsy multi-cause model (VAMCM) 
developed by the WHO Child Health Epidemiology Reference Group (CHERG),145 
adjusted post-hoc for the eﬀ ect of bednets and use of Haemophilus inﬂ uenzae 
type b (Hib) vaccine
• Deaths in children aged 5 years or older: “inferred from a relationship between 
levels of malaria mortality in diﬀ erent age groups and the intensity of malaria 
transmission”110
Uncertainty analysis For P falciparum countries:
• Uncertainty generated by CODEm
• CODEm generates uncertainty intervals for predicted death rates by sampling 
the posterior distribution of each of the component models in proportion to 
the weight of each model in the ensemble; mixed eﬀ ects component model 
uncertainty includes uncertainty in the betas and the hierarchical random 
eﬀ ects; spatiotemporal Gaussian Process Regression component models 
include uncertainty from the mean prior and the data variance
• Uncertainty interval coverage assessed objectively using out-of-sample 
predictive validity
For P vivax countries:
• 1000 draws generated from the variance-covariance matrix of coeﬃ  cients 
from negative binomial model
• Each country-year-age-sex draw adjusted so it is consistent with the sum 
of all GBD 2013 causes and the all-cause mortality estimate for that 
country-year-age-sex group
• Uncertainty distributions across countries were assumed to be 
independent
For countries outside Africa and low transmission African countries:
• Uncertainty in the case fatality rates assumed arbitrarily to be a uniform 
distribution between 0·225% and 0·675% for African countries and between 
0·15% and 0·45% for outside of Africa
• Incidence rates: see section on morbidity below
For high-transmission countries in Africa:
• For child deaths estimated by CHERG with the VAMCM, “the bootstrap method 
was employed to estimate uncertainty intervals by re-sampling from the 
study-level data to estimate the distribution of the predicted percent of deaths 
due to each cause”110
• For deaths in children aged 5 years or older: unknown
Main GBD 2013 diﬀ erences • Malaria mortality in all countries based on models constructed from VR 
and VA data
• VR and VA data corrected for garbage coding in children
• Models include drug resistance and ITN and IRS coverage
• Out-of-sample predictive validity testing used to select the ensemble model 
for estimating mortality in all countries (except those with mostly or all 
P vivax malaria)
• Sum of cause-speciﬁ c mortality estimates for a country-year-age-sex 
group must equal all-cause mortality estimate at the draw level 
(CoDCorrect algorithm)
• N/A
(Table 10 continues on next page)
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these estimates were aspirational and we have used 
growth rates over the 5 years 2008–12 to adjust these 2013 
estimates. Second, we have not independently validated 
the country reports of ART scale-up. We have added to the 
uncertainty by randomly varying ART scale-up by 
sampling a uniform distribution from plus to minus 10% 
but this presumes that, on average, ART scale-up is not 
exaggerated. Third, we have used 102 studies of ART 
outcomes to inform our assumptions of death rates on 
ART. There was much variation across sites. More recent 
programmes might be achieving better outcomes than 
previous studies have shown if there has been shared 
GBD 2013 WHO110,162
(Continued from previous page)
Morbidity
Country groupings As deﬁ ned by Hay and colleagues163
1 Countries with reliable surveillance systems (eight countries)
2 Countries with incomplete surveillance systems (55 countries)
3 Countries with unreliable surveillance systems (45 countries)
1 High-transmission countries in Africa
2 Countries outside Africa and low-malaria-transmission African countries
Key data sources • For countries with reliable surveillance systems and incomplete 
surveillance systems: national malaria control programme (NMCP) reports 
on the number of cases, supplemented with reported malaria case data at 
the subnational levels for China and Mexico
• For countries with unreliable surveillance systems: published epidemiological 
studies of malaria incidence
• For countries outside Africa and for African countries for which the quality of data 
were considered adequate: NMCP reports on malaria cases and nationally 
representative household surveys on source of care
• For countries with unreliable surveillance systems: published epidemiological 
studies of malaria incidence
Modelling strategy, 
including adjustments 
to data
• For countries with reliable surveillance systems: cases directly from NMCP 
report data
• For countries with incomplete surveillance systems: cases from NMCP 
data, adjusting for completeness of reporting with health system access 
proxy covariate using a regression model
• For countries with unreliable surveillance systems: cases estimated using 
the relation between studies of malaria incidence and malaria mortality 
rates estimated from CODEm with covariates for age group, active versus 
passive case detection, inside or outside Africa, and the ratio of site-
speciﬁ c to national PfPR from MAP2010
• For countries outside Africa and for African countries for which the quality of 
data were considered adequate: cases from NMCP report data adjusted for 
proportion of cases receiving a diagnostic test, completeness of reporting, and 
health-care seeking with the fraction of fever cases accessing facilities based on 
Demographic and Health Surveillance Surveys (DHS) and Multiple Indicator 
Cluster Survey (MICS), or other nationally representative household surveys
• For high-transmission countries in Africa: populations were classiﬁ ed as living at 
either high, low, or no risk of malaria and then high, low, or zero case-incidence 
rates were applied to the populations living in each endemicity class (procedure 
deﬁ ned by Snow and colleagues164). Estimates were adjusted post-hoc for urban 
and rural diﬀ erences and bednet and IRS eﬀ ects
• For countries with unreliable surveillance systems: high, low, and zero case-
incidence rates were applied to populations classiﬁ ed as living at either high, low, 
or no risk of malaria deﬁ ned according to climactic suitability (as per the 
Mapping Malaria Risk in Africa [MARA] project). Estimates were adjusted for 
urban and rural diﬀ erences, and the eﬀ ect of bednets and IRS
Uncertainty analysis For countries with unreliable surveillance systems (45 countries) and countries 
with incomplete surveillance systems (55 countries):
• 1000 draws generated from the variance-covariance matrix of coeﬃ  cients 
from the incidence regression
• Age pattern predicted with regression and applied to non-age-speciﬁ c 
WHO case report data for countries with reliable surveillance systems 
(eight countries)
For countries outside Africa and low-transmission African countries:
• uncertainty in the completeness of reporting assumed to be uniform for 
reported values between 50% and 80% (low and mid value at 80% and high 
values at 100%) and triangular distributions for values below 50% (low 0%, 
mid and high 50%) and above 80% (low and mid 80%, high 100%)
• Proportion of slide-positive cases assumed to have a normal distribution with 
SD from a least square regression of SDs on means across countries
• Uncertainty in the proportion of population with fever using health facilities 
that are covered by the health-facility reporting system of cases and 
proportion not seeking treatment: based on survey SDs
• Final uncertainty based on bootstrap methods assuming no correlation 
between sources of uncertainty within a country
• Uncertainty distribution correlation across countries unknown
For high-transmission countries in Africa:
• incidence rates by age and category of transmission risk
• triangular distributions (with low, mid, and high values based on median and 
interquartile values as reported by Snow and colleagues164) “truncated so that 
their lower limit did not fall below 1”
• Adjustments for rural or urban diﬀ erences and for coverage of malaria 
preventive activities (ITNs and IRS): not included in the description of 
uncertainty methods
• Uncertainty distribution correlation across countries unknown
GBD 2013 diﬀ erences • Malaria cases were predicted with a mortality-incidence model for 
countries with unreliable surveillance systems
• Predictions are adjusted for detection methods (active vs passive case 
detection)
• N/A
The description of WHO estimation methods was based on the World Malaria Report 2008 and World Malaria Report 2011.
Table 10: Comparison between Global Burden of Disease 2013 verses WHO 2013 malaria estimates
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Uncertainty is probably underestimated due to the 
limitations of verbal autopsy for malaria in children and 
adults. Tenth, ﬁ ndings from other studies in countries 
such as The Gambia suggest substantial decreases in 
malaria in these settings; in our analysis of mortality, 
however, these types of studies have not been used.158,159 
Eleventh, our analysis of tuberculosis assumes that local 
expert judgment about the case-detection rate is unbiased; 
this assumption, however, might be incorrect for 
countries with higher or lower case-detection rates. 
Twelfth, our uncertainty intervals for tuberculosis 
incidence and prevalence generated from DisMod-MR 2.0 
are probably underestimated. The intervals are narrow 
because we have extensive data inputs for essentially all 
countries in the form of adjusted case-notiﬁ cations and 
CODEm estimates of all-cause mortality. Although each 
data point has substantial uncertainty, the meta-
regression produces narrow estimates of the predicted 
mean value for an age-sex-country-year because of the 
extensive and often consistent data. These intervals do not 
capture the potential for systematic error in some of the 
data-processing steps such as the use of the expert-based 
case-detection rate. Despite these important limitations, 
the GBD approach has many advantages, primarily 
because it is a comprehensive and clearly documented 
approach to disease burden estimation that examines all 
the available data and invests substantial eﬀ ort into 
standardisation of deﬁ nitions, data adjustments, and 
modelling across all diseases and injuries.
The focus of the global health community on action to 
reduce HIV/AIDS, tuberculosis, and malaria, enshrined 
in MDG6, was not only appropriate in 2000 at the 
Millennium Declaration, but is increasingly relevant now 
in view of the slow but important progress that disease 
control strategies have yielded, particularly since 2005. 
Much remains to be done, however: although evidence 
now exists that the implementation of known 
interventions is beginning to have an eﬀ ect, it is probably 
less than is widely believed, or hoped. But these 
interventions are working, and need to be rapidly scaled 
up with more funding, more emphasis on national 
health system strengthening in key aﬀ ected countries to 
increase access to them by the poor, and more targeted 
research to accelerate progress. What is also clear from 
this analysis as we enter the ﬁ nal phase of the MDG era 
is how little we reliably know in many countries to track 
progress. Rapidly reducing the massive uncertainty that 
surrounds the measurement of these diseases, 
particularly malaria, will be essential if we are to better 
monitor, and respond to, evidence about progress, or not, 
with their control.
Contributors
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learning across programmes. Available studies might also 
be biased towards better outcomes through the publication 
bias; poor programmes are unlikely to seek to publish 
their results. There was insuﬃ  cient national data to use 
local information about each country on ART 
programmes. Our estimates might be biased up or down 
for a given country because local ART outcomes might be 
better or worse than the sub-Saharan Africa average. 
Future rounds of estimation will be substantially 
improved by more robust ART treatment outcome data 
obtained from nationally representative samples of 
patients on ART across a wider range of countries. Fourth, 
we have sought to ﬁ nd epidemic curves for the major 
generalised epidemics that are both consistent with 
available prevalence data and all-cause mortality data 
derived from sources such as vital registration or sibling 
histories in household surveys. The process of matching 
all-cause mortality draws and Spectrum outputs that are 
consistent also substantially reduces uncertainty. In view 
of the mismatch of these data sources, we are probably 
underestimating uncertainty in these countries. Fifth, we 
have not modiﬁ ed the UNAIDS assumptions for survival 
in children infected with HIV. However, published 
studies from high-income countries pre-ART suggest 
much higher survival.157 Our estimates of death in the 
age-groups 5–9 years and 10–14 years might therefore be 
exaggerated. Sixth, our estimates of uncertainty for HIV 
could be underestimated because some of our uncertainty 
ranges for parameter inputs have been selected arbitrarily 
and true variation, for example, in age-sex patterns of 
incidence might be larger. The idea that variations in age-
sex patterns of incidence might be larger is lent support 
by the number of age-sex-country-years in which our 
estimates of prevalence are diﬀ erent to those available 
from national prevalence surveys. Seventh, on the basis of 
debate over the burden of malaria in adults, we chose not 
to redistribute garbage code deaths onto malaria in verbal 
autopsy studies in adults, which led to a reduction in the 
estimated number of adult malaria deaths. Although this 
choice was informed by expert opinion, it was not based 
on any direct data. Even without the redistribution of 
garbage codes, the percentage of deaths occurring in 
adults in Africa is still high and has to be interpreted with 
caution in view of the potential for misclassiﬁ cation bias 
in verbal autopsies. Alternatively, the choice not to 
redistribute ill-deﬁ ned codes onto malaria might bias our 
adult deaths downwards. Eighth, Noor and colleagues 
have published PfPR for 2000 and 2010.142 A full time-
series of PfPR would be a useful covariate for modelling 
the burden of malaria. The Malaria Atlas Project is 
working on such time-series analysis of PfPR and when it 
is ﬁ nalised it would strengthen the analysis of malaria 
trends. Ninth, our uncertainty intervals for malaria 
incidence and mortality incorporate sampling uncertainty, 
non-sampling un certainty, and model-speciﬁ cation 
uncertainty, but do not incorporate the uncertainty that 
can stem from misclassiﬁ cation biases in verbal autopsy. 
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